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Abstract
Epstein-Barr Virus (EBV) is a human herpes virus associated with several 
malignancies including endemic Burkitt's lymphoma (eBL), nasopharyngeal 
carcinoma (NPC) and polyclonal B-cell lympho-proliferations in immunosuppressed 
individuals. Epstein-Barr virus nuclear antigen 1 (EBNA 1) plays a key role in the 
life cycle o f the virus and is consistently expressed in all these tumour types. 
However, no oncogenic activities o f EBNA 1 have been identified in cell cultures. 
Nevertheless, EBNA 1 is a viral oncogene when expressed in vivo in transgenic mice 
which succumb to monoclonal B cell lymphoma (Wilson and Levine, 1992, Wilson 
et al., 1996). The experiments described in this thesis were designed to explore how 
EBNA 1 may act as an oncogene in vivo.
EBNA 1 was found to be redundant in terms of tumour latency with Bcl2 in 
transgenic crossbreeding experiments. Therefore, the ability of EBNA 1 to inhibit 
cell death or differentiation was examined by cell culture techniques. Moreover, cell 
surface markers examined by FACS. Flow cytometric analysis of spleen and bone 
marrow (BM) cells from EpEBNA 1 transgenic mice revealed that the percentage of 
slg+ (and possibly CD23+) cells was statistically significantly higher when 
compared to the wild type control littermates. EpEBNA 1 spleen and bone marrow 
(BM) cell survival cultures showed no survival advantage over the wt cultures. 
However, a proliferation/survival assay revealed that EpEBNA 1 transgenic positive 
BM cells have statistically significant higher proliferation/ survival rate than the wt 
BM cells. These results may indicate that EBNA 1 drives cells to differentiate and 
supports their survival/proliferation leading to increased slg.
Since EBNA 1 is a DNA-binding protein acting as a transcriptional 
transactivator the expression levels of cellular genes involved in cell death and 
differentiation were examined in transgenic mice at pre- and post-tumour stages. 
The antiapoptotic gene BclxL was found up-regulated and the pro-apoptotic gene 
Bad was found downregulated. This strongly supports the earlier phenotypic 
observation that EBNA 1 may act in a similar fashion or through Bcl2 family genes. 
Moreover, Ragl and Rag2 genes were also found to be up-regulated in EpEBNA 1 
transgenic mouse spleens and this could lead to increased recombination, genome 
instability and possibly tumour development.
1
Further studies, using a macroarray for differential gene expression, suggest 
that several immediate early response genes such as Jun  and Fos family members 
and Egrl may be affected by EBNA 1. If EBNA 1 does up-regulate these genes this 
action could lead to increased differentiation and/or proliferation of EBNA 1 positive 
B cells.
Thus, there are several lines of evidence suggesting that EBNA 1 supports B 
cell survival/proliferation and differentiation through de-regulation o f genes 
responsible for the development of B cells. This may be the mechanism by which 
EBNA 1 causes tumourigenesis.
2
Chapter 1
Introduction
1.1 EBV associated diseases and latent genes
Epstein-Barr vims (EBV) is a B-lymphotropic gamma herpes virus which is 
widespread in all human populations and it is carried by the majority of individuals 
as a lifelong asymptomatic infection (Epstein and Achong, 1986). Most people 
become infected before they reach adulthood. In young children initial infection is 
usually asymptomatic, whilst post-puberty infection can lead to infectious 
mononucleosis (glandular fever). Primary EBV infection begins in the pharyngeal 
epithelium due to its permissive environment for viral replication. From there the 
virus spreads to the subepithelial B lymphocytes where it persists in a latent state 
(Faulkner et al., 2000).
EBV is strongly implicated in the pathogenesis of several human malignancies 
(Baumforth et al., 1999 and references therein; Kawa, 2000), notably in the endemic 
and in some cases of sporadic Burkitt’s lymphoma (BL), in approximately 50% of 
Hodgkin’s disease (HD) cases, nasal T-cell lymphomas and in undifferentiated 
nasopharyngeal carcinoma (NPC) (Magrath, 1990; Meijer et al., 1996; Rickinson and 
Kieff, 1996). Possible association of EBV with breast and gastric cancers has been 
reported recently (Chu et al., 1998; Bonnet et al., 1999; Takada, 1999). EBV is also 
responsible for a wide spectrum of acute and chronic ailments in healthy and 
immunocompromised individuals. In addition, potential involvement of EBV in a 
number of other clinical syndromes such as Duncan’s syndrome (X-linked 
lymphoproliferation) in oral hairy leukoplakia in AIDS patients and chronic 
mononucleosis, has been proposed (Khanna et al., 1995).
The EBV genome is a linear double stranded 172Kbp DNA (Fig. 1.1). EBV 
(B95.8 strain) was the first herpes virus to be completely sequenced (Baer et al., 
1984; Parker et al., 1990). Comparison of EBV with the other herpes viruses
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showed large regions with colinear, although distant, identity at the predicted protein 
level. The relatively conserved domains encode for EBV genes that function in early 
or late stages of lytic infection (Davison and Taylor, 1987). However, the EBV genes 
expressed in B lymphocyte latent infection have no detectable similarity to other 
herpes virus genes and may have arisen in part from cellular DNA (Heller et al., 1985; 
Moore et al., 1990; Henderson et al., 1993). In vitro, EBV infection is largely 
restricted to B lymphocytes. At least 10% of the infected normal resting B cells are 
capable of long-term growth in vitro as lymphoblastoid cell lines (LCLs). Most of 
our knowledge of EBV latent and lytic infection is based on infection of B 
lymphocytes in vitro, while in vitro infection of epithelial cells is largely abortive 
(Sixbey, 1983).
A large number of viral mRNA species (~30 early mRNAs and -30  late 
mRNAs) are expressed during lytic infection. In contrast, in LCLs EBV expresses six 
different nuclear proteins (EBV nuclear antigens, EBNAs): [EBNA 1, 2, 3A, 3B, 3C 
and LP (leader protein) (or alternative nomenclature EBNA 1, 2, 3, 4, 6 and 5)]; two 
different latent integral membrane proteins LMP1 and LMP2 (A and B forms which 
result from differential promoter usage) [or alternative nomenclature LMP1 and TP 
(1 and 2)]. Two small non-polyadenylated RNAs or EBERs (1 and 2) are also 
expressed. In addition, a set of 3’ coterminal spliced mRNAs located at U5 and 
transcribed through the BamHl A fragment of EBV have been detected at high levels 
in NPC. They have subsequently been found to be present at lower levels in latently 
infected B cells (Smith et al., 1993). More recently, these transcripts were shown to 
encode a number of proteins that are expressed in latently infected cells and in 
tumours (Fries et al., 1997).
EBV can establish different types of latency associated with malignancy, each 
of which is characterised by the differential expression of the group of latency genes 
and referred to as types I, II and III (Table 1.1). In type III latency, usually found in 
EBV infected LCLs and type III BL cell lines, all EBV latent genes are expressed 
(Hudson et al., 1985; Bodescot et al., 1987). Type III latency is characteristic of 
immunoblastic B cell lymphoma that arises in AIDS patients and artificially
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immunosuppressed individuals. In type I and II latency, the expression of nuclear 
antigens is restricted to EBNA 1 (Rowe et al., 1986). BL biopsy cells and type I cell 
lines (latency I) express only EBNA 1 and the EBERs (Rowe et al., 1987). Type II 
latency (characterised by NPC and Hodgkin’s disease) differs from latency I in the 
additional expression of variable combinations of LMP1, LMP2A and LMP2B and 
the BamUl transcripts (Brooks et al., 1992; Kerr et al., 1992). However, more 
recently another type of EBV latency has been identified in vivo, in resting B 
lymphocytes of healthy individuals, in which LMP2A is the only EBV latent protein 
expressed and possibly EBNA 1 persists (Miyashita et al., 1997).
During infection of B cells in culture EBNA LP and EBNA 2 are the first viral 
proteins to be expressed. EBNA LP makes an important, but not essential 
contribution to the outgrowth of B cells in culture (Hammerschmidt and Sugden, 
1989). Association of EBNA LP with Rb and p53 has been suggested based on in 
vitro biochemical interactions (Szekely et al., 1993). Expression of EBNA LP in 
transgenic mice, using the metalothionein promoter, was directed mainly to the heart, 
liver and kidney with no discernible effect on tumour development or incidence. 
However, the transgenic mouse heart phenotype was difficult to relate to gene 
function and even more to a possible role in EBV associated diseases (Huen et al., 
1993).
EBNA 2 transactivates viral genes (LMP1 and LMP2B) as well as 
upregulates certain cellular genes (CD21, CD23 and c-fgr) (Abbot et al., 1990; 
Calender et a l, 1990; Cordier et al., 1990; Fahraeus et al., 1990; Knutson, 1990; 
Woisetschlaeger, 1991; Zimber-Strobl et al., 1991; Jin and Speck, 1992; Ling et al., 
1993; Zimber-Strobl et al., 1993). EBNA 2 has been shown to exert its 
transactivating function through an interaction with the recombination binding protein 
RBP-Jk or CBF1, the homologue of Drosophila suppressor of Hairless (Henkel et 
al., 1994; Zinber-Strobl et al., 1994; Hsieh and Hayward, 1995). Activated (as well 
as mutant) cellular Notch protein binds to and activates CBF1 (Hsieh et al., 1997). 
The similarities between the Notch-CBFl and EBNA 2-CBF1 interactions are 
suggestive of a model in which EBNA 2 could mimic constitutive Notch signalling to
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block differentiation (Hsieh et al., 1996; 1997). Moreover, mutations of Notch family 
genes that result in constitutive Notch signalling have been identified in a number of 
tumours (reviewed in Wilson, 1997). Therefore EBNA 2 may act in a similar way in 
tumour development. In addition, c-myc expression is also up-regulated in primary 
B-lymphocyte infection at the time EBNA LP and EBNA 2 are expressed (Alfieri et 
al., 1991). Moreover, EBNA 2 was shown to transactivate p53 through induction of 
NFkB activity (Chen and Cooper, 1996). In contrast, in BL cells heterologous 
EBNA 2 expression down-regulates expression of the translocated lgH-c-myc gene, 
presumably through the IgH sequences (Jochner et al., 1996).
The EBNA 3 mRNAs are some of the least abundant EBNA mRNAs within 
the EBV infected B cell and have only a few molecules per latently infected cell 
(Petti, 1988; Robertson and Kieff, 1995; Kieff, 1996). EBNA 3A and 3C are 
essential for growth transformation and the immortalisation process of B cells in 
culture (Tomkinson and Kieff, 1992). EBNA 3C upregulates CD21 and may also be 
involved in the regulation of LMP1 expression (Allday et al., 1994; Sample and 
Parker, 1994; Marshal et al., 1995; Bain et al., 1996). EBNA 3B although dispensible 
for growth transformation, upregulates the expression of the cytoskeletal protein 
Vimentin as well as CD40 and can downregulate the BL associated antigen CD77 
(Silins et al., 1994). EBNA 3 proteins were shown to repress EBNA 2 mediated 
transactivation of the viral LMP2 promoter and possibly LMP1 promoter (Allday et 
al., 1994; Le Roux et al., 1995). They were also shown to interact with RBP-Jk 
(Robertson et al., 1996a).
LMP1, which is able to transform fully certain rodent fibroblast cell lines, is 
essential for immortalisation of resting B lymphocytes in culture and is required for 
continued proliferation of the resulting LCLs (Wang et al., 1985; Baichwal and 
Sugden, 1988; Peng and Lundgren, 1992; Kaye et al., 1993; Kilger et al., 1998). In 
addition, LMP1 induces epithelial hyperplasia in transgenic mice when expressed in 
the epidermis and induces B cell lymphoma when expressed in lymphoid tissues 
(Wilson et al., 1990; Wilson, 1997; Kulwicht et al., 1998). EBV negative B cells 
transfected in vitro with LMP1 expression vectors resemble B cells that are
proliferating in response to antigen or mitogen activation. They have increased 
expression of CD23, CD39, CD40, CD44 and cell adhesion molecules such as CD54 
(ICAM1), LFA1 and LFA3, as well as increased cytokine production. LMP1 
expression in B cells prevents apoptosis through the activation o f anti-apoptosis 
proteins such as Bcl2, Bclx, M cll, p53 and A20 (Wang et a l,  1990; Henderson et al., 
1991; Laherty et al, 1992; Rowe et al., 1994; Chen and Cooper, 1996; Fries et al., 
1996; Wang et al., 1996). However, ectopic overexpression of LMP1, using 
transfection assays in either B or epithelial cell lines, can inhibit differentiation or 
result in cytotoxic effects (Hammerschmidt et al., 1989; Eliopoulos et al., 1996; 
Floettman et al., 1996; Lu et al., 1996). The mechanism of action of LMP1 is 
beginning to be elucidated. LMP1 has been shown to engage similar signalling 
pathways to CD40 ligation (Eliopoulos et al., 1996; Gires et al, 1997; Kilger et al, 
1998). LMP1 activates NFkB, Janus kinase (JAK) and signal transducers and 
activators of transcription (STAT) and possibly mitogen activated protein kinase 
(MAPK) pathways all of which lead to changes in gene expression (Hammarskjold 
and Simurda, 1992; Herrero et a l, 1995; Kieser et a l, 1997; Eliopoulos and Young, 
1998; Eliopoulos et al., 1999; Roberts and Cooper, 1998). Nevertheless, it was 
recently demonstrated that LMP1 signalling is distinct from CD40 (Floettman et al.,
1998). LMP1 activation of the NFkB transcription factor was shown to be mediated 
through association with tumour necrosis factor receptor associated factors (TRAFs) 
and tumour necrosis factor receptor associated death domain (TRADD) (the latter of 
which does not associate with CD40, but rather another family member, TNFR) 
(Mosialos et al., 1995; Devergne et al., 1996; Izumi and Kieff, 1997).
LMP2 is important for viral persistence and efficient B cell immortalisation 
(Qu and Rowe, 1992, Chen et a l, 1995, Brielmeier et a l, 1996, Caldwell et al., 1998). 
LMP2A is phosphorylated by Syk protein tyrosine kinase and Src family protein 
kinases and possibly by MAPK (Burhkardt et a l, 1992, Fruehling and Longhecker, 
1997; Panousis et al., 1997). LMP2A blocks B cell receptor (BCR) signal 
transduction and prevents activation of lytic replication in EBV-transfected B cells in 
vitro (Longnecker and Miller, 1996). It was recently demonstrated that LMP2A
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mimics BCR signalling and provides a survival signal to progenitor and peripheral 
receptorless B cells in transgenic mice (Caldwell et al, 1998). A possible function of 
LMP2A in epithelial cells was recently suggested where LMP2A interacts with cell 
adhesion-initiated signalling pathways involving Csk, a negative regulator of Src 
kinase (Scholle et a l, 1999).
Another two viral gene products in latent infection are BHRF1 and BARFO 
RNAs. BHRF1 is abundantly expressed very early in EBV lytic replication cycle 
(where BHRF1 appears to have an antiapoptotic effect) (Austin et al., 1988; 
Henderson et al, 1993). Although BHRF1 is expressed during the lytic cycle, 
BHFR1 transcripts have been detected in latent infected cells (Pearson et al., 1987; 
Austin et al, 1988). BHRF1 has sequence similarity with the bcl2 protooncogene 
and it has been postulated that it may possess Bcl2-like activities. Nevertheless, 
deletion mutants showed that BHRF1 is nonessential for growth transformation of B 
cells and for virus replication and release from these cells in culture (Marchini et al, 
1991; Lee and Yates, 1992).
BARFO RNA and protein are expressed in EBV infected B cells and epithelial 
cells. The protein has also been detected in protein extracts of NPC and BL biopsies 
and in a latency type I BL cell line (Karran et al., 1992; Fries et al., 1997). Moreover, 
BARFO like EBNA 1 is not recognised by HLA class I-restricted EBV specific 
cytotoxic T cells (CTLs) (Khanna et al., 1992, Levitskaya et al., 1995). EBV 
recombinants lacking the entire BARFO RNA-encoding region suggested that it is 
dispensible for latent infection in primary B cells or for growth transformation of B 
cells into LCLs (Robertson et al, 1994).
EBV-encoded RNAs 1 and 2 (EBERs) are small nuclear RNAs transcribed by 
the RNA polymerase III system (Clarke et al., 1992). They are expressed 
abundantly in latently infected cells. To date, the biological functions of EBERs 
remain unclear, although they were found to be associated with cellular proteins 
(Clemens, 1994 and references therein). Nevertheless, EBV recombinants lacking the 
EBERs demonstrated that EBERs are dispensable for the B cell immortalising 
function of EBV (Swaminathan et al, 1991). However, it was recently suggested that
1 0
EBERs have oncogenic functions in BL cells which are possibly mediated through 
up-regulation of Bcl2 protein (Komano et al., 1999).
EBNA 1 has an established role in the replication and maintenance of the 
episomal form of the EBV genome (Lupton and Levine 1985; Yates et al., 1985; 
Chittenden et al., 1989; Leight and Sugden, 2000 and references therein). It was 
recently demonstrated that EBNA 1 is needed for efficient, stable infection by the 
virus (Lee et al., 1999). EBNA 1 expression is detected in all EBV associated 
tumours. While EBNA 1 does not show classical oncogenic activities in cell culture 
assays, transgenic mice that express EBNA 1 in the B cell compartment develop 
monoclonal B cell lymphoma (Wilson et al., 1992; 1996). The mechanism of its 
oncogenesis has now begun to be elucidated (the topic of this thesis).
1.2 BL
Burkitf s lymphoma (BL) is a childhood cancer, which occurs throughout the 
world. It is a malignant lymphoma composed of a clonal population of 
undifferentiated B lymphocytes, in which EBV was first described (Epstein and 
Achong, 1986). BL occurs in two forms: endemic and sporadic. The endemic BL 
(eBL) is found in equatorial Africa and New Guinea, areas with high incidence of 
malaria which is postulated to be a contributing factor in disease onset. It has been 
suggested that the immunosuppression caused by malarial infection is likely to 
increase the chances of BL development. The sporadic world-wide form of BL (sBL) 
represents less than 3% of childhood cancers in Europe and the USA. However, in 
all regions it represents about 35% of malignant non-Hodgkin’s lymphomas.
There is a strong association between eBL and EBV. All patients with eBL 
have antibodies to the viral capsid antigen (VCA) indicating that all individuals with 
the tumour have been infected by the virus. The evidence implicating EBV as 
factorial in eBL is strong, in that whilst 97% of the BL tumours in highly endemic 
areas carry the EBV genome, less than 1% of the total B cell population from the 
malaria carriers is detectably infected (Moss et al., 1983). EBV association with sBL 
is less clear with only approximately 20% of sBL cases being EBV positive.
1 1
However, recent studies on EBV association with sBL showed viral DNA integration 
in some sBL cases which is suggestive of a broader involvement of EBV in the onset 
of sBL than was previously assumed (Razzouk et al., 1996).
BL tumours display characteristic translocations involving the c-myc locus on 
chromosome 8 (8q24) and either the IgH locus on chromosome 14 (the “common” 
translocation seen in up to 80% of tumours) or one of the light chain loci on 
chromosomes 2 or 22 (the “variant” translocations seen in 10-20% of cases) 
(reviewed in Cory, 1986). All these translocations result in the de-regulation of c- 
myc expression. Although t(8:14) translocation is the most common one, in eBL and 
sBL there is a great heterogeneity of breakpoints with respect to both loci. For 
example, in sBL the breakpoint on chromosome 8 occurs in the region of c-myc intron 
or exon 1, which contains regulatory elements of c-myc expression. Hence, 
disruption of the regulatory function directly leads to the de-regulation of c-Myc 
expression. In these translocations the position of the breakpoint within the IgH 
locus on chromosome 14 most often involves the switch (S) region of the gene. 
Rodent plasmacytomas carry a c-Myc translocation similar in nature to that seen in 
sBL in which case the IgH enhancer on chromosome 12 becomes juxtaposed with a 
truncated c-myc gene on chromosome 15. In eBL tumours, the breakpoint on 
chromosome 8 occurs at some distance 5’ to the c-myc gene and translocations tend 
to involve the intronic enhancer/J region of the IgH locus on chromosome 14. This 
variation in the site of breakpoints within the IgH locus may reflect the different 
stage of cells involved in each tumour. For example, the translocations involving the 
IgH J region, as in eBL, are likely to occur in immature pro-B cells during V-D-J 
joining. The translocations involving S regions, as in sBL, imply a later event 
occurring in mature B cells involved in immunoglobulin class switching which is 
further supported by the observation that sBL B cells, but not eBL B cells, secrete 
IgM. In addition, BL tumours are monoclonal in terms of immunoglobulin 
rearrangements. Most of them are IgM+IgD' (pK or p?i) but a minority appear to be 
derived from cells which have already switched to IgG or IgA production albeit with 
appropriate light chain restrictions. These tumours display a remarkably consistent
1 2
cell surface profile characterised by the co-expression of CD 10 (CALLA) and the 
glycolipid moiety CD77 (BLA) which are used as diagnostic markers. Moreover, 
they lack B cell activation antigens such as CD23, CD30, CD39 and CD70, as well as 
ICAMI and LFA3 which are needed in cell adhesion to T cells and B7 necessary for 
T cell activation (Rowe et al., 1985; Gregory et al., 1988, 1990).
BL has a complex multistep pathogenesis involving deregulated c-myc 
expression and EBV as major contributing factors. However, the relative contribution 
of these factors and their order in the sequence of events is still unclear.
The mechanisms whereby EBV contributes to eBL development are still not 
fully understood. EBV is directly involved in B cell transformation in culture. 
Therefore, the potent growth transforming ability of the virus suggests that it could 
act early in the lymphomagenic process by expanding the population of cells at risk 
for translocation (Klein and Raab-Traub, 1987; Crawford et al., 1993). Alternatively, 
it could act on B cells carrying a translocation, increasing the likelihood of 
accumulation of further changes either by extending the survival capacity of the cells 
or by driving expansion of the translocation positive clone. The known transforming 
activities of LMP1 could be important in the development of eBL. However, EBNA 
1 is the only viral protein, along with the EBERs, consistently expressed in EBV- 
positive BL biopsies. Therefore, the EBV role in the development or at least the 
maintenance of BL phenotype could be mediated through EBNA 1 action and/or the 
EBERs. However, genetic deletion assays have shown that the EBERs are 
dispensable for transformation of B cells (Swaminathan, 1991). Conversely, 
transgenic mice for EBNA 1 succumb to monoclonal B cell lymphoma (Wilson et al., 
1992; 1996). This renders EBNA 1 as the main viral candidate oncoprotein 
performing a critical function at least in the maintenance of BL.
1.3 EBNA 1
EBNA 1 is the EBV protein that is present in most infection states and 
necessary for latent EBV infection. EBNA 1 is consistently expressed in EBV 
associated malignancies as described above (Table 1.1).
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EBNA 1 is a multifunctional protein which plays a crucial role in the latent 
phase of EBV infection, including activation of DNA replication and maintenance of 
the episomal form of the viral genome during cell division (Leight and Sugden, 2000). 
This is mediated by EBNA 1 protein binding sites at the origin of replication oriV. In 
addition, EBNA 1 influences the expression of latent gene products, including 
autoregulation (Yates et al., 1985; Sample et a l, 1986).
I) Viral and Cellular regulation of EBNA 1 expression
The open reading frame for EBNA 1 as defined on the physical map of the 
viral DNA is the BamUl K fragment right frame 1 (BKRF1, 107950-109872 map 
units of B95.8 strain) (Summers et al., 1982; Baer et a l, 1984). An analysis of 
cDNAs encoding EBNA 1 indicated that the message is a highly spliced bicistronic 
mRNA of 3.7Kbp which is expressed from the latent promoters in BamHl-C (Cp) 
and BamHl-W  (Wp) that lie 90 and 80 Kbp, respectively, upstream of the EBNA 1 
ORF (Speck and Strominger, 1985) (Fig. 1.1). The BamHl-W  promoter is 
constitutively active in B cells and is used on initial infection to drive expression of 
all EBNAs with individual transcripts being generated through differential splicing 
(Schlagere/ al., 1996). EBNA 1 and EBNA 2 then activate the BamHl-C  promoter 
which drives the latency III EBNA expression seen in infectious mononucleosis.
In latency I (exemplified by BL) and latency II (exemplified by NPC) cells 
Wp and Cp are inactive and EBNA 1 expression is driven from a distinct promoter 
lacking a TATA box (Qp), located in the BamHl-Q  region (Schaefer et a l, 1995). 
Methylation of Cp is the major factor in loss of Cp activity (Robertson et al., 1996; 
Schaefer et al., 1997). Qp activity is regulated by two important elements. First, an 
interferon-stimulated response element (ISRE) which lies upstream of the Qp 
transcriptional start site and is bound by members of the interferon regulatory factor 
(IRF) family (Nonkwelo et al., 1997; Schaefer et al., 1997; Zhang and Pagano, 1997). 
The second element is called the Q locus consisting of 2 (lower affinity relative to 
oriV) EBNA 1 binding sites, located immediately downstream of the start site 
(Ambinder et al, 1990). Although binding of EBNA 1 to the family of repeats (FR)
1 4
region of ori? leads to the up-regulation of the gene expression from Cp, EBNA 1 
binding to this region within BamUl-Q leads to down-regulation of viral gene 
expression (Sample et al, 1992; Tsai et al, 1995), speculated to be due to binding at a 
site 3’ of the RNA start possibly inhibiting transcriptional progress. This repression 
appears to override the effects of the positive regulatory elements that lie upstream 
of the Qp start site.
EBNA 1 mRNA expression from Qp during type I latency is also regulated 
by cell cycle proteins. A member of the E2F family of cellular transcription factors 
(E2F1) activates Qp in the presence of EBNA 1 by competing with it for the 
partially overlapping binding sites (EBNA 1 autorepression domain) on the Q locus 
(Sung et al., 1994; Davenport and Pagano, 1999). However, Ruf and Sample (1999) 
proposed that the E2F1 on its own does not a play significant role in the regulation 
of EBNA 1 expression but its primary function may be to target transcriptional 
repressors, such as pRb to Qp, to silence EBNA1 expression in resting B cells. 
Repression of Qp by pRb is mediated through variant E2F binding sites Qpl and 
QpII. Nevertheless, it was recently demonstrated that Qp is positively regulated by 
cellular JAKs and STATs (Leonard and O’Shea, 1998; Chen et al., 1999).
EBNA 1 is the only EBNA that continues to be produced during lytic 
infection. The lytic mRNA begins at a BamHl-F promoter (near 62.2kb map units of 
B95.8 strain) immediately upstream of Qp, which was previously thought to be the 
active promoter for EBNA 1 expression in type I and type II latency (Lear et al., 
1992; Schaefer et al., 1991). However, the Fp promoter was recently characterised as 
an exclusive lytic promoter (Schaefer et al., 1995). It is worth noting that a cellular 
protein LR1 which is a sequence specific DNA binding protein, has been identified as 
a key regulator of transcription from the Fp promoter (Bulfone-Paus et al., 1995).
II) EBNA 1 structure
EBNA 1 is a phosphoprotein with a high proline content, is charged and has 
an apparent molecular weight of 76KDa (varies with different repeat lengths) 
(Hennessy et al., 1983; Hennessy and Kieff, 1983). The EBNA 1 641 amino acid
1 5
(aa) polypeptide is composed of 3 distinct regions with functional subdomains (Fig. 
1.2 ).
a) The N-terminal basic region (l-89aa) is a short sequence contributing to 
some of the functions of EBNA 1. Interestingly, the EBNA 1 N-terminus shows 
internal polypeptide similarities with the myelin basic protein, implicated in multiple 
sclerosis (aa 64-68 and 74-78 in the EBNA 1 sequence) (Sumaya et al., 1980). 
Similarly it has been noted that EBNA 1 is identical over a doublet repetitive 
sequence between 40 and 49 aa in its N-terminus with a small ribonucleoprotein, the 
D polypeptide (SmD) (Sabbatini et al., 1993).
b) This is followed by the glycine/alanine (Gly-Ala) repeat, (from 90 to 328 
aa), a well conserved non-random gly-ala, gly-gly-ala and gly-gly-gly-ala array, that 
could form open coil tertiary structures and might participate in intramolecular 
interactions such as formation of multimeric viral and/or viral/cellular protein 
complexes. The size of EBNA 1 varies considerably in individual EBV-containing 
cell populations (from 69 to 94 KDa, by SDS-PAGE) and this depends on the 
number of these repeats within the protein. Importantly this region confers the 
ability to evade the host immune response. It was recently demonstrated that these 
internal repeats in EBNA 1 generate an inhibitory signal that acts in cis to interfere 
with antigen processing and MHC class I presentation (Levitskaya et al., 1995; 
Mukherjee et al., 1998). The majority of antigens presented via the MHC I pathway 
are subject to ATP-dependent ubiquitination and degradation by the proteasome. In 
vitro experiments using EBNA 1 deletion mutants and chimeric proteins EBNA 
1/EBNA 4 containing the gly-ala repeats, suggested that the gly-ala repeat may affect 
MHC I restricted responses by inhibiting antigen processing via the ubiquitin/ 
proteasome pathway (Levitskaya et al., 1997).
Flanking the Gly-Ala repeat, are Arg-Gly rich sequences that resemble the 
'RGG' motifs found in some RNA-binding proteins (Snudden et al., 1994).
c) The unique C-terminal region (328-64laa) contains most of the protein’s 
functional domains. It contains a proline-arginine rich region (327 to 377 aa) adjacent 
to the Gly-Ala repeat, functionally defined also in the N-terminal region, which
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mediates interactions between EBNA 1 molecules bound to distant DNA binding 
sites (DNA looping or 'linking') (Goldsmith et al., 1993; Mackey et al., 1995; 1997; 
Avolio-Hunter and Frappier, 1998). Sequences between amino acid residues 379 and 
387, adjacent to the one of the DNA looping domains, can function as a nuclear 
localisation signal (Ambinder et al., 1991). It was recently demonstrated that a 
human cellular protein EBP2 (EBNA 1-binding protein 2) specifically interacts with 
EBNA 1 sequences important for plasmid maintenance. The EBP2 interacting region 
of EBNA 1 maps to aa 325-386 shown in Fig. 1.2 (Ambinder et al., 1991) and an 
Arg-Gly region (determined using EBNA 1 deletion mutants) (Shire et a l, 1999). 
Another recently identified EBNA 1-interacting protein is the human cellular protein 
P3 2/TAP which specifically interacts with sequences important for DNA binding 
and transactivation. The C-terminal half of P3 2/TAP interacts with one N-terminal 
and one C-terminal region of EBNA 1 (aa 40-60 and aa 325-376) each of which 
contains arg-gly repeats (Wang et al., 1997; Chen et al., 1998).
Adjacent to this region there is a short serine-rich sequence that becomes 
phosphorylated (375-400aa) (Polvino-Boldnar, 1988). A long hydrophilic domain, 
from 459 to 607 aa, has sequence specific DNA binding and dimerisation activity. 
Mutational analyses of EBNA 1 showed that it has a bipartite dimerisation domain 
with residues located between 501 and 532 aa and between 554 to 598 aa, and DNA 
binding between residues 459 and 487 (Chen et al., 1993).
The structure of the EBNA 1 DNA binding and dimerisation regions was 
recently solved by X-ray crystallography at 2.4A resolution (Bochkarev et al., 1995; 
1996). EBNA 1 binds its DNA binding site as a dimer. The dimer is composed of 
two distinct DNA binding domains, the C-terminal or core domain and the flanking 
domain.
The core domain comprises residues 504-607 and contains the dimerisation 
interface. The structure of the EBNA 1 core domain is very similar to that of the 
DNA binding domain from the Bovine papilloma virus (BPV) protein E2, a 
transcriptional activator (Bochkarev et al., 1995). The major difference between the 
proteins reside in the loop between the 2nd and the 3rd strands of the |3 sheet (9
18
additional residues in EBNA 1) which is referred to as the proline loop due to high 
proline content. Notably, this structure in other proteins allows heterodimerisation 
with other proteins of the same class and such interactions can significantly modify 
the function of the individual proteins involved. The EBNA 1 proline loop has 
sequence identity to the herpes simplex ICP4 protein and hBPM protein (human 
homologue of the yeast SNF2/SW12 gene product) well known transcriptional 
activators (Muchardt and Yaniv, 1993). EBNA 1 acts as a transcriptional activator 
when bound to its consensus sequence. However, EBNA 1 does not appear to 
belong to any previously recognised class of DNA-binding proteins (Inoue et al., 
1991) and has not been shown to heterodimerise.
The EBNA 1 flanking domain comprises residues 461-504 and is unique to 
EBNA 1 with no sequence or structural similarity to any other known proteins. It 
consists of a connector (aa 490-503), an a  helix (aa 477-489) and an extended chain 
(aa 461-476). In the flanking domain a  helix is oriented perpendicular to the DNA 
and is connected to the core domain by the connector. The extended chain enters the 
minor groove of the DNA and makes all of the sequence determining contacts with 
the DNA. In vitro studies using EBNA 1 truncation mutants have indicated that in 
addition to contributing to the DNA binding affinity and stability of EBNA 1, this 
minor groove extended chain inhibits the passage of replication forks through the FR 
element (Ermacova et al, 1996).
The core domain of the EBNA 1 DNA binding site undergoes very little 
structural change upon binding to DNA as compared to the protein’s conformation in 
solution. In contrast, the flanking domain, although it adopts a similar structure in a 
dimer as it does in a monomer, its conformation changes dramatically upon DNA 
binding (Bochkarev et al., 1996).
The DNA binding and dimerisation region is followed by a highly acidic 
region at the C-terminus of the protein which, although is not required for DNA 
replication or transactivation, appears to play a role in the segregation of the EBV 
episomes during cell division and thus the plasmid maintenance function of EBNA 1 
(Yates and Camiolo, 1988).
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Ill) ori? and EBNA 1 binding
The role of EBNA 1 in the replication and maintenance of the viral episome is 
mediated through the latent origin of replication ori? (Fig. 1.3) (Yates et al., 1984; 
1985; Aiyar et al., 1998). Ori? consists of two regions containing multiple EBNA 1 
binding sites. The first, and highest affinity site consists of 20 tandem direct 30bp 
repeats, called FR, and is mapped at about 7Kbp from the left end of the genome. 
The second highest affinity site, located 980bp to the right of the FR, contains two 
symmetrically positioned EBNA 1 binding sites within a 65bp dyad symmetry (DS) 
that can form a 31 bp stem and a 3 bp loop structure and two additional binding sites 
flanking the symmetrical sequence located at the base of the stem-loop sequence.
The FR and DS sequences comprise an EBNA 1 dependent cis-acting element 
for EBV episomal maintenance and replication in the latently infected cells, although 
initiation of the replication events have been detected external to ori? (Little and 
Schildkraut, 1995). Only 6-12 copies of the 30bp-repeated sequence and 114bp 
containing the DS region are required for these functions (Reisman et al., 1985; 
Chittenden et al., 1989).
FR is required for efficient replication in vivo and for the stable maintenance 
of plasmids in cell lines (Reisman et al., 1985). In the presence o f EBNA 1, FR 
functions as a transcriptional enhancer element in either orientation for RNA polll- 
transcribed genes (Reisman and Sugden, 1986). This enhancement appears to 
function in cells in which the Cp promoter is active, suggestive of an autoregulation 
mechanism for EBNA 1 expression (Middleton et al., 1991). Cp also regulates the 
transcription of the other EBNAs during EBV latency and therefore EBNA 1-FR 
interaction may modulate viral gene expression. In addition, in cells in which the F p 
promoter is active there appears to be a requirement for a cis regulatory element 
within EBNA 1 itself, again suggestive of autoregulation and thus probably strict 
expression control (Reisman and Sugden, 1986).
Gahn and colleagues (1989) found that FR acts both as a replication fork 
barrier and as a replication termination site. As a result, replication initiation from 
ori? although usually bi-directional proceeds predominantly unidirectionally. The
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fork that moves towards the FR stops in the repeats, while the fork moving in the 
opposite direction progresses around the plasmid to meet the fork stalled in the FR 
repeats. In the presence of full length EBNA 1 protein, accumulation of replication 
forks stalled at the FR is enhanced. Deletion analyses revealed that the complete 
DNA-binding and dimerisation region of EBNA 1 is sufficient to elicit the pausing of 
replication forks, whereas deletion of a portion of the DNA binding domain abrogates 
the ability of EBNA 1 to stop replication forks (Platt et al., 1993; Ermakova et al., 
1996). Replication forks stall at the FR in different EBV genomes with variable 
termination levels, among different cell lines. Thus, it can be suggested that different 
EBV strains may differ in the regulation of termination events (Little and Schildkraut,
1995).
Genetic and biochemical analyses have determined that DS contains, or is 
close to, the site at which DNA synthesis initiates (Wysokenskie and Yates, 1989). 
The dyad repeat is absolutely required for episomal replication. DS can partially 
denature, forming bubble and cruciform structures, as measured by nuclease 
sensitivity assays (Orlowski and Miller, 1991; Williams and Kowalski, 1993). 
Denaturation of the dyad region is effected by EBNA 1 binding (Hearing et al, 1992). 
DS (as described above), contains 4 binding sites for EBNA 1 dimers termed 1-4 in 
order of their position, which differ in sequence and EBNA 1 binding affinity. Sites 1 
and 4 have higher affinity for EBNA 1 than do sites 2 and 3 (Ambinder et al., 1990; 
Summers et al., 1996). However, all four binding sites together are not required for 
origin activity. Plasmids that lack binding site 1 replicate, although less efficiently 
than plasmids containing an intact DS region. Deletions impinging upon binding sites 
2 and 4 abrogate the ability of mutated plasmids to replicate extra-chromosomally or 
result in abnormally large replication products of unknown structure (Chittenden et 
al., 1989). Without the FR, the DS is inefficient in enhancing transcription or in 
enhancing plasmid replication or persistence in the presence of EBNA 1.
Two cellular DNA binding proteins (OBPs) have been reported to compete 
with EBNA 1 to bind ori? (Wen et al., 1989; Zhang and Nonoyama, 1994). This
2 2
competition between EBNA 1 and OBPs may modulate the stability o f the EBV 
genome as plasmid and /or regulate the expression of the EBNAs from Cp promoter.
IV) Properties and functions of EBNA 1
EBNA 1 is a double-stranded and single-stranded DNA-binding protein and 
is phosphorylated on serine residues with all the phosphorylation sites lying in the 
C-terminal domain. Protein phosphorylation-de-phosphorylation has for long been 
known to be a mechanism for regulating the function of proteins. However, the 
effects of phosphorylation of EBNA 1 on any of its activities have not been reported 
(Hearing et al., 1985). Single stranded DNA-binding proteins have been implicated in 
key cellular processes such as DNA replication and genetic recombination. In 
general, this group of proteins binds to single stranded DNA irrespective of 
nucleotide sequence and binding results in a highly extended structure that may affect 
the ability of other proteins to interact with the nucleic acid. However, EBNA 1 has 
sequence-specific DNA binding properties.
Most of the known activities of EBNA 1 require that EBNA 1 maintain its 
ability to bind DNA and are mediated through EBNA 1 binding sites within the EBV 
genome (Yates and Camiolo, 1988; Polvino-Bodnar and Schaffer, 1992; Middleton 
and Sugden, 1994).
The interaction of EBNA 1 with the FR and the DS sites is co-operative, 
indicating facilitative alteration of the template and homotypic stabilising interaction 
between EBNA 1 molecules. Biochemical and electron microscopic studies indicate 
that EBNA 1 binding to the FR and the DS in the same oriP, results in such 
structures that lead to bending of the DNA, distortion of the duplex and looping out 
of the sequence between them bringing the two elements into close proximity 
(Frappier and O'Donnell, 1991a; 1992; Middleton and Sugden, 1992; Frappier et al., 
1994; Harrison et al., 1994; Bochkarev et al., 1996). One type of homotypic 
interaction involves interaction at a distance between EBNA 1 complexes assembled 
on the oriP. A similar EBNA 1-EBNA 1 interaction occurs between EBNA 1 
molecules bound to FR and DS elements on different DNA molecules which causes
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multiple DNA molecules to be linked together through a central EBNA 1 complex. 
The formation of this macromolecular complex is due to the ability of EBNA 1 to 
recognise both of these elements and to form homopolymers after associating with 
the templates (Frappier and O'Donnell, 1991b; Su et al., 1991; Goldsmith et al.,
1993).
Initially, deletion analyses indicated that the amino acids (336 to 450) 
responsible for this EBNA 1 action are located on the N-terminal side of its 
dimerisation domain (Harrison et al., 1994). Nevertheless, recent studies using 
overlapping internal deletion mutants indicated that two regions of EBNA 1 can 
cause DNA linking, aa 40-100 and aa 327-377. However, the stabilities of the linked 
complexes formed by the two regions vary dramatically; only complexes formed 
through the latter region are stable as shown by glycerol gradient sedimentation 
analysis (Mackey and Sugden, 1997; Avolio-Hunter and Frappier, 1998). However, 
the functional significance of the different stabilities of linked DNA complexes is not 
clear at present. Biochemical and EM studies suggest that only DNA-bound forms 
of EBNA 1 can interact through the DNA looping domain (Frappier and O'Donnell, 
1991a; 1991b; Goldsmith et al., 1993; Laine and Frappier, 1995). This may reflect a 
requirement for EBNA 1 to bind DNA, indicating that the looping domain must 
contact DNA and change its conformation in order to be active in mediating protein 
interactions.
DNA looping and linking mediated by the EBNA 1 looping domain (aa 327- 
377) has been shown to stabilise the EBNA 1 binding to the DS element, but the in 
vivo function of these interactions has not yet been determined (Su et al., 1991; 
Goldsmith et al., 1993; Frappier et al., 1994).
To date, no known enzymatic activity has been associated with EBNA 1 
(Frappier and O'Donnell, 1991b; Middleton and Sugden, 1992). Hence, EBNA 1 
must recruit a number of cellular proteins essential for initiation of replication, such 
as proliferating cell nuclear antigen (PCNA), replication factor C (RFC), the DNA 
polymerase, polymerase-primase, replication protein A (RPA) and the cellular 
helicase. It was recently demonstrated that EBNA 1 interacts with RPA (hSSB), a
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human single-stand DNA binding protein (Zhang et a l,  1998). RPA also interacts 
with a number of proteins involved in DNA metabolism including the viral proteins 
E2 of BPV (Li et al, 1993) and EBNA 2 (Tong et a l, 1995) and DNA polymerase a - 
primase. Thus EBNA 1, through its interaction with RPA could recruit cellular 
replication proteins to replicate the EBV genome.
The intervening sequence between FR and DS seems to be less critical and the 
sequence can be altered without affecting oriP function. Deletions, insertions and 
inversions made within oriP indicate that neither a precise distance nor a particular 
orientation of the FR and DS components, relative to one another, are required for the 
activity of ori? (Reisman et a l,  1985; Wysokenski and Yates, 1989; Middleton et al.,
1994). Nevertheless, deletion mutants showed that there is a lower limit of the 
intervening sequence length that permits loop formation.
Determinants for the subnuclear distribution of EBNA 1, its ability to persist 
in cells and its ability to associate with chromosomes during mitosis reside in the C- 
terminal half of the protein (Yates and Camiolo, 1988; Marechal et a l , 1999). EBNA 
1 has been shown to be invariably present on the chromosomes in metaphase 
preparations of mouse LTK cells and human Raji BL cells. In addition, circularised 
yeast artificial chromosomes containing ori? have been shown to interact in human 
cells expressing EBNA 1 (Grogan et a l, 1983; Harris et al., 1985; Simpson et al., 
1996). Three independent chromosome binding sites (CBS-1, -2 and -3) on the 
EBNA 1 sequence that mediate EBNA 1 binding to metaphase chromosomes have 
been recently identified. Interestingly, two of them (CBS-1 and -2) mapped to a 
region that have been previously demonstrated to be required for long term 
maintenance of on'P-containing plasmids and are included in the linking/looping 
regions (CBS-1 aa 72-84, CBS-2 aa 328-365) (Shire et al., 1999). The human cellular 
protein EBP2 (see section 1.3b) also interacts with specific EBNA 1 sequences, 
mapped within this same region (325-386 aa). Functional studies have shown that 
EBNA 1 mutants deficient in EBP2 binding can replicate ori? plasmids efficiently 
but are unable to maintain the plasmids after many cell generations. Therefore, 
EBNA 1 residues that mediate EBP2 interactions are required for the partitioning
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function of EBNA 1. It can be postulated that the component of mitotic 
chromosomes with which EBNA 1 interacts might be EBP2. This is supported by 
the finding that mutations in the Arg region that disrupt EBP2 binding also have 
profound effects on the DNA looping or linking activity of EBNA 1 (Shire et al.,
1999). However, at present it is unknown whether the loss of the partition function 
is due to the abrogation of EBP2 binding or to loss of the DNA linking activity. This 
property of EBNA 1 may be important in the segregation of episomes into progeny 
nuclei. It is possible that through anchorage to host cell metaphase chromosomes, 
approximately equal numbers of EBV episomes could be segregated on each 
metaphase plate and hence into each daughter cell.
Using the yeast two hybrid system another EBNA 1 associated protein 
P32/TAP was identified (section 1.3b). This protein binds approximately the same 
region (aa 40-60 and aa 325-376) to which EBP2 binds and CBS-1 and -2 mapped 
(Wang et a l, 1997). P32/TAP is an evolutionary conserved eukaryotic protein that is 
found predominantly in the mitochondrial matrix and less in the nucleus (Matthews 
and Russell, 1998). P32/TAP has been implicated in splicing (Honore et al, 1993), 
transactivation (Yu et al., 1995a and b) and receptor function (Ghebrehiwet et al., 
1994; 1995). EBNA 1 acts as a transcriptional transactivator in the viral genome 
regulating transcription from EBV Qp and Cp and LMP1 promoters (Sugden and 
Warren, 1989; Sample et al., 1992; Gahn and Sugden, 1995). In co-transfection 
assays, EBNA 1 can transactivate heterologous promoters when multiple EBNA 1 
binding sites are present within the target plasmids (Reisman and Sugden, 1986; 
Wysokenski and Yates, 1989). In addition, it was recently demonstrated, using a 
reporter assay, that EBNA 1 promotes hepatitis C virus (HCV) replication via its 
transactivation function, albeit indirectly, possibly through induction of transcription 
of a cellular gene (Sugawara et al, 1999). However, EBNA 1 does not have a 
specific transcriptional activation domain which was shown by different GAL4 
reporter constructs (Homer et al, 1995). Thus, other cellular proteins interacting 
with EBNA 1 may contribute to its transactivation ability. Deletion mutants lacking 
either of the two or both P3 2/TAP binding domains were unable to transactivate a
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reporter containing oriP EBNA 1 binding sites. Therefore, it is likely that P32/TAP 
may contribute to EBNA 1 -mediated transactivation.
EBNA 1 has been implicated in nuclear matrix attachment. It is notable that 
the ori? is contained within or immediately adjacent to the high affinity matrix 
attachment region (MAR) located within the BamWl-C fragment o f the EBV genome. 
This MAR consists of a~3.5 kb region which corresponds to nucleotides 6160-9699 
on the EBV B95-8 sequence (Baer et al., 1984). This region contains the EBER genes 
(nucleotides 6629-7128) and ori? (nucleotides 7135-9317). It has been shown that 
degradation of matrix-associated DNA leaves the EBNA 1 binding sites in ori? still 
associated with the nuclear matrix (Jankelevich et al., 1992). This property of EBNA 
1 could be important to its role in both replication and transcriptional activation.
A further recently identified activity of EBNA 1 is that it can bind to RNA, 
at least in vitro. Arginine-glycine-containing ("RGG") motifs have been found in 
several proteins that interact with RNA, including those involved in post- 
transcriptional processing of RNA (Burd and Drey fuss, 1994). EBNA 1 contains 
three potential "RGG" motifs (Fig. 1.2) located around the internal Gly-Ala-rich 
repetitive sequence o f the protein. These motifs could be involved in the observed 
association between EBNA 1 and RNA (Snudden et al, 1994). This observation 
raises the possibility that EBNA 1 may function through post-transcriptional as well 
as transcriptional gene regulation.
EBNA 1 can therefore potentially play many roles in the cell. A combination 
of its DNA and RNA binding properties and repression and transactivation functions 
certainly qualify the protein as a potential oncogene. Despite the fact that cell 
culture experiments showed no evidence of EBNA 1 oncogenic activity, in vivo 
studies suggested that is highly likely that EBNA 1 plays a dominant role in cellular 
immortalisation, at least in B cells, and possibly even in tumourigenesis as 
experiments in transgenic mice suggest (Wilson and Levine, 1992; Wilson et al.,
1996). However, the mechanism of action of EBNA 1 is still to be elucidated.
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1.4 B cell oncogenes and transgenic models of lymphoma
Tumourigenesis is a multistep process arising as a result o f a number of 
genetic and epigenetic changes (Hunter, 1991). These changes, although they vary in 
nature in different tumours, allow the cell to evade cell cycle controls and their effects 
fall into common categories. These include: acquisition of growth factor 
independence, ability to avoid restraining signals, induction o f angiogenesis, breach of 
surrounding tissues, escape from immunological surveillance and metastatic invasion.
Transgenic models of disease provide a powerful tool for the analysis of the 
effects of specific genetic changes in vivo. Analysis of tumour biopsies or cultured 
cells allow the investigation of only the endpoint events in the tumours. In contrast, 
transgenic models provide us with the ability to investigate pre-neoplastic changes in 
cells at specific stages during the process of tumourigenesis. In such systems 
overexpression or mutation of cellular and/or viral genes permit assessment of their 
oncogenic potential. In addition, inactivation o f specific genes by homologous 
recombination is used to assess candidate tumour suppressor genes. Genes identified 
as having oncogenic potential encode a wide range of proteins with variable function, 
from cell surface receptors to cytokines and nuclear transcription factors (Adams and 
Cory, 1991a, 1991b; Berns, 1991; Fowlis and Balmain, 1993; Berns et al., 1994; 
Brown and Balmain, 1995).
In assessing the oncogenic potential of cellular and viral genes it is very 
important to use the appropriate expression control sequences, in order to direct 
transgene expression in specific developmental stages or cell types. For example, the 
IgH (Ep) enhancer has been used to direct expression of several genes in both B and 
in some cases T cells, or occasionally even other cell types (Dildrop et al., 1989; 
Moroy et al., 1990,). E\k-c-myc, E\i-N-myc and E \x-L-myc mice develop B cell 
lymphomas (Adams et al., 1985; Rosenbaum et al., 1989; Sheppard et al., 1998), Ep- 
N-ras succumb to T cell lymphomas (Harris et al., 1988) and Ep-H-ras mice develop 
lung adenocarcinomas (Suda et al., 1987). Although directed enhancer gene 
expression in different cell types allows the investigation of the effects of a gene in
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those cells, cellular sequences flanking the transgene insertion site can affect its 
expression pattern.
In transgenic mouse models, the strain background is also important as it can 
influence the observed phenotype. For example, on a C57BL/6 or Balb/c background 
E\i-c-myc transgenic mice develop mostly B cell lymphoma. However, in the 
C3H/HeJ strain, E \x-c-myc mice develop predominantly T cell lymphomas (Yukawa 
eta l., 1989).
Analysis of pre-tumour tissues can yield information about the mechanism of 
action of the gene of interest. For example, pre-neoplastic changes observed in young 
mice positive for E\i-c-myc agreed with c-Myc action as a nuclear transcription factor 
active in cell cycle progression (Adams and Cory, 1991b; Morgenhesse and DePinho, 
1994; Henriksson and Luscher, 1996).
Transgenic mouse models for many tumour types are now available; amongst 
these are several B cell lymphomas which are particularly relevant to the work in this 
thesis (Adams and Cory, 1991a; Wilson, 1997 and references therein),
a) E^i-myc. Many haematopoietic malignancies are characterised by specific
chromosomal translocations e.g. c-myc translocation which juxtaposes the c-myc gene 
to an immunoglobulin locus in BL tumours, as well as in rodent plasmacytomas 
(reviewed in section 1.2). Evidence that the deregulated gene expression is oncogenic 
is derived from the transgenic mouse model. E\i-c-myc mice succumb to monoclonal 
nodal, pre-B or B cell type lymphomas (Adams et al., 1985). Recently, transgenic 
mice were generated in which a large (220Kb) IgHIc-myc translocation region carried 
in a yeast artificial chromosome (YAC) was introduced. Although these mice also 
develop monoclonal B cell lymphomas at an early age, the tumours in this case arise 
at non-nodal sites and consist of IgM+ B cells, similar to BL (Butzler et al., 1997).
c-Myc plays an important role in promoting normal cell growth. It is a 
nuclear transcription factor, expressed under tight regulation in normal cells. c-Myc 
expression is maintained in proliferating cells and down regulated as cells pass 
through differentiation. The c-Myc protein exerts its function through 
heterodimerisation with Max, another basic region helix-loop-helix leucine zipper
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protein (Amati et al., 1993). Except for its role in cell cycle induction, c-Myc has 
been shown to induce apoptosis upon cell cycle arrest. As a nuclear transcription 
factor, c-Myc has a number of transcriptional targets and particularly genes involved 
in cell cycle regulation. One of these genes, cdc-25A, is essential for the transition 
from G1 to S phase (Hoffmann et al., 1994). Its expression is stimulated by 
Myc/Max binding to regulatory elements in the cdc-25A gene. cdc-25A, is a 
phosphatase and display oncogenic properties in mammalian cells and like c-Myc, it 
co-operates with H-ras to transform normal rodent fibroblasts (Galaktionov et al., 
1995). Moreover, cdc-25A, like c-Myc, can induce p53-dependent apoptosis. In 
addition, c-Myc-driven apoptosis can be inhibited by cdc-25A antisense 
olinucleotides (Galaktionov et al., 1996). c-Myc can also exert its oncogenic action 
through its ability to inhibit growth cycle arrest by repressing the expression of 
gadd45, a growth arrest promoting gene (Marhin et al, 1997). A number of other 
cellular proteins including the transcriptional regulator YY1, the transcription factors 
AP2 and TFII-I and the zinc finger protein M izl, were found to interact with the C- 
terminal domain of c-Myc. The N-terminal domain of c-Myc, in addition to 
interaction with the Rb family protein p i 07, also interacts with a-tubulin and the 
novel adaptor proteins Binl, MM-1, Pam, TRRAP and AMY (Sakamuro and 
Pendergast, 1999 and references therein).
c-Myc belongs to a family of homologous proteins including also N-myc and 
L-myc. The other two members of the family were identified through their 
involvement in human tumourigenesis and by homology to c-Myc. N-myc is usually 
amplified in neuroblastomas whereas L-myc most commonly in small cell lung 
carcinomas (Marcu et al., 1992). Like c-Myc, N-myc and L-myc cause 
tumourigenesis when overexpressed in the lymphoid compartment in transgenic mice. 
E\i-N-myc mice also develop pre-B or B cell lymphomas and E\i-L-myc mice develop 
B or T cell lymphomas with lower penetrance and longer latency (Dildrop et al., 
1989; Rosenbaum et al., 1989; Moroy et al., 1990; Morgenbesser and DePinho, 1994; 
Sheppard et al., 1998).
3 0
b) En-Bcl2: Another characteristic chromosomal translocation t(14;18), typifying 
human follicular lymphoma, results in the juxtaposition of the bcl2 protooncogene 
and the IgH locus and leads to de-regulation of Bcl2 expression. E\i-Bcl2 transgenic 
mice develop monoclonal B cell lymphomas after long latency. These tumours result 
from the accumulation of excess non-cycling B cells of follicular origin and exhibit 
enhanced survival in vitro (McDonnell et al., 1990, 1991, Strasser et a l, 1991). Bcl2 
when overexpressed enhances cell survival without promoting proliferation. It 
prolongs the survival of haematopoietic cell in the absence of required factors and 
also in the presence of various stimuli inducing cellular death such as cytotoxic drugs 
or by apoptosis-inducing gene products (i.e. c-Myc) (Hockenbery, 1992; Strassser et 
a l, 1996 and references therein). Conversely, 5c/2-deficient mice demonstrate 
fulminant lymphoid apoptosis (Veis et al., 1993).
Bcl2 belongs to a family of proteins (Bcl2, Bclx, Bad, Bak and Bax) which 
play important roles in cell death regulation (Yang and Korsmeyer, 1996). Bclx 
alternative splicing yields two forms of Bclx mRNA, a long form BclxL (233aa 
protein) and a short form BclxS (170 aa protein). The two Bclx forms have opposing 
effects: BclxL enhances viability i.e. can protect a growth factor-dependent cell line 
from apoptosis; in contrast BclxS acts in a dominant negative fashion to inhibit the 
protective effects of BclxL.
BclxL is an apoptosis inhibitor and upon growth factor deprivation promotes 
cell survival even more effectively than Bcl2. Moreover, BclxL can inhibit apoptosis 
in cells that have undergone Fas-induced protease activation (Boise et al., 1993; 1997; 
Srivastava et al., 1999). BclxL is the major Bclx mRNA form expressed during murine 
development and like Bcl2 its product localises to mitochondria (Gonzalez-Garcia et 
a l, 1994). Analyses of BclxL-deficient chimeric mice demonstrated significant 
alteration in the maturation stage of B cell development characterised by extensive 
clonal selection. Constitutive expression of BclxL promoted accumulation of B cell 
precursors and mature B cells in the mouse and enhanced B cell survival in vitro. 
Coexpression of BclxL and Bcl2 leads to the enhanced accumulation of B cells in
3 1
transgenic mice and partially protected B cells from death, induced by IgD 
crosslinking using a specific anti-IgD antibody (Grillot et al., 1996).
Bax accelerates cell death and can oppose the effects of Bcl2 and BclxL. 
However, there is no evidence that Bax has any activity in their absence. Three 
isoforms of Bax (alpha, beta and gamma) are generated by alternative splicing. Bax 
can form homodimers as well as heterodimers with Bcl2 and BclxL, and the relative 
amounts of Bcl2/BclxL and Bax determine viability during growth factor deprivation.
A recently identified 5c/2-related gene designated Bak (for Bcl2 homologous 
antagonist/killer), the product of which interacts with Bcl2 and BclxL, is functionally 
similar to Bax and enhances apoptotic cell death following apoptotic stimuli 
(Chittenden et al., 1995; Kiefer et al, 1995). However, Bak can inhibit cell death in 
an EBV-transformed cell line possibly by inducing viral antiapoptotic factors such as 
the Bcl2 viral homologue BHRF1 (Kiefer et al., 1995).
Bad, a pro-apoptotic protein, can dimerise with Bcl2 and BclxL and when 
overexpressed can counter their survival promoting effects. It does so by displacing 
Bax from Bcl2/Bax and BclxL/Bax heterodimers, allowing more Bax/Bax homodimer 
formation, which promotes cell death (Yang et al., 1995).
Most members of the family have sequence identity, clustered in two 
conserved regions BH1 and BH2 (Fig. 1.4). Site-directed mutagenesis of BH1 and 
BH2 in Bcl2, showed that these domains are important for binding to Bax. In 
addition, single amino acid substitutions (Glyl42 with either Ala or Gla) in BH1 and 
(T rp l88 to Ala) in BH2 completely disturb Bcl2 binding to Bax and abrogate the 
death repressor effect of Bcl2. However, its homodimerisation property is not 
affected (Yin et al., 1994). The same effects were observed for BclxL (Sedlak et al.,
1995).
Bcl2 family members interact with each other in influencing cell death 
pathways (Craig, 1995). Bcl2 and BclxL form heterodimers with Bax and the relative 
amounts of Bcl2 or BclxL and Bax determine viability during growth factor 
deprivation with an increase in the amount of Bcl2 or BclxL relative to Bax promoting 
survival and an increase in the amount of Bax promoting death (Oltvai et
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tf/.,1993).Thus, the balance of Bcl2 family interactions is very fine and the slightest 
change could lead to either survival and hence tumour formation or apoptosis.
Both Bcl2 and BclxL are localised to mitochondria where they prevent 
apoptosis by blocking cytochrome c release and therefore caspase activation 
(Kharbanda et a l, 1997; Yang et al, 1997). Mitochondria play a pivotal role in a cell 
death pathway as cytochrome c is released from mitochondria in cells undergoing 
apoptosis (Kluk et al., 1997). Cytochrome c release results in caspase activation 
which in turn activates other death factors and leads to cell death (Bossy-Wetzel et 
a l,  1998).
The Bcl2 family genes also interact with other gene families e.g. Bcl2 has been 
shown to synergise with R-ras, c-Myc and Piml proteins (Fanidi et al., 1992; Acton 
et al., 1992). Transgenic cross breeding experiments have indicated a strong co­
operation between c-Myc and Bcl2 in tumourigenesis. E\\-c-mycfE\i-Bcl2 mice 
develop rapid onset tumours of a primitive haematopoietic cell type (Strasser et a l, 
1990, 1996; Cory et a l,  1999).
c) Eji-Pim l. Piml is another lymphoid proto-oncogene which belongs to a gene 
family including Pim2 and Pim3. Piml was first implicated in T cell lymphomas due 
to its frequent activation by proviral insertion in murine MoMLV-induced T cell 
lymphomas and it was first identified by proviral tagging (reviewed in Wilson, 1997). 
E\i-P im l transgenic mice develop T cell lymphomas with a long latency, in a dose 
dependent manner. However, its role in human lymphomas is not yet clear. 
Transgenic cross breeding between E\i-c-myc and E\i-P im l mice showed a dramatic 
synergy between the two genes. E\i-c-myc/E\x-Piml foetuses succumb to 
lymphoblastic leukaemia perinataly (Verbeek et a l, 1991). In addition, proviral 
tagging showed that Piml as well as Pim2 are frequently activated by MoMLV in 
E\i-c-myc mice (Haupt et al., 1991; van Lohuizen et a l,  1991; Berns et a l, 1994). 
Similarly, either c-myc or N-myc is usually activated in E\i-P im l transgenic mouse 
tumours. This is suggestive of a strong co-operation between the two gene families.
Piml codes for a serine/threonine kinase which may regulate the expression of 
transcription factors such as c-Myc, cJun, cMyb. There is evidence that it may
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inhibit apoptosis as well as differentiation (Allen and Bems, 1996). Lilly et al., 
(1999) reported that Piml prolongs cell survival and inhibits apoptosis-related 
mitochondrial disfunction in part through a Bcl2-dependent pathway. Bcl2 
expression is regulated by transforming proteins or signal transduction mediators 
which promote cell survival such as vH-ras gene product (Kinoshita et al., 1995a), 
activated cMyb (Salomoni et al., 1997), GMCSF (Kinoshita et al., 1995b) and 
activated Jak2 (Sakai and Kraft, 1997). Piml is regulated by GMCSF (Polotskaya et 
al., 1993; Sato et al., 1993) and Jak2 (Sakai and Kraft, 1997). Some studies suggest 
that since Piml and Bcl2 share at least some upstream regulators it is possible that 
there is a linear relationship between the two genes while other studies are suggestive 
of a synergistic interaction between the two genes to enhance lymphomagenesis. 
Thus, the first assumption is supported by the findings that Piml supported Bcl2 
mRNA expression after IL3 withdrawal without a corresponding suppression of Bax 
mRNA expression (Lilly et al., 1999). Moreover, Piml may act as a normal 
upstream regulator of Bcl2 expression possibly through regulation of cMyb activity 
via the p i00 transcription factor (Leverson et al., 1998). However, other studies 
involving transgenic mice suggested that Piml inhibits apoptosis in a Bcl2- 
independent manner (Acton et al., 1992).
d) O ther B cell oncogenes. Proviral activation of the Bmil gene has implicated 
Bmil as a collaborator of c-Myc in lymphomagenesis. The Bmil gene encodes a zinc 
finger protein related to the Drosophila Polycomb gene family. Bmil is believed to 
be important in the regulation of the proliferation of haematopoietic cells throughout 
pre- and postnatal life (Bems et al., 1994; Alkema et al., 1997).
Gfil was isolated from the p a ll locus. Proviral insertions in this locus lead to 
overexpression of Gfll (Schmidt et al., 1996; Scheijen et al., 1997). The Gfil protein 
functions as a transcriptional repressor. Gfil overexpression can extend 
haematopoietic cell survival upon withdrawal of growth factors in culture, probably 
through its ability to inhibit the expression of Bax (an apoptosis promotor) (Grimes 
et al., 1996a; 1996b; Zornig et al., 1996).
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A number of other oncogenes which co-operate with c-Myc in tumourigenesis 
(demonstrated by transgenic cross-breeding experiments) include N-ras (Harris et al, 
1988a; Alexander et al., 1989) a cytoplasmic G protein (Harris et al., 1988b), 
cyclinDl (Lovec et al., 1994), v-abl a tyrosine kinase (Rosenbaum et al., 1990) as 
well as tumour suppressor gene mutations (usually loss of function) such as p53. 
Interestingly, p53 mutations have been observed in sBL and eBL-derived cell lines 
(Farrell etal., 1991).
1.5 EBNA 1 and complementation groups of co-operative genes in 
lymphomagenesis
A combination o f the results of several studies of oncogene synergy in 
lymphomagenesis suggest that there are at least three different complementation 
groups of genes involved in tumour initiation and development (Fig. 1.5) (Wilson,
1997). One of the groups comprises the Myc family genes which are involved in cell 
proliferation. A second group contains the Pim family genes whose function is not 
very clear yet. The third group includes a number of different genes or factors which 
act to inhibit apoptosis, differentiation or senescence. The groupings are based on 
complementation studies in transgenic mice. For example, c-myc is never found 
activated in E[i-N-myc or E\i-L-myc tumours which suggest that they can substitute 
for c-Myc function in vivo and that their actions are redundant to some extent. 
Therefore these genes form one group (Adams and Cory, 1991b). In addition, 
crossing the strains of transgenic mice shows no synergy in lymphomagenesis, while 
a combination of transgenic cross breeding and proviral insertional mutagenesis 
helped considerably in the identification of co-operating genes between different 
complementation groups. For example, Bcl2 is an apoptosis inhibitor and Myc 
family proteins induce proliferation. Therefore, deregulated expression of both of 
these proteins could lead to accelerated tumour development (Strasser et al., 1990; 
Fanidi et al., 1992; Wagner et al., 1993). However, the mono- or oligoclonality of 
these tumours suggests that these two proteins, even together, are not sufficient for 
complete tumourigenesis.
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Activation of Bmil and Gfil in the same tumour is never seen and thus these 
two genes can be placed in the same complementation group. However, in tumours 
induced by proviral insertion of MoMLV in E p-P im l transgenic mice deregulated c- 
myc and Gfil co-expression has been observed placing Piml, c-myc and Gfil in three 
different groups (Bems et al., 1994; Schmidt et al., 1996; Scheijen et al., 1997).
Factors within a group could act in parallel pathways with redundant 
outcome. For example, MoMLV infection in either E\x-Bcl2 mice or p53  null mice 
did not show a dramatic acceleration in tumour development, whereas MoMLV 
infection in E \x-c-myc mice showed marked synergistic action. Therefore, MoMLV 
itself may lead to some apoptotic protection and is thus included in the same group 
as bcl2 and p53 loss or mutation (Acton et al., 1992; Baxter et al., 1996). 
Alternatively, the members of the same complementation group could act on the 
same signal transduction pathway but at different points. It has been suggested that 
Bcl2 and p53 can work as a repressor and effector in the same apoptosis pathway 
(Marin et al., 1994).
1.6 EBNA 1 transgenic mice
The important findings that EBNA 1 plays a key role in the life cycle of 
EBV, and is the only viral protein consistently expressed in EBV associated diseases, 
and in particular it is the only viral protein expressed in eBL, formed the basis for the 
construction of the EBNA 1 expressing transgenic mouse model (Wilson and Levine, 
1992, Wilson et al., 1996). Transgenic mice were generated harbouring a transgene 
designed to direct EBNA 1 expression to the B cell compartment. The transgene 
links the EBNA 1 coding region of the B95-8 strain of EBV to the polyoma virus 
(Py) early promoter and mouse IgH intronic enhancer (Ep; Wilson and Levine, 1992, 
Fig. 1.6). From the ten lines generated only mouse lines 26 and 59 expressed the 
protein and succumbed to monoclonal B cell lymphoma, albeit with different disease 
latency periods. Mice of line 26 have a higher tumour incidence at an earlier age of 
onset (4-12 months) and expressed higher levels of EBNA 1 RNA than mice of line 
59 (tumour onset 18-24 months). The differences in the tumour incidence may be
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due to the different expression patterns of the transgene in each line. Alternatively, it 
might be that the expressed protein in each of the lines has different oncogenic 
abilities. Moreover, it is possible that the transgene may have picked up a mutation. 
However, sequence analysis of line 59 tumour DNA revealed that the transgene is 
wild type B95.8. In addition using a single strand confirmation polymorphism 
(SSCP) analysis no mutations were found in line 26 transgene although it has not 
been sequenced (JBW pers. com.).
The hallmark of the disease of transgenic positive mice of both lines is a 
massive enlargement of the spleen, liver and/or lymph nodes (LNs), which are replete 
with neoplastic cells. The morphology of the tumour cells from these lines varies at 
different stages of B cell development. Notably, all have IgH locus rearrangements as 
demonstrated by Southern blot analyses, which also revealed that these lymphomas 
are monoclonal (Wilson et al., 1996). Although the latency differs between the two 
lines the lymphoma pathology is the same and is attributable to the EBNA 1 
transgene. Moreover, the correlation of transgene expression and lymphoma 
phenotype is absolute, revealing that the expression of EBNA 1 can predispose B 
cells to lymphoma. As such, EBNA 1 can be regarded as a viral oncogene.
The fact that the lymphomas arising in these mice are monoclonal suggests 
that EBNA 1 is not sufficient for complete tumourigenic conversion of B cells. 
Therefore, other cellular genes may be involved, which either mediate the oncogenic 
action of EBNA 1 or they may co-operate with it in the onset of oncogenesis.
1.7 Mechanism of action of EBNA 1 and co-operative factors in oncogenesis
Although the major roles of EBNA 1 in the regulation of viral RNA 
expression and DNA replication are well characterised, the effects of the EBNA 1 
protein on cellular components or factors are not well understood. EBNA 1 may 
exert its oncogenic effect through binding to cellular DNA sequences directly or 
indirectly and modifying transcription. Alternatively, EBNA 1 could modify DNA 
interactions (such as recombination), through binding to RNA and possibly effecting
4 0
translation, through other protein-protein interactions or through a combination of 
the above (reviewed in introduction section 1.3).
An obvious property of EBNA 1, which could be causal in its oncogenic 
function, is its ability to transactivate transcription. In transactivating cellular genes, 
EBNA 1 could directly regulate the expression of cellular proto-oncogenes known to 
be associated with lymphoproliferative disorders. Alternatively, EBNA 1 could 
modulate the expression of other genes which in turn effect the expression of proto- 
oncogenes or tumour suppressors.
Alterations of the c-myc gene structure and expression have been observed in 
many tumours including BL in which c-myc mRNA levels were higher than normal, 
and about 2 to 5 times increased relative to EBV-immortalised lymphocytes (Taub et 
al., 1984). A very interesting fact is that the lymphoma phenotype described earlier 
(section 1.5) for both EBNA 1 expressing lines 26 and 59 has a striking resemblance 
to that described for E \i-c-myc transgenic mice (Adams et al, 1985). The phenotypic 
similarity of these lymphomas is suggestive of the possibility that the tumourigenic 
action of EBNA 1 is mediated through c-Myc. However, direct transactivation of c- 
myc by EBNA 1 has not been reported. Moreover, there are no consensus EBNA 1 
binding sites found within the c-myc promoter and c-Myc has not been shown to be 
replaced by EBNA 1 in tissue culture assays. Furthermore, several lines of evidence 
from our laboratory indicate that EBNA 1 co-operates with c-Myc in 
lymphomagenesis and therefore does not act though it.
The other two members of the family, N-myc and L-myc, are also oncogenic 
(reviewed in section 1.4), although they differ in their oncogenic ability. 
Interestingly, in E[i-N-myc and E \i-L-myc transgenic tumours, no c-Myc expression 
was detected which is suggestive of a negative regulation of c-Myc expression and 
that N-myc and L-myc can substitute for c-Myc function in vivo (Adams and Cory, 
1991a and 1991b). Thus it can be postulated that EBNA 1 may also co-operate with 
N-myc and L-myc in tumourigenesis.
As mentioned earlier c-myc strongly co-operates with Bcl2 in transgenic 
cross-breeding experiments, (section 1.5). Since EBNA 1 co-operates with c-Myc,
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then factors which synergise with deregulated Myc expression in tumourigenesis 
could be redundant in the presence of EBNA 1. Transgenic cross-breeding 
experiments between EpEBNA 1 and E \l-B c12  mice showed that EBNA 1 is 
redundant with Bcl2 in that the survival or death rate between bi-transgenic mice and 
single transgenic controls was similar (Fig. 1.7). Therefore, EBNA 1 may act through 
it or in the same way as Bcl2 (conducted by M. Drotar and J. Coy in our laboratory, 
Tsimbouri et al., in preparation).
Piml also co-operates with c-Myc in lymphomagenesis which makes it a 
likely candidate for co-operation with EBNA 1. Data from cross-breeding 
experiments between E\i-Piml and EpEBNA 1 in our laboratory are too preliminary 
to be able to interpret co-operative action.
Proviral insertional mutagenesis in Efx-c-myc mice has identified a selection of 
genes which co-operate with c-Myc in tumourigenesis. These may also co-operate 
or be redundant with EBNA 1 in lymphomagenesis.
An alternative possible way in which EBNA 1 could exert its oncogenic effect 
is by modulating the cellular environment. One such mode of action could be through 
influencing the recombinogenic machinery which is active during B cell differentiation 
in generating functional immunoglobulin loci. This is supported by an observation 
which suggested that in EBV-positive BL cell lines, latent EBV gene expression (in 
the absence of LMP1 expression) correlates with increased transcription of the 
recombination activating genes Ragl and Rag2 (Kuhn-Hallek et al, 1995). The 
induction of RAG expression either directly or indirectly as a consequence of delayed 
cell maturity, may result in genomic instability. A very interesting observation is 
that, all of the EBNA 1 transgenic mouse lymphomas have undergone IgH 
rearrangement, as detected using a J-region probe (Wilson JB, personal 
communication).
Rag gene expression begins at the earliest stages of lymphocyte development 
(Hardy et al., 1991; Turka et a l, 1991; Wilson et a l,  1994; Grawunder et al, 1995b). 
In developing B cells, Rag transcript levels transiently decrease after successful 
immunoglobulin heavy chain gene rearrangement and increase again during light chain
4 3
gene rearrangement in pre-B cells (Grawunder et al, 1995b). Rag gene transcription 
persists in surface IgM+ immature bone marrow B cells but is absent in mature IgD+ 
peripheral B cells (Grawunder et al, 1995a). It was recently demonstrated that 
alteration of chromatin structure in the promoter region of Ragl gene, in addition to 
other control elements outside of the promoter region, is one of the mechanisms 
regulating tissue specific expression of the human Ragl (and possibly Rag2) gene(s) 
(Kitagawa et al, 1996). Post-translational regulation is also important for regulating 
Rag expression. Rag2 is regulated in a cell cycle dependent fashion and accumulates 
at G0/G1. Upon entry into S-phase Rag2 is phosphorylated and targeted for 
degradation by a cell cycle-dependent kinase (Lin and Desiderio, 1993; Grawunder et 
a l,  1996). In addition, it has been suggested that Rag2 may influence the stability of 
Ragl protein (Grawunder et a l , 1996). Using nuclear extracts from B cell lines, it 
was recently demonstrated that BSAP (PAX5, a B cell specific transcription factor) 
binds to a conserved sequence o f Rag2 promoter (Lauring and Schlissel, 1999) and 
regulates Rag2 expression. In addition, Verkoczy and Berinstein (1998), using a 
differential display approach, cloned BSAP as a transcript whose expression 
correlated with high levels of Rag2 transcription. Moreover, in this same region 
upstream of the Rag2 promoter there are potential binding sites for Ikaros and M yb 
which are essential factors expressed at multiple stages of B and T cell development 
(Luscher and Eisenman, 1990; Georgopoulos et al, 1997).
EBNA 1 is the only viral antigen which is consistently expressed in BL. 
However, other viral antigens could play a role in initiating and/or contributing in the 
tumour formation. Moreover, other cellular genes, either known or even completely 
novel ones could co-operate with EBNA 1 in the onset of tumourigenesis. Evidence 
from cross breeding experiments in our laboratory showed that EBNA 1 co-operates 
with c-Myc and is redundant with Bcl2 in lymphomagenesis. Therefore it can be 
postulated that EBNA 1 may be a member of the oncogenes which act to prevent cell 
death or cell differentiation such as Bcl2 and thus it may not be expected to co­
operate with other genes involved in apoptotic regulation.
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1.8 Project Aims
This research project has involved the analysis of EuEBNA 1 transgenic mice at the 
pre-tumour stage in order to elucidate the mechanism of action of EBNA 1 as an 
oncogene in vivo. The problem was divided into two areas o f study:
I) An examination of the effects of EBNA 1 action on the expression of key cellular 
genes in the B cell growth and differentiation pathways in vivo. Transgenic 
experiments in our laboratory demonstrated that EBNA 1 is an oncogene and 
responsible for the tumours arising in the EpEBNA 1 positive mice (Wilson and 
Levine, 1992; Wilson et al., 1996). EBNA 1 is a transcriptional transactivator and it 
is likely that it can regulate the expression of cellular genes involved in key pathways, 
either directly or indirectly by exerting its oncogenic action through or in the same 
way as them.
II) The investigation of influence of EBNA 1 on the B cell phenotype and properties. 
EBNA 1 could affect B cell phenotype through deregulating the genes responsible for 
normal B cell maturation and/or differentiation.
Approaches 
Chapter 3. B cell phenotype and growth characteristics
a) B cell phenotype
In order to evaluate the effects that EBNA 1 may have on B cell differentiation, 
spleen and bone marrow cells were collected from EpEBNA 1 mice and negative 
sibling control mice and fluorescence activated cell sorting (FACS) analysis using 
fluorescent conjugated antibodies was performed. Antibodies against B cell surface 
markers that are expressed differentially throughout differentiation were used and 
immunoglobulin gene expression characterised. This was conducted in order to 
evaluate the proportions of the various cell types within the tissue compartments as 
well as the stages of their maturation.
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b) Transgenic B cell properties: Cell survival
In order to gauge any effects of EBNA 1 on cell survival and /or apoptosis spleen and 
bone marrow cells were cultured under standard conditions for lymphocytes with or 
without the presence of growth factors. Cell survival or apoptosis over time was 
monitored.
Chapter 4 Effects of EBNA 1 on cellular gene expression I: selected genes
To investigate if EBNA 1 effects cellular gene expression in vivo before the
*
onset of tumourigenesis, slot blot analysis was performed using RNA samples. The 
slot blots were probed with selected genes that were postulated to be effected by 
EBNA 1, particularly members of the Bcl2 family. The blots were quantified by 
phosphoimaging and the data were statistically analysed for significant differences 
using the statistics program Minitab.
Chapter 5 Effects of EBNA 1 on cellular gene expression II: Differential 
expression
A different approach used to investigate the effects of EBNA 1 on cellular 
gene expression was taken using the Mouse Atlas Expression array; a cDNA macro­
array based technique very useful in profiling differential gene expression. 
Confirmation of gene de-regulation was subsequently done by slot blot analysis of 
pre-tumour and tumour samples. The data were statistically analysed for significance 
using the statistics program Minitab.
To test if the observed differential expression was apparent at the protein 
level, protein extract samples were western blotted with selected antisera and 
quantified by densitometric analysis. Furthermore, DNA binding activity (where 
appropriate) was assayed by band shift assays.
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Antisera.
anti-BclxL
anti-CD40
anti-cFos
anti-pancFos
anti-FosB
anti-Fral
anti-Fra2
anti-cJun
anti-JunB
anti-JunD
anti-CD45R/B220
anti-CD45R/B220
anti-CD90(Thy 1.2)
anti-IgD
anti-IgM-FITC
anti-IgM-PE
anti-slg
anti-Thb
anti-rabbit-HRP 
anti-active™ MAPK 
anti-ERK 1/2
MKK4
SAPK/JNK
R&D systems, rabbit polyclonal anti-BclxL, cat.no. AF800
Serotec, Rat anti-mouse CD40, cat.no.MCA 1143
Santa Cruz, cat.no. SC-52-G
Santa Cruz, cat.no. SC-253
Santa Cruz, cat.no. SC-1670
Santa Cruz, cat.no. SC-183
Santa Cruz, cat.no. SC-604
made at the Beatson Institute, Bearsden, no. 730-5
Santa Cruz, cat.no. SC-73
Santa Cruz, cat.no. SC-74
PharMingen, FITC conjugated rabbit polyclonal anti-mouse 
CD45R, cat.no. 01124A
Sigma, R-Phycoerythrin conjugated monoclonal anti-mouse 
CD45R purified rat immunoglobulin,cat.no. P-3567.
Sigma, FITC conjugated monoclonal anti-mouse Thy 1.2,
purified rat immunoglobulin, cat.no.F-7650
Southern Biothech Associates Inc, FITC conjugated
monoclonal anti-mouse IgD, cat.no. 1120-02
Sigma, FITC conjugated monoclonal anti-mouse IgM, cat.no.
F-7122
Sigma, R-Phycoerythrin conjugated monoclonal anti-mouse, 
cat.no.P-5185
Sigma, FITC conjugated goat anti-mouse polyvalent immuno­
globulins (IgA, IgG, IgM) affinity isolated antibody, cat.no. 
F-1010
Sigma, FITC conjugated monoclonal anti-mouse Thb, purified 
rat immunoglobulin, cat.no. F-3402 
New England Biolabs, cat.no.7071
Promega, (pTEpY) rabbit polyclonal antibody, cat.no. V8031 
Promega, rabbit polyclonal antibody, cat.no. V I141 
phospho-SEKl/
NewEngland Biolabs, antibody (Thr223) cat.no. 915IS 
NewEngland Biolabs, antibody recognises total SAPK, cat.no. 
9252
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Isotype controls
FITC: Serotec, Rat IgG2a negative control FITC, anti-mouse cat.no.
MCA1212F
PE: Serotec, Rat IgG2a negative control PE, anti-mouse cat.no.
MCA1212PE
2.1.2 Cell lines
• Line 26 primary spleen and bone marrow cells
• 3959:48 LN cells derived from a lymphoma from a transgenic mouse harbouring 
EpEBNA 1 (line 59) and EpLMPl (line 39)
• L 929 mouse fibroblasts: transfected with mouse CD40-ligand (K47)
transfected with vector only control cells (K5)
• Rat 1 fibroblast cell line
2.1.3 Growth Factors
IL2 Sigma, Recombinant mouse IL2, cat.no. 10523
IL4 Sigma, Recombinant mouse IL4, cat.no. 11020
IL6 Sigma, Recombinant mouse IL6, cat.no. 19646
IL7 Sigma, Recombinant mouse IL7, cat.no. 14892
2.1.4 Oligonucleotides MWG BIOTECH for EBNA 1 amplification:
oligoA 5 ’ CCCTTCCTCACCCTCATCTCC3 ’
oligoB 5 ’GCTCTCCTGGCTAGGAGTCACG3 ’
oligoS 55 CCATATACGAACACACCGGC3 ’
oligoT 5’CATCCGGGTCTCCACCGCGC3’
Fig. 2.1 oligonucleotide position in the EBNA 1 coding sequence
E B N A l  c o d i n g  s e q u e n c e
B  A
S  T
2.1.5 Plasmids and probes
(For the methods used to generate and isolate all probe fragments see Methods) 
Table 2.1 Epstein-Barr Virus derived sequences___________________________
G e n e P l a s m i d  L a b . n o . R e s t r i c t i o n
d i g e s t
F r a g m e n t
s i z e
R e f e r e n c e
3 ’ E B N A  1 1 1 4 B s t X I / E c o R I 1 K b W i l s o n  et al., 1 9 9 2
48
Table 2.2.Mouse derived sequences
G e n e P l a s m i d
L a b . n o .
R e s t r i c t i o n
d i g e s t
F r a g m e n t
s i z e
R e f e r e n c e
Gene
Families
Bcl2 family
B a d 4 6 7 E c o R I 0 . 7 K b Y a n g  et al., 1 9 9 5
B a x 4 6 6 E c o R I / X h o I 0 . 7 6 5 K b O l t v a i  et al., 1 9 9 3
B c l 2 6 7 E c o R I / H i n d l l l 0 . 8 6 5 K b N u n e z  et al, 1 9 8 9
B c l x , 4 6 8 E c o R I 1 K b B o i s e  et al.,  1 9 9 3
Jun family
c J u n 5 0 4 B a m H I 1 . 7 K b A n g e l  et al., 1 9 8 8
J u n B 5 0 2 E c o R I 1 . 8 K b R y d e r  et al., 1 9 8 8
J u n D 5 0 3 E c o R I 1 . 7 K b R y d e r  et al., 1 9 8 9
Myb family
A m y b 4 8 8 S a c I / P v u I I 0 . 6 6 3 K B F a c c h i n e t t i  et  al, 1 9 9 7
c M y b 4 9 0 N c o l / M l u l 1 . 9 K b B a d i a n i  et al., 1 9 9 4
Rag family
R a g l 2 9 4 ,  3 0 7 B a m H I / X b a l 3 . 4 K b R o m a n  &  B a l t i m o r e ,  
1 9 9 6
R a g 2 2 9 5 E c o R I 1 . 8 K b C u o m o  et al., 1 9 9 6
Genes
Araf 2 7 7 E c o R I 2 . 6 K b H u l e i h e l  et al.,  1 9 8 6
B2 5 1 4 E c o R I / P s t I 0 . 2 4 K b W h i t e  et al, 1 9 8 9
Bm il 3 2 5 E c o R I 2 . 2 K b H a u p t  et al, 1 9 9 1
c-Myc 5 6 X b a l 3 . 1 K b V e r b e e k  e t al.,  1 9 9 1 ,
Cyclin D1 2 7 2 E c o R I 1 . 3 K b N a k a g a w a  et al., 1 9 9 7
EBF 5 0 5 N c o l / N o t l 0 . 4 8 K b H a g m a n  e t al., 1 9 9 5
Egrl 5 1 0 E c o R I 2 . 5 K b C a r i c a s o l e  e t al., 1 9 9 6
cFos 2 6 9 B g l l l / P v u I I 1 . 3 K b T r e i s m a n ,  1 9 8 5
GAPDH 2 7 2 B a m H I / S a c I 0 . 3 1 6 K b S a b a t h  et al., 1 9 9 0
G fil 3 2 3 E c o R I 2 . 8 7 K b S c h e i j e n  et al., 1 9 9 7
GMCSF 4 7 3 P s t I 1 . 2 K b P a r k  et al., 1 9 9 2
HCK 5 1 5 E c o R I / N c o I 0 . 8 5 K b Z i e g l e r  et al., 1 9 8 7
hnRNPD 5 2 2 N o t l 2 K b D e m p s e y  et al, 1 9 9 8
IgH
( J  r e g io n )
7 9 X b a l / X h o l 0 . 9 K b W i l s o n  et a l ,  1 9 9 2
Ikaros 5 0 6 P C R  p r o d u c t 0 . 7 5 K b H a h m ,  1 9 9 4
MDM2 2 7 8 E c o R I 1 . 5 K b C h e n  et al., 1 9 9 3
M IP la 4 7 4 E c o R I / X h o I 0 . 3 K b D a v a t e l i s  et al., 1 9 8 8
Nras 5 2 1 P s t l / S s t l 1 . 6 5 K b C h a n g  et al., 1 9 8 7
Pax5 5 0 9 S a c I I / S a l l 0 . 3 7 3 K b A d a m s  et al., 1 9 9 2
Picl 5 1 3 X b a l / X h o l 1 . 4 K b H o w e  et al., 1 9 9 8
Piml 2 6 4 B a m H I 1 K b C u i p e r s  et al., 1 9 8 4
PML 5 1 5 E c o R I 1 . 6 K b G o d d a r d  et al., 1 9 9 5
p l6 4 5 4 X h o l 1 K b Q u e l l e  et al., 1 9 9 5
p53 7 1 S t u l / X h o l 1 K b O r e n  &  L e v i n e ,  1 9 8 3
s a t b i I2 511 H i n d l l l / B a m H I 1 . 2 K b N a k a g o m i  et al., 1 9 9 4
s a t b i 13 5 1 2 H i n d l l l / B a m H I 1 . 1 K b N a k o g o m i  e t a l ,  1 9 9 4
T cell 
receptor
JP1 4 6 3 E c o R I / B a m H I 3 . 3 K b P a l a c i o s  &  S a m a r i d e s ,  
1 9 9 1
J P 2 4 6 4 E c o R I / H i n d l l l 1 . 8 K b P a l a c i o s  &  S a m a r i d e s ,  
1 9 9 1
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2.1.6 Reagents and Equipment
Acrvlamide:
Agarose:
Animal supplies:
Annexin V-FITC
Antibiotics:
Autoradiography:
Cassettes:
Film:
Film development: 
Intensifying screens:
Phosphoimager:
Intensifying screen:
Bag sealer:
Buffered phenol:
Buffers:
Camera:
Centrifuges:
Chemicals:
Biorad
SeaKem LE agarose, Flowgen 
Low melting point (LMP), Gibco 
Mouse supplier, Harlan Olac 
Anaesthetic (Fluothane liquid), Zeneca Ltd 
Anaesthetising chamber, Fluotec 
Cauterising iron, International Market Supply 
Ear punch, ORME scientific 
Surgical instruments
Clontech, ApoAlertTM Annexin V-FITC cat.no. 8133-1 
Pharmingen, Annexin V-FITC cat.no. 65874H
Ampicillin, Sigma 
Kanamycin, Sigma
Genetic Research Instrumentation (GRI) Ltd.
Kodak XAR 
X-ograph compactX2 
GRI
Fuji
Fuji
Vacuum bag sealer, Salton
Buffer-saturated phenol, pH 7.5, Gibco
MOPS-E, Boehringer 
Tris-base, Boehringer
UVP image processor, Mitsubishi video 
copyprocessor
Beckman centrifuge model J2-21 
Eppendorf centrifuge 5415C 
Heraeus labofuge 400
Acetic acid, Fisher Scientific 
Acetone, Fisher Scientific 
Biotin-16dUTP, Boehringer 
BSA, Sigma
Chloroform, Fisher Scientific 
DAB, Sigma 
DEPC, BDH 
DMBA, Sigma 
Ethanol, Fisher Scientific 
Ethidium Bromide, Boehringer 
Formaldehyde, BDH 
Formamide, Sigma 
Gelatin, Sigma
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Detergents:
Electrophoresis: 
Electroblotter 
(DNA/RNA): 
Electrophoresis tank 
(DNA/RNA):
Power pack:
lOObp ladder:
1Kb ladder:
Enzymes:
FACS machine: 
Films:
Heating blocks:
Homogeniser:
Hotplates:
DNA/RNA 
hybridisation: 
Hybridisation: 
Pipette tips:
Probe purification:
Radio-isotopes:
Random primers: 
Scintillation counter: 
Scintillation fluid:
Membranes:
Microscopy:
Hydrogen peroxide, Sigma 
Isopropanol, Fisher Scientific 
Methanol, Fisher Scientific 
Mercaptoethanol, Bio-rad 
Propidium Iodide, Molecular probes
SDS, Fisons/Sigma 
Triton X-100, Biorad 
Tween 20, Biorad
TE series TransphorElectroblotter, Hoeffer
Kodak international biotechnologies inc 
0-250V; 0.25A, Kikusui electronics
Gibco/Promega
Gibco
DNA restriction enzymes, Gibco 
Exo(-) Klenow, Stratagene 
Lysozyme, Sigma 
Proteinase K, Boehringer
Terminal deoxynucleotidyl transferase TdT, Boehringer
Trypsin, Sigma
DNA T4 ligase, Boehringer
Becton-Dickinson flow cytometer
Mitsubishi thermal paper K65HM FP4
Eppendorf thermomixer 5436
Kinematica polytron
Fisons
Hybaid midi oven and Hybaid hybridisation tubes 
Aerosol Resistant Tips (ART), Gibco
Push column beta shield device and Nuctrap probe purification 
cc^umns, Stratagene.
a  P dCTP (3000ci/mmol). Supplied in 0-4°C storage liquid 
Easytide forrn  ^NCN or Dupond.
Amersham a 3 P dATP (3000ci/mmol).
Stratagene Prime-IT II Kit (including buffers and Klenow) 
Beckman LSI801 liquid scintillation systems 
Ecoscint scintillation solution, National Diagnostics.
Biodyne A+B, Pall biosupport membranes 
Imobillon P membrane, Millipore
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Microscopes:
Slides:
PCR:
Buffer+MgCl2:
dNTPs:
Oligonucleotides: 
PCR cycler:
DNA
purification columns: 
Taq polymerase:
Protein protocols:
RNA protocols: 
Total RNA 
extraction:
PolyA+RNA
extraction:
Tubes:
Shaking platforms:
Slot-blot apparatus:
Spectrophotometer:
Stirrers:
Tissue culture: 
Medium:
FCS:
Fungizon:
L-glutamine:
Mytomycin:
Penicillin:
Streptomycin:
DMSO:
Freezing container:
In c u b a to r:
P las ticw are :
Olympus CK2 (cell counts and tissue culture) Leitz orthoplan 
(Fluorescence, Karyotyping and higher power magnification 
[x25-xl00])
Superfrost, Menzel-Glazer
Gibco
Boehringer
MWG BIOTECH
Appligene ONCOR Crocodilelll
PTC-200, MJ Research
Stratagene
Gibco and Stratagene Pfu turbo DNA Polymerase 
Time saver^M CDNA synthesis Kit (RT-PCR), Pharmacia
Aprotinin,
Benzamidine,
DTT,
Dye Reagent Concentrate, Biolab 
Hepes,
Leupeptin, 
o-Vanadate,
Pepsatin,
PMSF, Sigma
TRI-REAGENT from Sigma was used for all total RNA 
extractions.
Oligotex mRNA Kit from Qiagen, used for the isolation of 
polyA+ from total RNA.
6ml Falcon tubes, used to homogenise tissues and isolate RNA. 
1.5ml RNAse-free Eppendorf tubes, used for the collection and 
storage of both total and polyA+ RNAs.
Rocking, rolling and shaking platforms, Hoeffer
Schleicher and Schuell minifold 2
Spectronic 601, Milton Roy
Fisons
RPMI1640 without L-glutamate, Gibco
Gibco
Gibco
Gibco
Sigma
Gibco
Gibco
Sigma
Nalgene
Heraeus
C o rn in g
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UV equipment:
S tra ta lin k e r : U V  s tra ta lin k e r  1800, S tra ta g e n e
T ra n s il lu m in a to r :  U V P  u ltra v io le t T ra n s illu m in a to r , G R I
W a te rb a th s : G ra n t
2.2 Formulation of the most frequently used solutions
A n n e x in  V -F IT C
A n n e x in V -b in d in g
b u ffe r
A n n e x in  V -F IT C  b u ffe re d  in: 
5 0 m M  T ris , pH  8 .0  
8 0 m M  N a C l 
Im M  E D T A
0 .0 9 %  (w /v ) so d iu m  az id e  
0 .2 %  (v /v )  B S A
lO m M  H e p e s /N a O H , p H  7.4 
140m M  N a C l 
2 .5 m M  C a C l2, so lu tio n  s to re d  a t 4°C
C h u rch  B u ffe r
D e n a tu r in g  so lu tio n
1% (w /v) B S A  
Im M  E D T A  
5 0 0 m M  N a P O  
7%  (w /v ) SD S
0 .6 M  N aC l 
0 .4 M  N a O H
at p H  7.2
2FC
B u ffe red  neu tra l 
fo rm a lin  (5 0 0 m l)
lOx G o a t w ash
KC1 b u ffe r  (p ro te in )
lOx L o ad in g  b u ffe r  
(D N A )
4 9 .4 5 %  (v /v )  c h lo ro fo rm  
0 .1 %  (w /v ) 8 -h y d ro x y q u in o lin e  
1% (v /v ) iso a m y l a lco h o l 
4 9 .4 5 %  (v /v )  re -d is ti lle d  p h en o l 
S a tu ra ted  w ith  1M T ris  pH  8.0
50 m l o f  4 0 %  (v /v )  fo rm a lh e h y d e  
1.75g  N a H  P O  
3 .2 5 g  N a  H P 0 4 
d H 20  up to  500m l
10%  (v /v ) G o a t serum  
1.3M  N aC l
7 0 m M  N a  H P O  .2 H  O 
3 0 m M  N a k  P O * .H 20  
0 .5%  (w /v ) S o d iu m  az ide  
2 %  (v /v )  T rito n -x -1 0 0  
0 .5 %  (v /v ) T w e e n  20
0 .02  o r  0 .6 M  KC1 
2 0 m M  T ris -C l, pH  7.3 
25 %  G ly ce ro l 
1 .5m M  M g C l 
0 .2 m M  E D T A  
dH 20
0 .2 5 %  (w /v )  B ro m o p h e n o l b lu e  
0 .1 M  E D T A  p H 8 .0  
20 %  (v /v )  F ic o ll 
2 5 %  (w /v ) X C
L o a d in g  b u ffe r  
(R N A )
lO x L o a d in g  d y e  
(D N A /R N A )
M O P S -E  b u ffe r
N H 4C1 so lu tio n  
(A C T )
PB S
P B S .A
P ro p id iu m  
Io d id e  s ta in in g  sol.
P I - lx P B S  bu ffe r:
P ro te in  b u f fe rs : 
B lo ttin g  b u ffe r:
C o o m a ss ie  s ta in
G el fix in g  so lu tio n : 
M E N S A  buffer:
N u c le a r  p ro te in  
e x tra c tio n  bu ffe r:
17 .8%  (v /v )  fo rm a ld e h y d e
50%  (v /v )  p u re , d e io n ise d  fo rm a m id e
lx  M O P S -E
0 .1 %  (w /v ) B ro m o p h e n o l b lu e  
5 0 %  (v /v )  g ly c e ro l (a u to c la v e d )
0 .1 %  (w /v ) X C
Im M  E D T A  
2 0 m M  M O P S
5 m M  N a O A c  p H /N a O H /7 .0
9 v o ls  o f  N H  C l [0 .8 3 %  (w /v ) in  H  O ]
1 v o l o f  T ris  [2 .0 6 %  (w /v ) in  H 20 ,  p H 7 .6 5 ] 
c h e c k  p H 7 .2 , f il te r  s te r i lisa tio n
2 .7 m M  KC1 
1 .4 m M  K H  P O  
1 37m M  N aC l
4 .3 m M  N a 2P 0 4 p H /H C l/7 .3
0 .0 2 5 %  (w /v ) KC1 
0 .0 2 5 %  (w /v )  K H  P O  
1% (w /v )  N aC l 
0 .1 4 %  (w /v ) N a 2P 0 4
5p,g PI /m l lx P B S
200jug/m l D N A se -fre e  R N A se  (S ig m a) 
so lu tio n  a lw a y s  m ad e  fre sh  b e fo re  use
8g N aC l 
0 .2 g  KC1
1.44g  N a 2H P 0 4'7 H 20  
0 .2 4 g  K H 2P 0 4
H 20  to  1 It, pH  7 .2
2 5 m M  T ris  
1 9 2m M  G ly c in e
2 0 %  (v /v )  M e th a n o l (a n a ly tic a l g ra d e )
10%  (v /v )  A c e tic  ac id  
0 .0 0 6 %  (w /v ) C o o m a ss ie  sta in
2 5 %  (v /v )  Iso p ro p a n o l 
10%  (v /v )  A ce tic  ac id
6 2 .5 m M  T ris -H C l, pH  6.8 
2%  (w /v) SD S
5 0 m M  S o d iu m  2 -M e rc a p to e th a n o l
2 0 m M  H ep es , p H  7.9 
0 .4 M  N aC l 
Im M  E D T A , pH  8 
Im M  E G T A , pH  8 
Im M  D T T
Im M  P M S F  fre sh ly  added
lO x P ro te in  
b in d in g  b u ffe r
P ro te in  e x tra c tio n  
b u ffe r  ( to ta l):
P ro te in a s e  in h ib ito r  
m ix  20 0 x :
4 x  R e so lv in g  buffer:
R u n n in g  bu ffe r:
S D S -P A G E  gel:
10%  (v /v )  R e so lv in g
2x  S tac k in g  buffer: 
S tack in g  gel:
S ucrose  b u ffe r 
(N u c le a r  ex tra c ts ):
SSC
S T E
T A E  (5 0 x  s to ck  
s o ln .IL t)
lOOm M  H ep e s , p H  7 .9  
2 m M  E D T A  
1M  N aC l 
1 m g /m l B S A  
10%  (v /v )  g ly c e ro l
2 0 m M  H ep e s , pH  7 .9
5 m M  E D T A
lO m M  E G T A
0 .4 M  KC1
10%  (v /v )  G ly ce ro l
0 .4 %  (v /v )  T rito n  X -1 0 0
lO O m M  B e n z a m id in e  
20 0 ^ ig /m l L e u p e p tin  
200 p ,g /m l P e p sa tin A
1.5M  T ris .H C l p H  8 .8  
0 .2 4 %  (v /v )  T E M E D
0.4%  (w /v ) SD S S to re  a t 4°C  fo r  up  to  a m o n th
5 0 m M  T ris  
3 8 0 m M  G ly c in e  
0 .1%  (w /v ) SD S
gel: 2 8 m l H 2 0
14m l re so lv in g  b u ffe r
14m l B is  A cry la m id e  4 0 %  (v /v )
0 .3 3 m l 10%  (v /v )  A P S
0 .2 5 M  T ris .H C l p H 6 .8  
0 .2 4 %  (v /v )  T E M E D  
0 .2%  (w /v ) SD S
15 .5m l H 20
19 .5m l S tac k in g  b u ffe r
4m l B is  A c ry la m id e  40%  (v /v )
0 .5 8 5 m l 10%  (v /v )  A P S
0 .3 2 M  S u cro se  
lO m M  T ris , pH  7.9 
2 m M  M g A c.
3 m M  C aC l
0 .1 %  (v /v )  T rito n  X -1 0 0  
150m M  N a C l
150m M  S o d iu m  c itra te  p H /N a O H /7 .5
Im M  E D T A  
lO m M  N aC l 
lO m M  T ris .C l pH 7.5
57 .1m l G lac ia l ac e tic  acid  
3 7 .2g  N a  E D T A .2 H  O  
2 4 2 g  Tris2 base , pH8?5
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Tail solution
TBE (lOx stock 
soIn.ILt)
TBS
TE
Trypan blue 
staining solution:
Trypsin solution:
Washing buffer 
(Dynabeads)
lOOmM EDTA pH8.0 
150mM NaCl 
1% (w/v) SDS 
lOmM Tris-HCl pH7.5
55g Boric acid 
40ml 0.5M EDTA 
108g Tris base
140mM NaCl 
20mM Tris
ImM EDTA 
lOmM Tris base
pH/HCl/7.6
pH/HCl/7.6
Trypan Blue [0.4% (w/v)]
0.8% (w/v) NaCl 
0.06% (w/v) KH2P 04
0.25% (v/v) trypsin 
0.02% (v/v) EDTA 
diluted in PBS
1% (v/v) FCS final concentration in PBS
2.3 Formulation of most frequently used growth media
Agar plates
Luria-Bertani 
(L-broth)
Complete tissue 
culture medium
Methylcellulose
medium
‘Transfer’ medium:
250ml dH20
lOg Tryptone Oxoid L42 
5g Yeast extract (Oxoid) 
lOg NaCl
make up to 1 It with dH20 pH 7.54 (NaOH)
1% (w/v) Bacto-tryptone
0.5% (w/v) Bacto-yeast extract 
1 % (w/v) NaCl
RPMI 1640 medium 
5-20% (v/v) FCS
2% (v/v) L-glutamine (200mM stock)
2% (v/v) Penicillin/Streptomycin (10,000U/ml stock)
1% (v/v) methylcellulose in Iscove’s MDM,
30% (v/v) FCS,
10‘^M 2-Mercaptoethanol,
2mM L- glutamine 
lOng/ml rodent IL-7.
RPMI 1640 medium
1% (v/v) Fungizon (250mcg/ml stock)
5% (v/v) L-glutamine (200mM stock)
4% (v/v) Penicillin/Streptomycin (10,000U/ml stock)
1.5% (v/v) gentamicin (50mg/ml stock)
Freezing medium: per ml of medium add
200pl FCS (20% final volume) and
lOOpl DMSO (10% final volume)
2.4. Methods
2.4.1 Animal procedures
All mouse procedures were performed according to the Home Office 
regulations and as detailed in the project licence. Unless stated, the procedures were 
conducted by me as described in my Home Office personal licence. Where the use of 
brief anaesthesia was required, a halothane/oxygen mixture was used in an anaesthesia 
chamber.
I. Breeding and numbering of transgenic mice
All food, water and bedding requirements were handled by the technicians in 
the animal house. Pairing of breeding animals and monitoring of litters was performed 
by the animal technicians and myself. At the age of three weeks, the pups were 
weaned and males and females were separated. The mice were given numbers (in 
consecutive sequence for each line), identified by ear punching, and a small biopsy 
(tail tip of 0.5-lcm) was taken under halothane anaesthesia. The biopsy sample was 
transferred to a Eppendorf tube for subsequent genomic DNA extraction and 
assessment of the transgenic status of the animal. The mouse tail tip was cauterised 
with a hot iron to stop bleeding and sterilise the wound.
II. Monitoring animal health status
According to the procedures as described in the Home Office project licence, 
all animals were monitored regularly for signs of ill health and discomfort. Any 
animal suffering (e.g. lymphoma) was euthanised without delay and a dissection was 
performed to examine the cause of illness.
III. Mouse lines 
Line number Transgene Expression Reference
26 EpEBNAl B cells Wilson and Levine, 1992; Wilson et al., 1996 
59 EpJEBNAl B cells Wilson and Levine, 1992; Wilson et a l, 1996
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IV. Tissue collection from transgenic mice
Animals were euthanised by a schedule 1 method according to guidelines. 
Mice were always dissected in the same way.
The fur of the animal was wetted with ethanol to exclude loose hair from the 
samples. Leaving the peritoneum intact the skin of the animal was cut back with fine 
scissors and forceps, and the peripheral lymph nodes (LN) collected. The 
peritoneum was then opened and the spleen, mesenteric LNs and liver were collected 
by careful excisions. The chest cavity was then opened and the thymus and cervical 
LNs collected. Any abnormalities in any of these or other tissues were noted and the 
lesion(s) collected. Part of the lesion was then put into 10% (v/v) buffered neutral 
formalin fixative and the rest snap frozen in liquid N 2 for -70°C storage. In every 
case a piece of tail and/or the brain was also frozen for further genomic analysis and 
confirmation of transgenic status if required.
Samples in fixative were sent for histopathological analysis to a pathologist 
contracted to the Glasgow Vet. School histopathology service where necessary.
2.4.2 Mammalian cell culture techniques
I. Explantation of lymphomas
The explantation of tissues was performed under sterile conditions. Surfaces 
and equipment were always cleaned with 100% (v/v) ethanol.
The lymphoma was excised, rinsed thoroughly in lxPBS and cut in two 
pieces. The bigger piece was placed in explant transfer medium and placed on ice. 
The smaller piece was further cut in two, one piece was snap frozen and stored at - 
70°C and the other was placed in fixative for pathology. The lymphoma sample was 
transferred to a petri dish with 37°C warmed complete tissue culture medium with 
20% (v/v) FCS.
The lymphoma was cut into small pieces using a sterile scalpel or mashed 
between two microscope slides with frosted ends, and then placed in a F25cm3 
culture flask. 5ml of warm complete tissue culture medium was added and the flask 
was incubated at 37°C, 5% (v/v) C 0 2 for 3 to 5 days. Cell suspensions were then
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transferred to a new F25cm3 flask with 5-7ml complete tissue culture medium and 
incubated for further time. Cell growth was monitored and the suspension cells 
cultured in complete tissue culture 20% (v/v) FCS containing medium until their 
number expanded dramatically. At this point the growth medium was reduced to a 
10% (v/v) FCS content. The cells were sub-cultured and then stored as frozen stocks 
as described bellow.
II. Sub-culturing of mammalian cells
When the cell populations were expanded they were sub-cultured to allow 
maintenance of the cell line. In the case o f lymphoma or suspension cells, the cells 
were transferred to an appropriate volume falcon tube and pelleted in a Heraeus 400 
centrifuge at 1000rpm/194x g/rotor no.8172 for 5 minutes. The cell pellet was then 
resuspended in fresh medium at the required density.
In the case of adherent cells, the medium was aspirated and the cells were 
washed in PBS.A/EDTA. Trypsin solution was gently added over the cells and 
incubated at 37°C for 5 minutes to dislodge the cells. The cells were then pelleted in 
exactly 194xg/5mins and then resuspended in the appropriate medium at the required 
density.
III. Storage of frozen cell stocks
After the cell population had expanded, the suspension cells were pelleted as 
above and resuspended in complete tissue culture medium with 20% (v/v) FCS and 
10% (v/v) dimethyl sulphoxide (DMSO). 1ml aliquots of approximately lxlO6 cells 
were placed in 1ml cryovials and transferred in Nalgene cryo 1°C freezing container 
which was placed in a -70°C freezer for 24 hours to ensure gradual (l°C/min) chilling 
of the cells. The vials were then transferred to a liquid N 2 container for long term 
storage.
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IV. Defrosting of frozen cell stocks
Required cell stocks were removed and transferred to the culture room in a 
liquid N2 container, where they were quickly thawed in a 37°C water bath. The cells 
were washed in medium (minus FCS) by centrifugation 194xg for 5mins, to remove 
DMSO. They were then transferred to a F25cm2 flask containing 5ml of appropriate 
medium.
V. Erythrocyte exclusion
Primary cells to be treated were transferred in an appropriate sized Falcon 
tube and pelletted at 194x g for 5 minutes. The cell pellet was resuspended at a 
concentration of 3x108 cells/ml in NH4C1 buffer and incubated for 10 min at room 
temperature. This time is adequate to lyse erythrocytes because of their permeability 
to ammonium ions. 37°C does damage cells and at 4°C lysis is slower. Cells were 
immediately diluted with greater than a 5-fold excess of medium, mixed well by 
inverting the tube a few times and pelleted by spinning the tube at 194xg for 5 min. 
The supernatant was discarded, the cell pellet was resuspended in 10ml complete 
tissue culture medium or lxPBS and a cell count was then undertaken.
VI. Viable cell counting by trypan blue exclusion
Immediately before counting, cells in a 10ml suspension were evenly 
distributed by gentle pipetting. 1 OOjLtl of the cell suspension was mixed with 400jll1 
of trypan blue staining solution in a Eppendorf tube. Cell counting was performed 
using a haemocytometer. An aliquot of the stained cells was transferred to one half 
of the cleaned chamber, sufficient to cover the semi-chamber area but not flood the 
surrounding trough. Cells were counted under 40x objective and only the non-blue 
cells wholly inside the area or touching the upper and left borders of the squares were 
scored. Cell number was calculated by multiplying the average count per 0.2mm2 
squares by the dilution factor (x5 in this case) and by 104 to give the viable cell 
count/ml. (Both live and dead cells can be scored using the trypan blue-exclusion 
method because dead cells take up the dye and are stained blue).
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VII. B cell selection using DynaBeads, Dynal
Immunomagnetic cell isolation using Dynabeads Mouse panB (B220) is a fast 
and reliable method for isolation of B220 positive cells by positive selection.
i. Dynabeads washing procedure. The Dynabeads should be washed before use. 
The beads (already supplied in a buffer) were resuspended thoroughly in the vial and 
the desired amount was transferred to a Eppendorf tube. The tube was placed on a 
Dynal MPC magnetic device for 2 min and the fluid was pipetted off. l-2ml of 
PBS/1 % (v/v) FCS washing solution was added, the tube was removed from the 
magnetic device and the beads resuspended by inverting the tube. The wash was 
repeated and finally the beads were resuspended in an equal volume of washing buffer 
that was originally pipetted from the vial.
ii. Positive selection of B220 (+) mouse cells. Cells were isolated from spleen by 
squeezing the tissue between the frosted sides of two microscope slides releasing 
suspension splenocytes into PBS. Red blood cells (RBCs) were lysed, cells were 
washed in PBS and counted using the Trypan blue-exclusion method. All the 
subsequent steps were performed at 4°C to reduce any non-specific attachment of 
phagocytic cells to Dynabeads. Volumes were kept small for easier handling. After 
cell counting an estimation of the number o f target cells was made and the required 
volume of pre-washed Dynabeads mouse panB (B220) was added (100|Lil= 4 x 107 
beads/ 107 target cells) directly to the cells suspension. The contents were mixed by 
gentle vortexing for 1 second and incubated for 20min at 4°C by gentle tilting and 
rotation. The tubes were then placed in the Dynal MPC magnetic device for 2 min to 
collect the beads/cells. The supernatant was decanted and the beads/cells were gently 
resuspended in 1ml lx PBS/0.1% (v/v) FCS by gentle pipetting. The wash was 
repeated twice. At this point the isolated cells can be used for various research 
applications or stored at -70°C for later use.
Note: If detachment of the beads is required this can be achieved by overnight 
incubation of the rosetted cells at 37°C followed by agitation by pipetting. The 
detached cells are then removed in the supernatant when the tube is placed in the 
magnetic device.
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VIII. FACS of primary cells
The spleen was excised and rinsed thoroughly in EtOH and was then placed 
in cold PBS solution. The femurs, collected for bone marrow (BM) extraction, were 
rinsed in EtOH and placed in cold PBS. The tissues were transported from the 
animal house to the laboratory, in PBS on ice. They were then transferred to 3ml 
(each) of cold fresh PBS in a petri dish in the culture hood. The spleen cells were 
released as described above. The BM was obtained from the femurs using a syringe 
and forcing PBS solution through the bone. The cells were collected into 15ml Falcon 
tubes containing 10ml PBS and centrifuged 194x g for 5min. Erythrocytes were 
excluded as described above. The cells were washed twice in cold PBS and counted, 
using the trypan blue exclusion method. 5x105 cells were transferred to 1.5ml 
Eppendorf tubes for each staining. The cells were pelleted, in the bench top 
centrifuge, (300xg for 5min) and the cell pellet was resuspended in 0.5ml of PBS. 
20pl of lx “goat wash” was added, mixed by flicking the tube and incubated at 4°C 
for 20min. This blocking step was performed in order to minimise any non-specific 
binding. The cells were pelleted, washed in PBS, and resuspended in 0.5 ml PBS 2- 
4(xl (approximately lpg) of each antiserum was added, and incubated for 30min- 
lhour at 4°C (for antisera see Materials section 2.1.1). Samples were then pelleted, 
the supernatant was carefully removed, were washed in PBS once, to remove any 
residual unbound antibodies, and resuspended in 0.5ml PBS. Fluorescence was 
analysed using a Becton-Dickinson flow cytometer using 5-10 x 103 cells per sample. 
Negative staining controls were always used. Negative controls (isotype controls) 
establish background fluorescence and non-specific staining of the primary and/or 
secondary antibodies FITC or PE conjugated. They should not be reactive with the 
cells being analysed and should be used at the same concentration as the fluorophore 
conjugated specific antibody. The degree of auto fluorescence or negative control 
reagent fluorescence will vary with the type of cells under study and sensitivity of 
the instrument used.
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IX. Proliferation: Colony assay (methylcellulose cultures)
Methylcellulose culture was performed by using a modification of a technique 
described by Iscove et a l (1974). The complete methylcellulose medium for murine 
pre-B cell colony assays consists of: 1% (v/v) methylcellulose in Iscove’s M DM , 
30% (v/v) FCS, 10'4M 2-Mercaptoethanol, 2mM L-glutamine and lOng/ml rodent IL- 
7. 5xl04 BM or spleen cells were inoculated in a 1:10 (v/v) ratio to the
methylcellulose medium. 0.5ml of cells were added to 4ml medium to yield 
quadruplicate 1.1ml cultures. Because methylcellulose medium is very viscous, after 
the cells were added, it was mixed well by shaking and left to sit for lOmin to allow 
bubbles to rise to the top before dispensing. Dispensing into 22mm plates was done 
using a syringe and a 16 gauge blunt needle and then it was evenly distributed by 
gently tilting and rotating the plates. On day 7 of culture, aggregates consisting of 
approximately >40 cells were scored as a colony and aggregates consisting of 
approximately <40 cells were defined as clusters.
X. Apoptosis detection: AnnexinV-FITC/PI staining (Vermes et al., 1995)
Cells were prepared as for the FACS analysis described in section VIII. This 
approach can be used directly in normal cultures after the induction of apoptosis.
Cells were washed with cold PBS and then resuspended in lx binding buffer (see 
solutions section) at a concentration o f lxlO6 cells/ml. lOOpl of the solution (lxlO5 
cells) were then transferred to a FACS tube. 5pl of Annexin V-FITC and 10pl of PI 
were added per sample. The samples were gently vortexed and incubated for 15min 
at room temperature (20-25°C) in the dark. 400pl of lx binding buffer was added to 
each sample and cells were analysed by FACS within 1 hr. The early apoptotic cells 
are Annexin V+/PI-. Cells that stain positive for both Annexin V-FITC and PI are 
either in the end stage of apoptosis, undergoing necrosis, or are already dead. Cells 
that stain negative for both Annexin V-FITC and PI are alive and not undergoing any 
measurable apoptosis.
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XI. Rat 1 cells -  MAPK and SAPK activation controls
For the MAPK activation controls, Rat 1 cells were grown to 70% confluence 
in 5% (v/v) Dulbeco’s medium supplemented with penicilin/streptomycin (P/S) and 
L-glutamine. The medium was then aspirated and washed once with lxPBS. The 
cells were then serum starved in medium containing only 0.25% (v/v) FCS +P/S+L- 
glutamine for 48hr. The serum concentration was then increased to 10% (v/v) and the 
cells incubated for only 15 min. Brief incubation is important because M APK 
activation is transient and maximal at about 15min. The medium was then aspirated 
and cells were rinsed with ice cold lxPBS. The cells were collected using a cell 
scraper, they were transferred and pelleted into a Eppendorf 1.5ml tube and snap 
frozen in LN2 and stored at -70°C. Negative controls were Rat 1 cells grown in 5% 
(v/v) FCS containing medium that were then frozen as above.
For the SAPK activation Rat 1 cells were grown to 70% confluence with 5% 
(v/v) FCS containing medium. Anisomycin (a protein synthesis inhibitor) was then 
added to a concentration of lOpM for 15min incubation. The medium was then 
aspirated, cells washed in ice cold lxPBS and frozen as above. Negative controls 
were Rat 1 cells grown in 5% (v/v) medium with no anisomycin treatment.
XII. CD40-ligand producer layer: Feeder layer preparation for B cell activation
CD40 ligand (CD40L) producing cells (K47) are L929 mouse fibroblasts transfected 
with aCD40L expressing construct. Control cells were L929 cells transfected with 
the vector only. All cells were cultured in RPMI medium supplemented with 5% 
(v/v) FCS, G418 (0.3mg/ml) (a selective agent permitting growth of those cells 
carrying the G418 resistant plasmid), L-glutamine and antibiotics. Cells were 
cultured until they reached confluence and washed with PBS to remove any residual 
FCS. They were then killed by adding mitomycin C at a concentration of 5pg/ml for 
lhour and then washed 3 times with PBS to wash off any residual mitomycin. 
Primary cells could then be added to perform the planned assay.
65
2.4.3 Bacterial cell culture techniques
I. Bacterial cell cultures
The genotypes of all the strains of Escherichia coli (E.coli) are detailed by 
Maniatis et al., (1982) as are the basic techniques used for the bacterial growth, 
plating and purification. E.coli DH5 was used for all plasmid propagation and was 
grown in Luria- Bertani (L-broth) medium. E.coli, Amp+ resistant cells, were grown 
in L-broth supplemented with 50pg/ml Ampicillin. E.coli M l5, used for the 
propagation o f puC19 plasmid vectors, was grown in L-broth supplemented with 
50 fig/ml Ampicillin and 50|ag/ml kanomycin. Glycerol stocks made and stored at - 
70°C.
II. Plasmid DNA transformation of E.coli DH5
For each transformation, E.coli DH5 competent cells were used. Cells were 
made competent according to the CaCl2 method described in Current protocols in 
Molecular Biology (by Wiley Interscience) Lab mannual by a laboratory technician. 
An aliquot of lab stock competent cells were thawed and incubated for lOmins on ice. 
1 OOng of plasmid DNA in a maximum volume o f 80jal, was added to the cells and 
incubated for a further 15mins on ice. The cells were then heat-shocked at 42°C for 
90secs and returned to ice for 2mins. 0.8ml of warmed L-broth was added and the 
cells incubated, with gentle agitation, at 37°C for 30mins. The culture was 
centrifuged at 9,000 xg for lmin to collect the cells and then, most of the medium was 
aspirated. The cells were resuspended, by gently tapping the tube, and plated on 
duplicate L-broth (+/- ampicillin as required) 1.1% (w/v) agar plates and incubated 
inverted at 37°C overnight.
2.4.4 DNA extraction and manipulation
I. Small scale preparation of plasmid DNA
The Wizard™ Plus Miniprep DNA purification system from Promega was 
used for small scale plasmid DNA isolation according to the manufacturers protocol 
(adapted from the method of Bimboim and Doly, 1979). 1.5ml of bacterial culture
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was transferred into an Eppendorf tube and pelleted in a microcentrifuge for 1 -2 min. 
The supernatant was removed completely and the cell pellet was resuspended in 
0.2ml of cell re-suspension solution [50mM Tris (pH 7.5), lOpM EDTA and 
100pg/ml RNAse A]. 0.2ml of cell lysis solution [0.2 M NaOH and 1% (w/v) SDS] 
was added and the contents were mixed by inverting the tubes a few times. (Some 
bacterial cells are more resistant to lysis and may require incubation for 3-5 min for 
efficient lysis). 0.2ml neutralisation solution (1.32M potassium acetate) was added 
and the contents were mixed by inverting the tube a few times. The lysate was 
centrifuged at 10,000xg in a microfiige for 15min. Meanwhile, one Wizard™ 
Minicolumn was prepared for each miniprep. The barrel from a disposable 3ml Luer- 
LockR syringe was attached to the extension of the minicolumn and 1ml of the 
resuspended resin was placed into the barrel. The cleared lysate from each miniprep 
was transferred into the barrel of the minicolumn/ syringe assembly containing the 
resin. The syringe plunger was inserted carefully and the slurry was gently pushed 
into the minicolumn. 2ml of Column Wash Solution [80mM potassium acetate, 
8.3mM Tris-HCl (pH 7.5), 40pM EDTA and 55% (v/v) EtOH] was added into the 
barrel of the assembly and was gently pushed through the minicolumn. The syringe 
was then removed and the minicolumn was transferred to a 1.5ml Eppendorf and 
centrifuged at 10,000xg in a microcentrifuge for 2 min to dry the resin. The 
minicolumn was then transferred to a new tube, 50pl of TE (heated at 70°C) was 
added and minipreps were centrifuged at 10,000xg for 20 seconds to elute the DNA. 
The minicolumn was discarded and the plasmid DNA was stored at -20°C.
II. Large scale preparation of plasmid DNA (alkaline)
This protocol is a modification of the method of Bimboim and Doly (1979) 
and works well with all commonly used strains of E. coli.
200ml of selective LB medium were inoculated (with 100pi of a liquid mini 
culture) with the desired plasmid-containing bacteria and grown at 37°C for 12-16 
hours with vigorous shaking (~300rpm). The bacteria were harvested by 
centrifugation at 6,000xg for 15mins at 4°C (in a Beckman JA-17 rotor). The
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bacterial pellet was resuspended in 10ml of Soli (50mM glucose, 25mM TrisCl [pH 
8.0], lOmM EDTA [pH8.0]), with 1ml of freshly prepared solution of lysozyme 
[lOmg/ml in lOmM TrisCl (pH8.0)]. 20ml of freshly prepared Solution II [200mM 
NaOH, 0.1% (w/v) SDS] was added and the contents were mixed thoroughly by 
gently inverting the tube several times and incubated at room temperature for 10 
mins. 15ml of ice cold Solution III (5M potassium acetate, glacial acetic acid [3M K, 
5M acetate]) were added and the contents were mixed by shaking the tube several 
times. The samples were then incubated on ice for lOmins. A flocculent white 
precipitate formed at this stage consisting of chromosomal DNA, HMW RNA and 
K/SDS/protein/membrane complexes. The bacterial lysate was centrifuged at 11,000 
xg (in a Becckman JA-17 rotor) for 15mins at 4°C. The supernatant was then filtered 
through a Whatman paper into a 250ml centrifuge tube. 28ml (0.6 volume) of 
isopropanol was added to the filtered supernatant, mixed well and incubated for 
lOmin at room temperature. The plasmid DNA was recovered by centrifugation at 
11,000 xg for 15mins at room temperature. The supernatant was carefully removed 
and the DNA pellet washed in 70% (v/v) EtOH at room temperature. The EtOH 
was removed by spinning the samples again at 11,000 xg for 15mins and aspiration. 
The pellet was air dried and resuspended in 3ml TE (pH8.0) buffer. The sample was 
then transferred to Eppendorf tubes.
The DNA was protein extracted once with equal volume of 
chloroform/isoamyl alcohol (24:1) and once with phenol/chloroform/isoamyl alcohol 
(25:24:1). The liquid phases where separated by centrifugation at 13,000xg for 
15mins at 4°C in an Eppendorf centrifuge. The upper liquid phase containing the 
DNA was transferred to clean sterile tubes. The DNA was precipitated by adding 
equal volume of isopropanol and 1/10 volume (of the total) of 5M NaCl, at -20°C for 
30 mins. The tubes were then centrifuged at full speed for 15 mins at 4°C, the DNA 
pellet washed with 70% (v/v) EtOH, air dried and resuspended in 1ml TE (pH 8.0). 
lOpl o f RNase A added and incubated at 37°C for 30mins. The DNA pellet was 
protein extracted once more with equal volume of phenol and precipitated as before. 
The DNA pellet was washed with 70% (v/v) EtOH, air-dried and resuspended in
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300|xl of TE buffer. The DNA was then quantitated and digested with the 
appropriate enzymes to obtain the fragments of interest and analysed agarose gel 
electrophoresis.
III. High molecular weight/genomic DNA extraction
Genomic DNA was extracted from tissues or tails using a standard phenol/ 
chloroform/chloroform method (Wilson et al., 1990). A tissue or tail segment was 
placed in a 1.5ml Eppendorf tube containing 0.7ml of tail solution. 35p,l of 
proteinase K (0.47mg/ml final concentration) was added to each sample and incubated 
at 55°C in an Eppendorf thermomixer, shaking, overnight. At this stage, samples can 
be stored at 4°C indefinitely. The nucleic acids were separated from protein by 
adding an equal volume of buffer saturated phenol (pH7.5) and thoroughly mixing by 
inverting the tubes 15-20 times (no vortexing). The samples were then centrifuged in 
an Eppendorf centrifuge 13,000 xg for 5mins. The upper aqueous layer containing 
the DNA/RNA was carefully transferred into a fresh Eppendorf tube, without 
disturbing the interface, and protein further extracted by mixing with an equal volume 
of 2FC (see Solutions section). The samples were centrifuged in the Eppendorf 
centrifuge at 13,000 xg for 5mins. Again, the upper aqueous layer was carefully 
transferred into a fresh Eppendorf tube and mixed with 1 OOjLil of 10M NH4OAc and 
750|fi o f ice cold EtOH by shaking vigorously for several seconds (no vortexing). 
The samples were then centrifuged at 8,000 xg for 2mins to pellet the high molecular 
(HMW) DNA. The supernatant was removed without disturbing the pellet. The 
pellet was then washed with 1ml of 70% (v/v) EtOH, centrifuged for 2mins at 8,000 
xg and air dried for few mins. The DNA was then resuspended in 215jxl TE buffer 
(pH 7.6-8) by heating to 65°C for lOmins (or longer as required) with occasional 
agitation. The samples can then be stored at 4°C indefinitely.
IV. Quantitation of DNA
The optical density OD260 of DNA was measured by using aliquots of each 
DNA sample (OD=l=50mg/ml DNA). This allows the DNA concentration to be 
ascertained. The samples were then adjusted to the required concentration (usually
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0 .3 3 jn g /|L il for genomic DNAs or lmg/ml for plasmid DNAs) and stored at 4°C for 
HMW DNA or -20°C for plasmid DNA.
V. Restriction and electrophoresis of DNA
Restriction and electrophoresis of DNA was performed according to Wilson 
et al., (1990). 5-10pg of genomic DNA was usually digested with restriction
enzyme (1 unit/jul) (0.5units/pg of DNA) and the manufacturers recommended buffer 
(1/10th of the total volume) at 37°C overnight for complete digestion. If  necessary, 
further restriction enzyme was added and incubated for 2 hours at this point. The 
reaction was stopped by heating the samples for lOmin at 65°C. 10% (v/v) loading 
buffer was added to each reaction and 3-5pg of the samples were loaded onto a 0.8% 
(w/v) agarose gel made up in lxTAE. In a 300ml gel lOpl o f lOmg/ml EtBr were 
added. The samples were electrophoresed in a horizontal tank in lxTAE buffer for 
5hrs at 100V. lpg of 1Kb DNA ladder was also loaded to one o f the wells for 
subsequent band size evaluation. The DNA was visualised on a short wave (280nm) 
UV transiluminator to ensure the DNA was intact and equally loaded. A photograph 
was always taken for records.
VI. Isolation of specific DNA fragments
Specific DNA fragments were isolated in two ways. The first was used for 
easily separable fragments and the second was used for less well resolvable DNA 
fragments and purer isolation.
A. 10-20pg of the plasmid containing the required DNA to be used as probe, 
were digested with appropriate restriction enzymes to generate the required DNA 
fragment(s). The digested DNA was electrophoresed at 50V for 4-6hrs in low 
melting agarose (LMP-agarose) in lxTAE with 2\x\ of lOmg/ml EtBr/lOOml. The 
DNA was visualised on a long wave transiluminator to estimate the DNA content of 
the desired fragment. The fragment was collected using a scalpel into a Eppendorf 
tube and was heated to 70°C to melt the agarose and the volume was estimated. The
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fragment concentration was then adjusted to approximately 5ng/ml and stored at - 
20°C.
B. Purer DNA fragments were obtained using DEAE paper (NA45). The 
restricted DNA sample was electrophoresed in a 1% (w/v) agarose gel at 100V for 
4hrs. A small piece o f NA45 paper was inserted into a cut in the gel made in front of 
the desired DNA fragment. Another piece of paper was inserted behind the fragment 
to prevent contamination with the more slowly migrating DNA fragments or 
alternatively the gel above the fragment was cut off and discarded. The sample was 
run for a further 2hrs to transfer the DNA onto the paper, which was monitored 
under long wave UV to ensure successful transfer. The paper was rinsed in TE and 
the DNA eluted with 2xl5mins incubations in 250jli1 1M NaCl at 70°C. Eluates were 
pooled and extracted with 2FC and chloroform, the DNA was EtOH precipitated, 
dissolved in TE and stored at -20°C for further use.
VII. Southern blotting of DNA
The gel containing the DNA samples was trimmed to remove ladder tracks 
and was then treated with DNA denaturant (0.6M NaCl, 0.4M NaOH) for 45mins 
on a shaking platform. The gel was then washed 3x5mins in lxTAE buffer. The 
DNA was transferred onto a nylon membrane (Biodyne B) by electroblotting for 
3hrs 75V/1.5A in lxTAE in a Hoeffer electroblotting tank as described by Wilson et 
al. (1990). The filter was then UV cross linked using a stratalinker and baked for lhr 
at 80°C. The filter was stored at -20°C or probed directly (Wilson et al., 1990).
VIII. Preparation of 32P labelled DNA probe and hybridisation
Hybridisation probes for all blots were made using digested DNA fragments 
for plasmid DNA usually contained within LGT agarose. 25ng of the DNA fragment 
was used for each probe reaction. The Prime-It kit for Stratagene was used for probe 
preparation. lOpl of random 9-mer primers (27 OD units/p.1) and 19p,l of dH20  were 
added to the DNA. The mixture was then heated for 5mins at 90-100°C to denature 
the dsDNA. Then, 1 OjllI of 5xdCTP buffer, 5(^ 1 of a 32P dCTP (3000ci/mmol) and 1 jllI
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of exo(-) Klenow polymerase were added to the reaction and incubated at 37°C for at 
least 15mins. Stratagene Nuctrap probe purification columns were used to remove 
any unincorporated nucleotides from the probe, in the Stratagene push column beta 
shield device, using STE buffer (according to the Stratagene Prime-It II random primer 
labelling kit instruction manual). l|xl of the purified probe was used to assess the 
specific activity of the labelled DNA (>5xl08cpm/pg). The probe could either be 
stored at -70°C for few days or used directly.
For hybridisation, the blot was placed in a hybridisation tube with 10ml 
church buffer (see solutions section) in a hybridisation oven and rotated for at least 
3hrs at 65-68°C for prehybridisation. The purified probe was denatured by heating 
for lOmins at 100°C, added directly to the hybridisation tube containing the 
membrane and rotated at 65-68°C overnight. The blot was then stringently washed 
4xl0mins in 2xSSC, 0.1% (w/v) SDS at room temperature, on a shaking platform, 
followed by 2x30mins in O.lxSSC, 0.1% (w/v) SDS at 68°C in a shaking waterbath. 
The filter was then stored in polythene bag and taped into an autoradiography 
cassette with intensifying screen. The filter was exposed to Kodak XAR film at - 
70°C for the required time and the film was processed in a Kodak X-omat developer.
IX. DNA sequencing-preparation of samples
In house service using the MBSU-DNA sequencing in the Anderson complex, 
Molecular Genetics, Glasgow University.
2.4.5 RNA extraction and manipulation
To avoid RNA degradation form ribonucleases, all solutions were made up 
using autoclaved and diethyl-pyrocarbonate (DEPC)-treated H20 . Eppendorf tubes 
and pipette tips were autoclaved and kept along with the RNA solutions in a 
designated RNAse-free cupboard. All surfaces and equipment to be used during the 
procedures were carefully cleared prior to use with 1% (w/v) SDS and then 75% (v/v) 
EtOH (made up with DEPC-treated H20). Gloves were worn at all times and 
changed frequently to avoid any contamination with RNAses.
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I. Total RNA extraction
Frozen tissues were cut (if necessary) on dry ice using a sterile scalpel, 
without allowing the sample to thaw before preparation. The frozen sample was 
placed in a 7ml RNAse-free tube and homogenised in TRI-REAGENT (Sigma) (~lml/ 
50-100mg of tissue) using a polytron homogeniser [Chomczynski and Sacchi (1987) 
method slightly modified]. 0.2ml of chloroform per ml o f TRI-REAGENT was 
added to the homogenate, the sample was shaken vigorously by hand for 15 secs and 
allowed to stand for 2-15mins at room temperature. The resulting mixture was 
centrifuged at ll,000xg (10,000rpm in a JA-20 rotor) for 15mins at 4°C. 
Centrifugation separates the mixture into 3 phases: a red organic phase (containing 
protein), an interphase (containing DNA), and a colourless upper aqueous phase 
(containing RNA). The upper layer was carefully transferred into a fresh tube and
0.5ml of isopropanol/ml of TRI-REAGENT was added. The sample was mixed 
vigorously for 15secs and allowed to stand for 5-10mins at room temperature. The 
RNA sample was centrifuged at ll,000xg for 15mins at 4°C. The RNA precipitate 
formed a pellet on the side and bottom of the tube. The pellet was washed once with 
75% (v/v) EtOH by vortexing and subsequent centrifugation at 7,500xg for lOmins at 
4°C. The pellet was briefly air-dried, resuspended in 300pl TE/1% (w/v) SDS and 
transferred to an RNAse-free Eppendorf tube. The RNA was then precipitated by 
adding LiCl to a final concentration 2.5mM (lOmM stock which preferentially 
precipitates RNA instead of DNA), mixed well and precipitated either -70°C for 
30mins or -20°C overnight. The samples were then centrifuged at 13,000 xg for 
30mins at 4°C. The supernatant was aspirated and the RNA pellet washed with 70% 
(v/v) EtOH and then resuspended in TE/0.1% (w/v) SDS and stored at -70°C.
II. mRNA extraction
mRNA (polyA+) was purified using oligo-dT cellulose columns (Stratagene 
or Qiagen, oligotex Quick polyA+ RNA extraction kit) according to the 
manufacturers protocol. This involves binding of the polyA+ fraction of RNA to a 
(0.5ml) cellulose oligo-dTcolumn, in a high salt (500mM NaCl) buffer (the flow­
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through being the poly A- fraction). The column was then washed at low salt 
concentration (lOOmM NaCl) buffer and the mRNA eluted in a salt-free buffer. The 
mRNA was ethanol precipitated, quantitated and stored as described previously. 
Using this protocol, the mRNA yield is approximately 3% of the original total RNA 
sample used.
III. Quantitation and analysis of RNA
4pi of RNA were added to 16pl RNA loading buffer and heated to 65°C for 
lOmins, 2pl of lOx RNA loading dye was added and the samples were microfuged 
briefly. The samples were then loaded onto a formaldehyde gel. For a 50ml minigel,
0.7g agarose/40ml DEPC-H20 melted, 5ml MOPS-E (lOx) added and cooled to 60°C 
before adding 2.6ml formaldehyde. The gel was electrophoresed at 100V for lhr in 
lxTAE buffer (DEPC-H20). The RNA was then viewed on a UV transiluminator to 
check the integrity of the RNA sample (presence of the three ribosomal bands). 
Degraded samples were not used further.
5jli1 of RNA was used to measure the OD260/280 at 1/60 dilution (OD26o= l = 
40mg/ml). The OD280 was measured to estimate the purity of the sample. Proteins 
have an absorbance maximum at 280nm. An OD260/280 ratio of 1.8 or greater is 
taken as an acceptable level of purity. The RNA samples were adjusted to a 
concentration of 0.2-0.5mg/ml by adding TE/1% (w/v) SDS and absolute EtOH (in a 
final ratio of 1:2.5 aqueus:EtOH) and stored at -70°C. Required amounts of RNA for 
analysis were taken and precipitated with 3M NaOAc (1/35 volume).
IV. Northern blotting and detection of specific RNA bands
Gel tank and combs were treated with 3% (v/v) H20 2 for lOmin and rinsed 
thoroughly with DEPC-H20  to remove any RNAses. 20pg of each total RNA or 1 - 
5pg mRNA sample ]TE/0.1% (w/v) SDS/100% (v/v) EtOH] was aliquoted into fresh 
Eppendorfs and precipitated with 3M NaOAc (1/35 volume). The RNA pellet was 
resuspended thoroughly in 4pl DEPC-H20  by heating to 65°C and vortexing. 16pl of 
RNA loading buffer was added and the sample was heated to 68°C for lOmins and
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then transferred to ice. 2pl of lOx RNA loading dye was added and the samples were 
loaded on a formaldehyde gel. 1% (w/w) agarose in MOPS electrophoresis buffer 
(MOPS-E) was melted and cooled to 60°C before adding 17.8% (v/v) formaldehyde 
[of the 38% (w/v) stock solution] plus H20  to the final volume for pouring. The gel 
was electrophoresed in circulating lxMOPS-E buffer, slowly (50V) at 4°C for ~10hrs 
(Wilson et al., 1990).
The gel was then trimmed and soaked 3x20mins in 0.5xTAE and 
electroblotted onto a nylon filter as described for southern blotting in section 2.4.4. 
The membranes were then treated and hybridised in the same way as described 
previously for Southern blots (section 2.4.4).
V. Slot blot analysis of total cell RNA
The slot blotting is a less time consuming technique than Northern blotting as 
it does not involve electrophoresis and separate blotting. It is particularly useful for 
quantifying expression levels of a specific gene, as all the sample is located at one 
point and not separated by electrophoresis (as in Northern).
The slot blot apparatus (Schieder and Schell) was treated with 3% H20 2 for 
lOmins and then thoroughly rinsed with DEPC-treated H20  to remove any RNAses. 
(Slot blots were prepared in quadruplicate to have enough blots for all probes because 
each blot can be used approximately five times). 22pg of each RNA sample 
(5|Xg/slot) was resuspended in 44pi TE/0.1% (w/v) SDS. 132pl loading buffer was 
added to each sample, which was heated at 65°C for lOmins in an Eppendorf 
thermomixer. The tubes were then placed on ice and 44pl of cold 20xSSC was added 
in each. The slot blot apparatus was assembled with two pieces of pre-wetted 3mm 
paper underlying the nylon BiodyneB membrane (cut to size and pre-soaked in 
lxTAE for 30 mins). The samples were loaded, 50pl/slot (~5pg) and then the 
vacuum was applied. When the samples had been sucked through, one drop 
(approximately 20pl) of 5xTAE was added to each slot and sucked through. The 
membrane was then UV cross linked and baked, and the blot probed and washed 
exactly as a Southern or a Northern blot membrane (Wilson et al., 1990).
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VI. cDNA synthesis
i. First strand cDNA synthesis
cDNA synthesis was performed using the Superscript Pre-amplification 
system for first strand cDNA synthesis (Gibco) according to the manufacturers 
protocol. The procedure uses 1 to 5 fig of total RNA to produce the first strand 
cDNA.
All solutions and equipment were RNase-free. Usually 2|xg of total RNA (n 
jliI) was mixed with lp l oligo(dT)12-18 primers (0.5fig/|Lil) and made up to 12|il with 
DEPC-treated H20  in a 0.2ml PCR tube. The mixtures were incubated at 70°C for 
lOmins, in a PCR cycler, and then placed on ice for at least lnriin. In a separate 
Eppendorf tube the master reaction mix (2pl of lOxPCR buffer, 2jil of 25mM MgCl2, 
1 jliI of lOmMdNTP mix and 2|il o f 0.1 M DTT) was prepared. 7pl of the master mix 
were added to each RNA/primer mixture, mixed gently, and collected by brief 
centrifugation. The mixture was then incubated at 42°C for 5min. l|il (20units) of 
Superscript II RT was added to each tube, mixed and incubated at 42°C for a further 
50min period. The reactions were terminated by heating at 70°C for 15min and 
chilled on ice. The reactions were then collected by brief centrifugation, 1 pil of 
RnaseH (0.5mg/ml final concentration) was added to each tube and incubated at 37°C 
for 20min. The samples if not directly used can be stored at -20°C indefinitely.
ii. Second strand synthesis and amplification of target cDNA
10% of the first strand cDNA reaction was used for the amplification of the 
target cDNA. The following components were added in a thin walled 0.2ml PCR 
tube: 5pl of lOx PCR buffer, 3pl of 25mM MgCl2, lp l dNTP mix (0.2mM final 
concentration), 1 jliI of each specific amplification primer (lOmM), 2pl of the first 
strand cDNA and 0.5|il o f Taq DNA polymerase (2 units). Autoclaved distilled 
water was added up to a 50jli1 final volume. The reactions were incubated at 94°C for 
5mins to denature the RNA/cDNA hybrid and 30 cycles of PCR of the optimised 
programme for each specific primer pair were performed in the PTC200 thermal
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cycler. lOpl of the amplified sample was usually analysed using agarose gel 
electrophoresis.
2.4.6 Mouse Atlas cDNA Expression Array (Clontech Laboratories, Inc). 
(Methods are according the manufacturers instructions)
I. Preparation of cDNA probes
Two, duplicate, Atlas array membranes are provided with this kit, on which 
are duplicate spots of cDNAs isolated from 588 murine genes, including several 
house keeping genes to act as loading controls. The full list o f genes included in this 
array is given in Appendix 5.1
i. cDNA synthesis
The lOpl reaction described below, converts lpg of polyA+ RNA into 32P 
labelled first strand cDNA. All solutions and equipment were RNAse free. The 
Master Mix for all labelling reactions (plus one extra reaction to ensure that there is 
sufficient volume) was prepared in a 0.5ml microfiige tube by combining the 
following (per reaction): 2pl of 5x reaction buffer (provided in the kit), lp l of lOx 
dNTP mix (for dATP label), 3.5pl [a32P]dATP (3,000Ci/mmol, lOpCi/ml, 
Amersham), 0.5pl DTT (lOOmM) and lp l MMLV reverse transcriptase (50units/pl). 
The components were mixed well and the mix was stored on ice. lpg (1 -2jll1) of 
polyA+ RNA sample was mixed with 1 pi 1 Ox CDC (cDNA cocktail) primer mix, in a
0.2ml PCR tube, by vortexing. The tubes were then centrifuged briefly in a microfuge 
and incubated in a preheated PCR thermal cycler (Peltier PTC-200 from MGR) at 
70°C for 2min. The temperature of the thermal cycler was then reduced to 50°C and 
the samples were incubated for 2min. 8pl of the master mix was added to each 
reaction tube and the contents were mixed by gentle pipetting. The tubes were then 
incubated in the PCR thermal cycler at 50°C for 20min. The reaction was stopped 
by adding 1 pi of lOx termination mix.
ii. Column chromatography
Purification of the 32P labelled cDNA fragments (>0.1 kb) was performed 
using CHROMASPIN-200 DEPC-H20  columns (supplied by the manufacturer).
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After the gel matrix in the column was set, the sample was carefully applied in the 
centre of the gel bed’s flat surface and allowed to be fully absorbed into the resin bed. 
The column was washed once with 40pl deionised H20  and once with 250ptl 
deionised H20  (the washes were discarded in appropriate container for radioactive 
waste) and the column was then transferred to a clean 1.5ml Eppendorf tube. Four 
fractions were collected by adding lOOpl of deionised H20  to the column and 
allowing the H20  to completely drain out of the column (each fraction was collected 
into a separate tube). The fractions were monitored for 32P incorporation into the 
probe using the Cerenkov method (Reichert and French, 1994) and were then stored at 
-70°C. In this method the entire sample can be counted without the addition of 
scintilation cocktail to the tubes. The samples are counted in the tritium (3H) 
channel. Plotting the elution profile (which will give 2 peaks), the purified labelled 
probe is the first peak of the Cerenkov counts (usually fraction 2 and maybe 3), the 
second peak consists o f the unincorporated nucleotides). The fractions used for the 
hybridisation of the Atlas membranes should be ~2-5xl06 cpm.
II. Hybridisation of the mouse Atlas Array
A test hybridisation was always performed using the sample probe and a 
blank piece of Nytran-Plus membrane to assess the level of high background 
(indicative of poor quality probe) which could affect the hybridisation signals. Only 
low background probes were used.
A solution of ExpressHyb (supplied by the manufacturer) and sheared 
salmon testes DNA was freshly prepared: 15ml of ExpressHyb solution prewarmed 
at 68°C. 1.5mg of the sheared salmon testes DNA was denatured at 95-100°C for 
5min, chilled quickly on ice and then mixed with the prewarmed ExpressHyb 
solution. The mixture was kept at 68°C until ready to use. The Atlas Array 
membrane was wetted with deionised H20  and placed into a Hybridisation tube. 
10ml of the prehybridisation solution was added and prehybridised for 30min with 
continuous agitation at 68°C.
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The labelled cDNA probe (-200pi, 2-5x106cpm) was mixed with 1/10th of 
the total volume (about 22pl) of lOx denaturing solution (1M NaOH, lOmM EDTA) 
and incubated at 68°C for 20min. 5pi (lmg/ml) of C0t-1 DNA (a mixture of highly 
repetitive DNA to reduce non-specific binding) was added and an equal volume 
(~225pl) of 2x neutralising solution (lM N aH 2P 0 4 [pH 7.0]) was added. The probe 
was incubated for a further 10 min at 68°C (the final probe concentration was ~0.5- 
lx l0 6cpm). The probe was then mixed with 5ml of the prewarmed solution prepared 
earlier. The prehyb solution was discarded and replaced with the solution containing 
the cDNA probe which was evenly distributed over the membrane and hybridised 
overnight with continuous agitation at 68°C.
Two washing solutions I and II were prepared and prewarmed at 68°C. The 
hybridisation solution was discarded in an appropriate container and replaced with 
200ml of prewarmed solution I [2xSSC,l% (w/v) SDS]. The Atlas Array was 
washed four times for 20 mins at 68°C. Two additional 20min-washes were 
performed in 200ml o f prewarmed solution II [O.lxSSC, 0.5% (w/v) SDS] with 
continuous agitation at 68°C. Using forceps, the Atlas Array membrane was 
removed from the bottle and wrapped in plastic wrap. The membrane was then 
exposed to a phosphoimaging screen at room temperature or to x-ray film at -70°C 
with an intensifying screen for different exposures of variable length of time. The 
image was analysed using phosphoimager.
2.4.7 Protein extraction and manipulation
I. Whole cell protein extraction (adapted from Marais et al., 1993)
The following protocol can be used for protein extraction from either tissue 
culture cells, frozen cell pellets or homogenised tissue. Cells were collected, washed 
with TBS (Tris buffered saline) and pelletted by centrifugation at 1500xg for 5min. 
The pellet was resuspended in 1ml TBS and transferred into an Eppendorf tube and 
pelleted again by brief centrifugation (~15 seconds) in a microfuge. TBS was 
removed and cells were lysed by the gradual addition and flipping the tube, o f protein 
extraction buffer (600pl in total). Cells were then lysed completely by pipetting up
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and down (using a yellow tip) a few times. The lysate was then centrifuged at 
14000xg for 15 min in a microfuge in the cold room. The supernatant was then 
transferred into a fresh Eppendorf tube. 5|xl o f the lysate was used for protein 
estimation and the remainder was stored at -70°C in aliquots.
II. Nuclear protein extraction
Nuclear protein extracts were obtained using a modification o f the protocol 
described by Schreiber etal., (1989). Fresh splenocytes were collected (as described 
above, section 2.4.2) in 5ml of ice cold PBS and then transferred into a 15ml Falcon 
tube on ice. Samples were harvested by centrifugation at 194xg (Heraeus 400 
centrifuge rotor no. 8175) for lOmin at 4°C. Cells were resuspended in 5ml Sucrose 
buffer and large debris was allowed to settle for a couple of minutes. Cells were then 
transferred (leaving debris behind) to a 7ml dounce homogeniser and cells lysed by 7 
strokes using a loose pestle and transferred into a 15ml Falcon tube. Samples were 
then centrifuged at 3,500 rpm for 15min at 4°C to pellet nuclei, the cytoplasm was 
discarded (unless required) and the tubes were drained briefly on a tissue paper. The 
nuclear pellet was transferred into an Eppendorf tube and resuspended in 200p,l 
nuclear protein extraction buffer containing proteinase inhibitors (Materials section 
2.1.2), which was added dropwise with mixing, and then the tube was vigorously 
rocked at 4°C for 15min on a shaking platform. The samples were centrifuged for 
5min in a microfuge at 4°C at 16,000xg and the supernatant (nuclear extract) stored in 
aliquots at -70°C.
III. Nuclear matrix protein extraction protocol
This is a combination o f the Schreiber et al., (1989) and Smith and Berezney, 
(1980), protocols with slight modifications. All steps were performed on ice.
Homogenisation o f tissues or lysis o f cells was performed with a dounce 
homogeniser using pestle A (the tight one, by 50 strokes) in 0.2ml (for cells) or 1ml 
(for tissue) of nuclear extraction buffer. The samples were centrifuged in a microfuge 
at 16,000xg for 30min at 4°C. The supernatant was then transferred into new tubes 
and stored at -20 or -70°C. The pellet was resuspended in isotonic buffer and 20fig 
of DNase 1/ml was added. The samples were incubated for 16hours at 4°C. The next
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day, the samples were sonicated 4 times for 30sec each, at 50 watt. The samples 
were then centrifuged at lOOOxg for lOmin at 4°C. (The supernatant is the DNAse 
fraction). The pellet was then re-extracted with 0.5ml high salt lysis buffer. The 
samples were pelleted by cetrifugation at 6,000xg for lOmin at 4°C yielding the high 
salt supernatant which was transferred into a new tube and stored at -70°C. 2% 
(w/v) SDS and 1% (v/v) p-mercaptoethanol were added to the pellet and was boiled 
at 100°C for 5 min and then stored at -20°C or -70°C.
IV. Quantitation of proteins: Protein assay (microassay procedure l-20pg 
protein/ml, BioRad)
5 dilutions of protein standard containing 1.25, 2.5, 5, 10 and 20 pg/ml BSA 
in TE buffer were prepared and used to generate a standard curve. 0.8ml of standards 
and appropriately diluted samples were placed in clean and dry plastic 1cm3 
cuvettes. A “blank” was also included containing 0.8ml sample buffer. 0.2ml Dye 
Reagent Concentrate (BioRad) was added and samples were mixed several times by 
gentle inversion o f the cuvettes. After a period o f 5min to 1 hour, OD595 versus 
reagent blank was measured and O D 595 values of the standards were plotted versus 
concentration. Test samples were read from the standard curve.
V. DNA-Protein binding assay (adapted from Frame et al., 1991)
i. Acrylamide gel preparation for EMSAs. After assembling the apparatus and 
making sure that it was not leaking the non-denaturing polyacrylamide gel was 
prepared. 7ml of 30% (v/v) Acrylamide (30:1.579 acrykBis) was mixed with 2.25ml 
lOxTBE, 40ml dH20, 350pl 10% (v/v) APS and 25pi TEMED. The gel was then 
polymerised for at least 1 hour before loading. The wells were numbered 1-14 (to be 
able to see them) on the outer glass plate prior to adding buffer (0.5x TBE) to 
reservoirs.
ii. Sample preparation. A master mix of the reaction components was first 
prepared by combining the following components: (for 15x30pl reactions) 45pi of 
lOxBinding buffer (see materials), 30pl poly-dl.dC (2pg/reaction), 2pl DTT (4mM
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final concentration), 320pl ddH20 . 25\i\ master mix was aliquoted in Eppendorf 
tubes on ice, 5pg of nuclear protein added and ddH20  added (if required) to adjust 
final volume to 30pl. The binding assay was initiated by adding lp l o f 32P labelled 
oligo probe (0.2-lng/reaction) and samples incubated on ice for 15-30min. 
Meanwhile the gel [6% (v/v) non-denaturing polyacrylamide gel] was set up in the 
cold room and was pre-electrophoresed for 30min (150V). After 30min of binding, 
samples were loaded carefully into the bottom of each well using a round-bore 
sequencing tip. lOpl of loading tracking dye was added into one well to monitor 
progress. Samples were electrophoresed at 150V constant until the dye was 
approximately 3cm from the bottom of the gel. The running buffer was disposed into 
a radioactive sink (even though the probe was retained in the gel), glass plates were 
separated cautiously and the gel very carefully was placed into a glass dish with 
fixative [10% (v/v) acetic acid-10% (v/v) methanol] and gently agitated for 15-30min. 
The fixative was then drained off and a double thickness of Whattman 3MM paper 
was firmly pressed onto the gel. The gel was then lifted, covered with saran wrap 
and dried using a vacuum drier for 60min. The dried gel was exposed to X-AR Kodak 
film for the required time.
VI. Labelling oligonucleotide probes and purification
200ng of double-stranded oligo probe was mixed with 2pi of lOx PNK buffer 
(50mM Tris-HCl pH 7.6, lOmM MgCl2, 5mM DTT, O.lmM EDTA), 3pl (20pCi) 
[32P] yATP, 13pl ddH20  and 1 jllI T4 polynucleotide kinase. The reactions were 
incubated at 37°C for 30-60 min and then DNA was separated from unincorporated 
ATP by gel purification. The labelling reaction was resolved on neutral 15% (v/v) 
acrylamide/TBE gel, running the dye only 1/2 way to the bottom of the gel. The 
DNA was located by auto-radiography of the gel (2-5min exposure) and the DNA 
band was excised. The DNA was eluted by soaking the macerated gel slice in 200pl 
TE overnight at room temperature. The eluate was filtered through glass-wool and 
stored at -20°C.
Radiolabelled API probes were kindly prepared by Dr. David Gillespie.
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VII. Western Blotting
75-100pg of whole or nuclear protein extracts were used per reaction. An 
equal volume of 2xGBS [125mM Tris-HCl pH6.8, 20% (v/v) glycerol, 10% (v/v) (3- 
mercaptoethanol, 4% (w/v) SDS, 0.004% (w/v) bromophenol blue] was added to each 
sample. The samples were then boiled for 5min at 100°C and transferred on ice until 
loaded. 20pl of prestained molecular weight markers (BenchMark™ pre-stained 
protein ladder, Gibco) were loaded along with the samples and separated on a 10% 
(v/v) SDS PAGE gel with 5% (v/v) stacking gel at 200V using. Proteins were then 
transferred to an Imobillon P membrane (pre-wet in methanol) for 2.5hours at 100V 
in blotting buffer. The membrane was then stained in Ponceau solution (protein 
stain) to check for the efficiency of the protein transfer and then blocked for lhour in 
blocking buffer [5% (w/v) non-fat milk in TBS-T (Tris-Borate -Triton X I00) buffer]. 
This blocking step helps to reduce non-specific binding and hence background signal 
at the later detection step. The membrane was then incubated overnight at 4°C with 
primary antibody (at the appropriate dilution usually 1:5000) in TBS-T buffer, then 
washed 4x in TBS-T buffer and reblocked [5% (w/v) non-fat milk in TBS-T buffer]. . 
The secondary antibody (anti-rabbit HRP-conjugated) was then added to the 
membrane and incubated for 1 hour at room temperature. The blot was then washed 
as above. 5ml of each buffer of the ECL luminol system kit were mixed together and 
added to the membrane, immediately, in the dark and gently shook by hand for 2 min. 
The solution was discarded and the membrane was immediately exposed to X-AR 
photographic film for the required time (usually 1-15 min).
VIII. Stripping and reprobing of western blots
The membrane was incubated at 55°C with pre-heated MENS A buffer 
[62.5mM Tris-HCl pH6.8, 2% (w/v) SDS, 50mM sodium 2-mercaptoethanol] for 30 
min. The membrane was then rinsed with SDS wash buffer [62.5mM Tris-HCl 
pH6.8, 2% (w/v) SDS) and twice with PBS-T (1% (v/v) Tween®-20 in lOxPBS] and 
was then blocked [5% (w/v) non-fat milk in TBS-T buffer] and reprobed as per 
method described above. Membranes were stored in plastic wrap at -20°C.
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Chapter 3
Cell phenotype and growth characteristics
3.1 Introduction
A series of experimental approaches have been employed to determine whether 
EBNA 1 has any effects on B cell phenotype. Initially (section 3.2), FACS analysis 
was used to examine any EBNA 1 effects on B cell differentiation using antibodies to 
B cell surface markers that are differentially expressed through B cell development. 
Using this method it was possible to determine the proportions and maturation stage 
o f B cells in the lymphoid tissue compartments. Secondly (section 3.3), short term 
cultures (up to 3 weeks) o f freshly explanted spleen and bone marrow (BM) cells 
were set up to examine cell survival and proliferation. Cell survival cultures were 
supplemented with different growth factors known to support B cell growth.
-IL2 is produced primarily by activated T helper 1 (Thl) cells. It acts 
through a specific, saturable, multisubunit IL-2 receptor complex found primarily on 
T cells, B cells and natural killer (NK) cells. The precise role of IL-2 in vivo is not 
known. However, transgenic mouse models suggest that it may play a role in the 
establishment of an anergic state at the T cell level (Kneitz et al., 1995). It has also 
been reported that it augments B cell growth and Ig production (Ceuppens et al, 
1985).
-IL4 is produced by the Th2 subset of activated T cells but also from CD 8+ 
T cells and is also known as B Cell Growth Factor (BCGF). IL4 induces IgM- 
stimulated B cells to enter S-phase (Howard et al 1982), upregulates IgGl, IgE and 
slgM production by B cells (Snapper et al, 1988). IL4 also upregulates Fc receptor 
expression for IgE (CD23) on B cells and monocytes (Vercelli et al., 1988) and MHC 
class II expression in resting B cells (Musso et al., 1994). IL4 is known to support B 
cell growth in culture.
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-IL6 is produced by a variety of cell types including lymphocytes and is also 
known as monocyte-derived human B cell growth factor and as B cell Stimulating 
Factor (BSF-2). IL6 is reported to exhibit multiple activities including induction of 
proliferation in a number of cells including EBV transformed B cells, and induction of 
B cell differentiation and stimulation of IgG secretion (Tosato et al., 1988).
-IL7 is a product of BM stromal cells and is able to induce the growth and 
differentiation of precursor B lymphocytes, specifically B220+ pre-B cells (Williams 
et al., 1990, Hayashi et a l,  1990).
-CD40 stimulation of different B cell lines has different effects on their 
growth, proliferation and differentiation depending on the activation status of the B 
cells. CD40 (aCD40) antibody/ligand stimulates entry o f B cells to S-phase (Gordon, 
J., 1995; Parry et al., 1994).
Cell population growth was monitored initially by counting viable cells at 24 
hour intervals using trypan blue exclusion of dead cells. Normal splenocytes usually 
die by 2 weeks in explant culture and major changes to cell viability could be readily 
measured in this way. The effects of EBNA 1 on immature cell proliferation were 
detected by methylcellulose cultures of BM cells (section 3.4). The apoptosis rate of 
EpEBNA 1 positive cells versus wild type (wt) cells was assessed by a combination 
of AnnexinV and PI staining and FACS analysis (section 3.4). The cells used in these 
experiments were isolated from EBNA 1 transgenic positive and negative control 
sibling mice from line 26 (in which tumour incidence occurs between 4-12 months). 
At 2 months old, mice are young adults and developmentally mature and free of 
tumours. Therefore, the effects o f EBNA 1 on adult B cell phenotype can be 
addressed without the influence of tumour progression.
3.2 Transgenic B cell phenotype
Splenocytes or BM cells were isolated from 2 month old EpEBNA 1 
transgenic positive animals from line 26 and wt controls (as described in Methods 
section 2.4.2). After red blood cell (RBC) lysis, cells were stained with different cell 
markers and analysed by FACS using 5xl05cells/ sample.
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3.2.1 Does EBNA 1 influence the size or proportion of the B cell component in 
the spleen cell population?
To determine the percentage of B and T cell populations in the spleens of 
transgenic positive and negative animals a flow cytometric analysis was performed on 
splenic cells from EpEBNA 1 positive and wt 2 month old mice from line 26. 
Phycoerythrin (PE)-conjugated (red fluorescence) antibodies, which recognise the 
panB cell surface marker CD45R/B220, were used to detect and estimate the 
percentage of B cells in the spleens of 21 transgenic positive and 20 wt mice. 
Fluorescein isothiocyanate (FITC)-conjugated (green fluorescence) antibodies which 
recognise the T cell (but also cross react with some activated B cells) surface marker 
Thy 1.2, were used to detect and also estimate the percentage of T cells (also 
activated B cells) in the spleens from 7 transgenic positive and 7 wt mice. Staining 
controls were always included: an unstained control to measure and exclude the 
autofluorescence of the cells, and one single stained control for each different stain 
used. These controls are required to allow the flow cytometer to be calibrated and 
adjusted as necessary. Isotype controls for each type o f antibody (when available) 
were used as a non-specific staining control. All FACS results were analysed as dot 
plots and representative data are shown in Fig. 3.1 (the markers used in this figure are 
discussed later). The mean fluorescence intensity was used as an alternative way of 
comparing two cell populations. The FACS collects the fluorescence intensity values 
o f each individual cell and then calculates the average or mean intensity of the cell 
population in question which reflects the level of expression of a particular marker.
The results of the B cell/ T cell experiment are summarised in Table 3.1 and 
graphically and statistically depicted in Fig. 3.2. Statistical analysis was performed 
using the Two-sample T-test. Statistical significance with 95% confidence intervals is 
reached when P<0.05. A box plot displays the median, quartile values and range of 
the data set thereby providing more visual information concerning the data spread 
than a barr graph. The box plot also reads outlying data points. Minitab calculates 
outlying values depending on how concentrated are the groups of data analysed. The
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symmetry of the results and any outlying observations can be seen. The total number 
o f splenocytes isolated from the spleens of EpEBNA 1 positive and wt control 
animals was approximately 5x107, with no significant difference between the two. 
However, occasionally an enlarged spleen, with greater cell number, was isolated from 
a transgenic positive animal. This was attributed to early neoplastic changes and 
these data were excluded from this pre-tumour analysis. 70-85% of the splenocytes 
were B220+ (B cells) and 20-28% were Thy 1.2+ cells (T and some activated B cells). 
No significant difference is seen in the overall proportion o f B cells in the spleens 
between EpEBNA 1 positive and wt animals. As expected no significant difference 
was observed in the proportion o f Thy 1.2+ cells (predominantly T cells) between 
transgenic positive and wt spleen populations.
3.2.2 Does EBNA 1 distort the proportion of B cell subtypes in the spleen cells?
To determine the effects of EBNA 1 expression on peripheral B cell 
populations, flow cytometric analysis for B cell surface markers which are expressed 
throughout B cell differentiation, was performed on primary splenic cells from 
EpEBNA 1 positive and negative siblings from 2 month old line 26 mice. In Fig. 3.3 
the B cell maturation stages are illustrated and the surface markers expressed at each 
stage are indicated at the bottom of the figure by colour coded arrows. B cells 
differentiate from lymphoid stem cells into virgin/naive B cells and upon antigen 
stimulation they may become memory or plasma cells. The genes coding for 
antibodies are rearranged in the course of progenitor cell development. Pre-B cells 
express cytoplasmic p chains only. The immature B cell has surface IgM, whereas 
mature B cells have other Ig molecules.
Thb was used as a marker for B cell immaturity, which is expressed in 
immature B cells and approximately 70% of thymocytes. As a marker of maturity, 
polyvalent surface immunoglobulin (slg) (IgM, IgG and IgA) was used which is 
expressed on naive and mature differentiated B cells. Individual Igs were used as 
markers to examine the stage of the B cell differentiation. For example, IgD is 
expressed on naive B cells. IgM is expressed on B cells before isotype switching.
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CD23 is expressed on mature B cells and was used as marker of B cell activation 
state. CD5 is a marker for a minor sub-population of B cells referred to as B1 cells.
After RBC lysis, cells were counted and aliquots of 5x105 cells/sample (for 
both test and control samples) were stained with PE-conjugated antibodies to B220 
for total B cell population percentage and a FITC-conjugated second marker (those 
described above) and samples were analysed as in section 3.2.1. The percentage of 
B220+ cells and percentage of B cells expressing each of the secondary markers 
tested were calculated and are presented in Tables 3.2 and 3.3.
Representative dot plots for each staining are shown in Fig. 3.4. These dot 
plots are representatives from 4 separate experiments with at least 4 transgenic 
positive and 4 wt mice in each experiment. For each staining, the representative dot 
plots were chosen according to how close their percentage of positive cells was to the 
mean percentage of the positive cell population o f the group. Equally, the mean 
fluorescence intensity of the dot plot chosen was as close as possible to the mean 
value of the group.
Statistical analysis was performed using Minitab to perform a Two-sample 
T-test in order to test if the values observed between transgenic positive and wt 
control mice were statistically significantly different. The results o f the analysis are 
graphically illustrated and statistically depicted in Fig. 3.5. As it can be seen from 
Fig. 3.5b, there is no difference in the overall proportion and fluorescence intensity of 
most stains of B cells in the spleen between the EpEBNA 1 transgenic positive and 
wt mice, with the exception of slg. Similar proportions of immature (Thb+) B cells as 
well as IgM+ and IgD+ B cells were obtained from both EpEBNA 1 positive and wt 
spleens. However, EpEBNA 1 transgenic samples showed a statistically significantly 
(P=0.014) higher proportion o f slg+ B cells compared to wt (by 1.5-fold), with 72% 
in EpEBNA 1 positives and 54% in wt. The slg fluorescence intensity was also 
higher in the EpEBNA 1 positives with a relative value o f 90% compared to 66% in 
wt. As can be seen more clearly in the histogram representation of the data in Fig. 3.6 
the EpEBNA 1 B cells show 2 peaks o f slg staining of high and low intensity with 
roughly equal proportions. In contrast, the negative control shows a bias to low
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Fig. 3.4 FACS analysis of spleen cells stained by immunofluorescence and 
analysed by flow cytometry. Y axis: FL2-PE labelled antibody. X-axis: FL1- 
FITC labelled antibody. A forward and side scatter dot plot for each sample is 
also shown. Splenocytes from WT mice (A) are compared with splenocytes 
from E/^EBNA 1 positive transgenic mice (B). The horizontal and vertical 
cursor lines are positioned based on autofluorescence of unstained cells. Based 
on this cut-off, the % of PE/FITC stained cells in each case was calculated by 
the number of double stained cells divided by the total number of PE-stained 
cells. The percentage and mean fluorescence intensity of individual quadrants 
are shown in red and green (respectively) inside each quadrant. A and B are 
each representative of 9 samples.
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Fig. 3.6. Histogram illustrating the difference in the % of slg+ cells between wt (blue) 
and EpEBNA 1 transgenic positive (magenta) spleen. The % o f B cells positive for 
slg and the mean intensity o f slg (green) are given in the top comer of the histogram. 
The results shown have been gated so is not to include the isotype match control peak.
intensity stain of cells. Nevertheless, since there is no obvious increase in the 
proportions of IgM+ or IgD+ cells, the increase in slg may be due to increased 
proportion of IgA or IgG. This may suggest that there is an increase in the number of 
mature cells. However, this needs to be confirmed. Conversely, all spleen samples 
(both transgenic and wt) showed a high level of immature cells (average 51% of all 
cells were Thb+) suggesting perhaps, that this antigen may still be expressed on 
maturing B cells.
No difference in the proportion of B1 cells (CD5+) in EpEBNA 1 positive in 
comparison with wt spleen was observed. Results from 2 separate sets of 
experiments suggest that CD23 might be upregulated by EBNA 1. While the 
percentage of CD23+ cells was no different between the EpEBNA 1 and wt samples 
the fluorescence intensity was higher in EpEBNA 1 positive cells. That may indicate 
that more samples need to be tested in order to reach statistically significant levels.
3.2.3. Does EBNA 1 distort the population of B cell subtypes in BM cells?
To examine B cell development in EpEBNA 1 mice, BM cells from transgenic 
and non-transgenic animals were analysed for expression of Thb, IgD and slg. BM  
cells were collected as described in methods section 2.4.2 and were treated in the 
same way as described earlier for the spleen cells. Aliquots of 5x105 cells/sample 
were stained with different B cell surface markers and analysed by flow cytometry. 
The Two-sample T-test was used to statistically analyse the results of this 
experiment. The results are summarised in Table 3.4 and graphically illustrated in 
Fig. 3.7. Thb+ and IgD+ B cell populations were found to be similar between 
transgenic positive and negative mice. However, as in the spleen samples, the mature 
(slg+) B cell population was found to be statistically significantly higher in the 
EpEBNA 1 mice when compared to wt controls (62.4% versus 46.6%).
The polyvalent antibody to slgs recognises IgM, IgA and IgG. However, BM 
cells express only IgM and almost no IgG and IgA and therefore, the high percentage 
of mature B cells in the BM is likely to be due to the IgM marker. In order to
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characterise the individual cell types stained with slg, single staining using B220/IgM, 
B220/IgG and B220/IgA should be performed.
Based on these observations it can be postulated that EBNA 1 may promote 
maturation of B cells or allow mature B cells to survive longer or promote the 
expression of slg in a manner independent o f cell maturity. However, there was no 
increase in B cell numbers in the EpEBNA 1 positive tissues.
3.3. Transgenic B cell properties I: Cell survival
To address if EBNA 1 has any effects on B cell growth and survival, a series 
of cell culture experiments were performed using combinations o f growth factors and 
different foetal calf serum (FCS) concentrations.
3.3.1 Does EBNA 1 influence Spleen and BM cell survival?
Spleen and BM cells from 3 EpEBNA 1 transgenic positive 2 month old mice 
(line 26), were cultured in parallel with splenocytes and BM cells from 2 wt siblings 
which served as controls. Splenocytes and BM cells were prepared as described in 
Methods section 2.4.2 and cultured in RPMI medium supplemented with 10% (v/v) 
FCS at an initial density of 4xl06cells/ml for BM and 3xl06cells/ml for spleen cells. 
Live cells were counted at 24hour-intervals by trypan blue exclusion (Fig. 3.8.).
BM cells from both EpEBNA 1 transgenic positive and negative animals 
showed an exponential decrease in their survival rate over 9 days of culture. Due to 
the contamination of the spleen cell cultures the results were incomplete but a 
comparable decrease in survival rate was observed in positive and negative samples. 
No differences were observed between EpEBNA 1 positive and negative samples.
3.3.2 FCS concentration influence on cell survival
Given that no advantage was evident in the survival o f EpEBNA 1 positive 
cells under normal culture conditions, it was decided to employ conditions which 
might highlight any survival or growth advantage endowed by EBNA 1 under minimal 
growth conditions. Spleen and BM cells from 4 EpEBNA 1 positive and 4 wt 2
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month old mice (line 26) were collected and cells cultured as described above. In this 
experiment, the cells were split in RPMI medium supplemented with either 1% (v/v) 
or 5% (v/v) FCS at an initial density of 5xl06cells/ml.
No difference was observed in the cell survival between the EpEBNA 1 
positive and wt (Fig. 3.9). However, as expected, cells from cultures containing only 
1% FCS showed significant reduction in the cell survival (few live cells left at 6 days) 
compared to the cell cultures with 5% FCS (14 days).
3.3.3 Growth factor influence on cell survival
To examine the possibility that EBNA 1 might co-operate with various 
cytokines/growth factors to stimulate cell survival, the experiment was repeated with 
some modifications. Amongst the growth factors that have specific activity on B cell 
proliferation, differentiation and Ig production are IL2, IL4, IL6, IL7 and CD40 ligand 
(see Introduction).
Splenocytes and BM cells from 2 EpEBNA 1 positive and 2 wt transgenic 2 
month old mice (line 26) were prepared as before and cultured in RPMI medium 
supplemented with 10% (v/v) FCS at an initial density o f 5xl06cells/ml. Aliquots 
were grown with (lng/ml of each growth factor) aCD40+IL4 and with IL6+IL7 for 
spleen cells and with aCD40+IL4+IL6+IL7 for BM cells. Live cells were counted 
again at 24 hour intervals by trypan blue exclusion over a period o f 24 days.
All cells showed a prolonged survival, in the presence of growth factors in 
comparison to the absence of cytokines (Fig 3.10 versus Fig. 3.8). From the two 
combinations of growth factors in the spleen cell cultures, IL4 and aCD-40 
supported cell survival slightly more effectively compared to the spleen culture 
supplemented with IL6 and IL7 (Fig 3.10b). However, while the EpEBNA 1 
transgenic positive cultures consistently showed a slightly better growth/survival 
pattern than the wt cultures (red lines always above blue ones), no dramatic 
difference was observed. In agreement with previous data (Armitage and Alderson, 
1995 and references therein), the addition of growth factors promoted cell growth.
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Fig. 3.9. The influence of FCS concentration on cell survival. Splenocytes and BM cells were 
grown in RPMI medium supplemented with antibiotics and either 1% (v/v) FCS (a) or 5% (v/v) 
FCS (b). Cells were seeded at a density of 5xl06 cells/ml and live cells were counted at 24 hour 
intervals by trypan blue exclusion. EpEBNA 1 positive samples are shown in red and wt samples 
in blue.
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Fig. 3.10. Influence of growth factors on cell survival. Spleen and BM cells from 2 EpEBNA 1 
positive and 2 wt 2 month old mice from line 26 were grown in RPMI medium supplemented 
with 10% (v/v) FCS. a) BM cells were grown in the presence of IL4, IL6, IL7 and aCD40. b) 
Spleen cells were grown in the presence of IL4 and aCD40 or IL6 and IL7. lng/ml of each 
growth factor was used in each case. Live cells were counted at 24 hour intervals by trypan blue 
exclusion. Medium replacement days are indicated at the bottom of each graph. EpEBNA 1 
positive samples are shown in red and wt samples in blue.
To extend these observations we examined the effect of a combination of growth 
factors with low FCS concentration upon cell survival. Bone marrow and spleen cells 
from 4 EpEBNA 1 positive and 4 wt 2 month old mice were collected and cells 
cultured as described earlier. In this case, the cells were grown in RPMI medium 
supplemented with 1% (v/v) and 5% (v/v) FCS at an initial density of 5xl06cells/ml. 
For each FCS concentration no factors, IL4 only, aCD40 only and IL4+aCD40, 
were added (Fig. 3.1 la  and b and Fig. 3.12). Although no difference was observed in 
the survival between EBNA 1 positive and negative cell populations under each 
condition, the effects of the cytokines used were again obvious by the extended 
survival o f all cultures in comparison to no growth factor addition.
CD40 antibodies in combination with IL4 have previously been shown to 
maintain proliferation of cells that are in active cell cycle (Armitage and Alderson, 
1995). However, this was not evident here. Although IL4-containing cultures from 
both tissues and at both FCS concentrations showed better survival rates as 
compared to those without IL4, the CD40 antibody made no difference to the cell 
survival. A representative case is shown (Fig. 3.13). This may be due to antibody 
concentration, some laboratories recommend up to lOOng of growth factor/ml of 
culture while lng/ml o f growth factor and antibody has been used in these assays. 
However, IL4 addition did provide a growth/survival advantage. Functionality of the 
growth factor is also important, for example, use o f CD40 ligand instead o f CD40 
antibody may have been more effective in cell stimulation.
For this reason it was decided to repeat the experiment with slight 
modifications. In this case spleen cells were cultured in RPMI medium supplemented 
with 10% (v/v) FCS at an initial density of 5xl06 cells/ml. Each cell culture, which 
was derived from 2.5 mouse spleens, was split into 5 aliquots each with a different 
combination o f growth factors including IL2, IL4 at a concentration of 1.5ng/ml of 
culture.
This time CD40 activation was supplied in the form of CD40 ligand 
(CD40L), which was derived from a CD40-producing cell line. The CD40L- 
producing cells (K47) are L929 mouse fibroblasts transfected with CD40L [or the
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Fig. 3.11 Splenocyte survival in RPMI medium supplemented with 1% (v/v) (a) and 5% 
(v/v) (b) FCS. 2 EpEBNA 1 positive and 2 wt sibling mice were used in each case. Cells 
were seeded at a density of 5x106 cells/ml in the absence of growth factors (i), with 
lng/ml of aCD40 (ii), with lng/ml of IL4 (iii) and lng/ml of each aCD40 and IL4 (iv). 
Live cells were counted at 24 hour intervals by trypan blue exclusion. EpEBNA 1 
positive samples are shown in red and wt samples in blue.
a) BM cell survival curve (1% v/v FCS) b) BM cell survival curve (5% v/v FCS)
106
o CMo 00
D ays
2 6 1 2 6 9
2 6 1 2 6 1
2 6 1 2 7 8
2 6 1 2 6 2
oc oo
D ays
2 6 1 2 7 4
2 6 1 2 7 5 — A —
2 6 1 2 7 6
2 6 1 2 7 7 ^ ---
Fig, 3,12 Logarithmic representation of BM cell survival rate. Cells from 2 EpEBNA 1 
positive and 2 wt mice were grown in culture medium containing either 1% (v/v) (a) or 5% 
(v/v) (b) FCS and was supplemented with aCD40 and IL4 at a concentration of lng/ml of 
each factor. Live cells were counted at 24 hour intervals by trypan blue exclusion. EpEBNA 
1 positive samples are shown in red and wt samples in blue.
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Fig. 3.13 Graphical representation of spleen cell survival rate from a wt control mouse in the 
presence or absence of growth factors. Cells were cultured for 11 days in medium containing 
5% (v/v) FCS supplemented with different combinations of growth factors as indicated. Cells 
were seeded at an initial density of 5xl06 cells/ml and counted at 24 hour intervals by trypan 
blue exclusion.
vector alone (K5) as negative controls]. CD40 is not secreted but is attached to the 
cell surface of the CD40L-producing cells and therefore the cells were grown as a 
feeder layer and killed by adding mitomycin C.
To eliminate any doubts that the observed effect was due to CD40L itself and 
not due to other possible growth factors produced by the fibroblasts themselves, 
cells transfected with only the K5 vector were used as controls. These cells were 
treated exactly in the same way as the K47 cells. Thus, the 5 combinations used in 
this experiment were K47-CD40L+IL4+IL2, K5+IL2+IL4, K47-CD40+IL4, 
K5+IL4, no growth factor added (Fig. 3.14). In this experiment the results were 
consistent with those described above.
Despite analysing cell growth/survival under these multiple conditions, there 
is no obvious difference in the survival rate between EpEBNA 1 transgenic positive 
when compared to wt control splenocyte samples (Fig. 3.14a). The presence of IL4 
always enhanced cell growth/survival. CD40L provided under these conditions (or 
activation by antibodies) showed little or no effect upon these cells. However, the 
IL2+IL4 combination supported cell survival a little better as shown by the slight 
shift in the curve (Fig. 3.14b). Moreover, the combination o f all three growth factors 
together was the most effective in supporting cell survival.
3.4 Transgenic B cell properties II: Cell differentiation and proliferation 
3.4.1. Spleen and BM cell proliferation (methylcellulose cultures)
To study the capacity of BM B cells to proliferate and differentiate, 
EpEBNA 1 positive mouse cells were compared to negative ones. Two separate 
experiments were performed, the first using 2 EpEBNA 1 positive and 2 wt mice 
(shown in Fig. 3.16 and indicated by an asterisk) and the second using 4 transgenic 
positive and 4 wt controls. BM and spleen cells were cultured in quadruplicates in 
semisolid methylcellulose IL7-containing medium. In the presence of IL7 compact 
colonies often consisting of >100 small cells, were formed by the BM cells (Fig.
3.15). Mouse spleen cells formed very few, <30 cell clusters formed in the presence 
of IL7. The colonies were apparent by day 3 of culture and the size reached a plateau
112
a ) i) Cell survival in the presence of CD40L +IL4+IL2 ii) Cell survival in the  presence of control cells+IL4+lL2
£
c
uO
00 oo <N
Days
i i i )  C e l l  s u r v i v a l  in  t h e  p r e s e n c e  o f  C D 4 0 L +  I L 4
1 0 ' “
106 “
3
oc 105 -
V
U
104 -
1 0 5 -
Days
v )  C e l l  s u r v i v a l  in  t h e  a b s e n c e  o f  g r o w t h  f a c t o r s
£
oc
oo <N 00
Days
2 6 1 5 6 2  O  2 6 1 5 6 8
—  O —  2 6 1 5 7 3  ----- A -----  2 6 1 5 7 6
£
oc
uU
ooo (Mo
Days
i v )  C e l l  s u r v i v a l  in  t h e  p r e s e n c e  o f  c o n t r o l  c e l l s  + I L 4
£
oc
DO
oX (No
Days
b )  S p l e e n  c e l l  s u r v i v a l
. . . . . . . . .
Days
C D 4 0 L + I L 2 + I L 4  
C D 4 0 L + I L 4  
N o  g r o w th  f a c t o r s
I L 2 + I L 4
I L 4
Fig. 3.14. Splenocyte survival in RPMI medium supplemented with 10% (v/v)FCS. 2 EpEBNA 1 
positive (red) and 2 wt (blue) sibling mice were used, a) Cells were seeded at a density of 3.2X106 
cells/ml in the presence of CD40L supplied by K47 cells (see text) +IL2+IL4 (i), K5 (control 
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growth factor was used at a concentration of 1 5ng/ml of culture, b) effectiveness of each growth 
factor on cell growth within each culture.
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on day 7. For each sample (quadruplicate) the cell colonies were counted and their 
frequency calculated. Each colony number was placed into one o f three subjective 
categories of approximately 10-40 cells, approximately 40-80 cells and >80 cells (Fig.
3.15). In all cultures there was a large number of single cells or very small clusters of
2-5 cells. Cell colony frequency was counted for each size category. Total colony 
numbers in these categories is shown in Fig. 3.16, while the proportion of the colony 
sizes are shown in Fig. 3.17 (where the colony number is taken as 100% for each 
culture).
As shown in Fig. 3.16a and c, it appeared that the overall number of colonies 
was lower in the first experiment (indicated by asterisk). Such differences are not 
unusual between two culture experiments. However, the proportion of the different 
colony sizes in experiment 1, shown in Fig. 3.17a is equivalent to the second 
experiment. From both experiments, it appeared that BM cells from EpEBNA 1 
positive mice formed more colonies than the wild type control samples. The 
difference was apparent in the number of the larger colonies, with more large ones in 
the EpEBNA 1 positive cultures.
Statistical analysis was performed on all 6 EpEBNA 1 positive and 6 wt 
control samples, in order to test if the observed differences in the number and the 
frequency of the different colonies between the transgenic and wt cultures were 
significant. Highly statistically significant different number o f colonies of the range of 
>80 cells was found in the transgenic cultures compared with wt (1.6-fold higher in 
EpEBNA 1 positive cultures, P=0.0006). Colonies in the range of 40-80 cells were 
also higher in the transgenic cultures. However, this is on the margin of statistical 
significance (P=0.051) (Fig. 3.16b). Figure 3.17 shows the relative proportions of 
these colony categories. The relative proportion of large colonies is greater in the 
EpEBNA 1 transgenic positive compared to wt mice (P=0.0000) and balancing this, 
the relative proportion of the small colonies (10-40 cells) is higher in the wt controls 
(P=0.0004).
The colony size classification is quite subjective and therefore a total cell 
count was performed for each separate sample using the trypan blue exclusion
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method, to determine if the total cell number present in each culture was consistent 
with the colony size classification. No significant difference was observed in the cell 
number between positive and negative for EpEBNA 1 positive BM cells (Fig. 3.18). 
However, in both positive and negative samples there was a large number o f cells that 
only divided a few times (small clusters of cells). By calculating the total number of 
colonies per sample (on average 80) and comparing it with the initial number of cells 
inoculated per culture ( lx l0 4), then it is clear that only a small proportion o f cells 
contribute to the colonies. As such, the final cell count merely reflects the bulk of the 
cells which did not divide, or only formed small colonies and the large colony cells are 
a very small proportion of this count, hence this count does not reflect the data 
presented in Figures 3.16 and 3.17.
Based on the above results it can be suggested that EBNA 1 may confer a 
survival or proliferative advantage to developing B cells in the transgenic BM cultures 
in comparison to the wt cultures.
3,4.2 Cell Apoptosis
To examine cell death specifically, AnnexinV/PI staining was performed on 
splenocytes from both EpEBNA 1 transgenic and wt siblings. Apoptosis is 
characterised by a variety of morphological features. Changes in the plasma 
membrane, such as the translocation of the membrane phosphatidyl serine (PS) from 
the inner to the outer cell membrane, are one o f the earliest of these features. 
AnnexinV is a Ca2+-dependent phospholipid binding protein that has high affinity for 
PS and binds to cells with exposed PS. Because extemalisation o f PS occurs in the 
earlier stages of apoptosis AnnexinV staining can identify apoptosis at an earlier 
stage than assays based on nuclear changes such as DNA fragmentation. AnnexinV 
staining precedes the loss of membrane integrity, which accompanies the latest 
changes of cell death resulting from either apoptotic or necrotic processes. Therefore 
staining with AnnexinV in conjunction with PI allows the investigator to distinguish 
early apoptotic cells (AnnexinV+/PI-). In combination with FACS analysis it was
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possible to calculate the percentage of apoptotic and dead cells in transgenic and wt 
cell cultures.
Splenocytes from 4 EpEBNA 1 positive mice and 4 wt controls were cultured 
in RPMI medium supplemented with 10% (v/v) FCS. Cell samples were taken at Ohr, 
2hr, 4hr and 20hr of culture. Cells were stained with AnnexinV- FITC/B220-PE to 
quantitatively determine the percentage of B cells undergoing apoptosis. Cells were 
also stained with AnnexinV-FITC/PI to distinguish the early apoptotic cells 
(AnnexinV+/PI-). Cells that stain positive for both AnnexinV-FITC and PI are either 
in the end stage of apoptosis, undergoing necrosis, or are already dead. As shown in 
Fig. 3.19a the apoptotic rate of B cells (AnnexinV+/B220+) started to increase in the 
first 4hr and approximately 55% of the B cells were or started to apoptose within 20 
hr. The total number o f cells entering apoptosis in the total population 
(AnnexinV+/PI-) (Fig. 3.19b) was calculated by subtracting the AnnexinV+ only cells 
from the AnnexinV+/PI+ cell population. The number of cells entering apoptosis 
(AnnexinV+/PI+ cells) started to increase in the first 4hr and then started to decrease 
because in 20hr approximately 60% of all cells were dead (AnnexinV+/PI+). 
However, no significant difference was observed in the cell death rate between 
transgenic and wt spleen cells. These results are in accordance with the cell survival 
experiments described earlier.
While the data do not demonstrate any effect of EBNA 1 upon apoptosis, the 
negative data do not prove that EBNA 1 does not have any effect on B cell survival. 
It may be that EBNA 1 provides resistance to an apoptosis triggering factor, for 
example a strong cell cycle insult, or that any effect is only evident in vivo.
3.5 Discussion
A variety of approaches have been used to identify possible B cell 
characteristics that EBNA 1 may effect.
Flow cytometric analysis o f splenic and BM cells from EpEBNA 1 transgenic 
mice revealed that the percentage of B220+/IgM+, B220+/IgD+, IgM+/IgD+, 
B220+/Thb+ and B220+/CD5+ cell populations was similar to that of control
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littermates. The B220+/CD23+ cell population may be effected, but this was less 
conclusive. However, the percentage of B220+/sIg+ cells was higher in both spleen 
and BM from transgenic positive animals when compared to the wt control siblings. 
The fact that slg+ B cell number was higher in both these tissues supports the result. 
Moreover, statistical analysis validates these results as the increased percentage of 
slg+ B cells in the EBNA 1 transgenic positive spleen and BM was found to be 
statistically significant both for the proportion of slg+ B cells and for the intensity of 
slg staining.
As mentioned earlier in the text, the slg polyvalent antibody used recognises 
IgM, IgG and IgA on the B cell surface. IgM is expressed in both immature and 
mature (naive and activated) B cells. Surface IgG and IgA are both expressed later 
during B cell maturation. Thus, by staining with B220/IgM, B220/IgG and B220/IgA 
separately it would be possible to calculate the percentage of immature or mature 
cells in the EpEBNA 1 positive and wt spleens and BM. In addition, after 
immunisation of the animals with a specific antigen and then measuring the secreted 
IgG in the serum by ELISA, it will be possible to monitor if  EBNA 1 really effects B 
cell antibody production.
Further staining with markers that are expressed at certain stages of B cell 
maturation would help to distinguish the different B cell subtypes. CD38 is 
expressed in pro- and pre-B cells and then again later on the plasma cells surface 
whereas CD43 expression is restricted to the pro-B cells. In addition, PNA (peanut 
agglutinin) and GL-7 are two markers expressed on the surface of germinal centre B 
cells. CD25 would be another useful marker to examine since it is expressed only on 
activated B cells. Moreover, staining with CD25 antibody would indicate if  CD25 
expression is increased in the transgenic splenocytes of the BL model as has been 
reported in a Hodgkin’s cell line expressing EBNA 1 (Kube et al., 1999).
The cell survival/proliferation assay on developing B cells in the BM  
(methylcellulose colony assay) showed that EpEBNA 1 transgenic positive BM cells 
have a higher survival/proliferation rate than wt BM cells. Statistical analysis revealed 
that this survival/proliferation advantage, illustrated by the increased number and
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proportion of larger colonies in the EpEBNA 1 transgenic cultures, was statistically 
significant (P=0.0006 and P=0.0000 respectively). However, it was not possible to 
characterise the cells o f the colonies formed. In order to do that a FACS analysis 
could be performed using B cells surface markers that are expressed through 
development/differentiation such as those mentioned above. Nevertheless, the 
methylcellulose colony assay is quite subjective. Therefore, in order to make this 
assay more objective B cell selection could be performed prior to culture followed by 
measurement of the survival/proliferation o f the sorted populations.
In order to examine proliferation directly, other approaches can be applied 
either in culture or in vivo. One such approach is to measure proliferation in culture 
by 3H-thymidine incorporation. The addition of tritiated thymidine provides a 
labelled nucleotide that can be incorporated into replicating DNA. A specific activity 
of [3H]-thymidine of 2Ci/mmol gives significant incorporation into DNA with a 
minimal amount of radiological damage.
Alternatively, proliferation can be assayed in vivo. This can be achieved by 
supplying BrdU to the EpEBNA 1 transgenic and wt animals. BrdU incorporates 
into replicating cells. Dividing B cells that will move from the BM to the spleen can 
either be sorted by FACS or seen in situ (in spleen sections) (Kline et al., 1999). The 
effects of EBNA 1 may become obvious since in such experiments the cells are in 
their natural, permissive environment.
EpEBNA 1 cells did not show any survival advantage in culture when 
compared to wt ones under any conditions used. Although the results from these cell 
survival experiments were negative this does not definitively demonstrate that EBNA 
1 does not effect cell survival. The results may not reflect what happens in vivo 
because the assays may be too stringent and not mimic the in vivo environment. 
There are many factors that may be responsible for the outcome of these results. 
First o f all, because the cell cultures contained not only B cells but also other cell 
types i.e. T cells, macrophages and fibroblasts, there may be interactions between the 
different cell types which could influence the data. Within a cell culture of such
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nature different cells may secrete factors (chemokines) which either induce cells to 
proliferate or to apoptose.
Other factors influencing the results may be the form, the functionality and 
the concentration of the growth factor used in the assay. IL4 supported cell growth 
far more effectively than any other growth factor used. In addition to its activities 
described earlier (Introduction), IL4 upregulates the expression of CD40 and also 
preferentially boosts the induction o f DNA synthesis in B cells mediated by the 
combination of aCD40 and IgM. Thus, anti-CD40 or CD40L (ligand) were included 
in this assay and used in combination with IL4 to activate and support B cell growth. 
Either the CD40 antibody or the CD40L on their own were not very efficient in 
supporting the cell cultures. This could be due to the low concentration of CD40 
antibody used or the feeder layer of CD40L-producing cells was not very effective in 
producing the CD40L required for B cell activation. Although IL2R (CD25) 
expression levels were found upregulated in a EBNA 1 transfected Hodgkin’s cell 
line, supplement of cell cultures with IL2 marginally improved cell survival in both 
EpEBNA 1 positive and wt cell cultures.
To eliminate the influence o f other cell types in culture a B cell selection prior 
to culture could be undertaken and greater concentrations of growth factors could be 
tried.
The apoptosis rate o f EpEBNA 1 transgenic cells was similar to that of w t 
cells in culture. These results agree with the cell survival assay results in which case 
no differences were observed between transgenic and wt cell cultures under any 
culture conditions tested. Being negative, however, these results do not support but 
neither refute that EBNA 1 does effect B cell survival. Cell culture conditions may 
have been very stringent in comparison to the in vivo environment. The cell cultures 
used in the AnnexinV/PI staining contained other cells which could have influence the 
data. B220 staining was included in the assay to help distinguish the B cell 
population. However, as the staining was only in combination with AnnexinV/FITC 
it was not possible to say if the B220+ cells were at early apoptotic stages or if they
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were dead. In approaching this problem, a B cell selection before the induction of 
apoptosis would be helpful and eliminate the staining problems for cell analysis.
Another limiting factor in this assay is that it did not distinguish between cells 
that have already undergone an apoptotic death and those that have died as a result of 
a necrotic pathway, because in either case the dead cells will be AnnexinV+/PI+. In 
approaching this problem, a strong and effective death insult, such as ionising 
radiation to trigger specific cell apoptosis pathways may be informative. In addition, 
taking samples at shorter time intervals might make it easier to gauge if EBNA 1 has 
any subtle effects on cell survival since the whole process would be faster.
Apoptotic cells characteristically exhibit DNA strand breaks and there is an 
alteration in their ability to scatter light at a forward angle reflecting cell size and at 
90° reflecting cell granularity. Such changes can be detected using the terminal 
deoxinucleotidyl transferase TdT mediated dUTP Nick End Labelling (TUNEL) 
assay in combination with flow cytometry.
It is tempting to speculate that EBNA 1 promotes B cell differentiation and 
hence the increased slg B cell population. If  this is the case then the increase in 
methylcellulose colony numbers perhaps indicates that EBNA 1 drives more cells 
through differentiation and causes them to form more and larger colonies in vitro.
Alternatively, EBNA 1 may support the survival/proliferation of immature B 
cells, supported by the methycellulose colony numbers, and then drives them to 
differentiate and survive leading to increased slg. However, at the moment we do not 
know the stage of B cell maturation in these colonies.
The accumulated data are therefore suggestive of a role for EBNA 1 in the 
survival or proliferation o f immature or mature B cells. EBNA 1 has been shown to 
be redundant with Bcl2 in transgenic crossbreeding experiments, and consequently it 
is suggested that these genes act in the same pathway. Since Bcl2 plays a critical role 
in blocking apoptosis and in the development of mature naive lymphocytes 
(Nakayama et al., 1993) EBNA 1 may act directly or indirectly through deregulation 
of other cellular genes to effect the same pathway.
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Chapter 4
Effects of EBNA 1 on cellular gene expression I: Selected genes
4.1 Introduction
The most up to date information concerning the transactivation function of 
EBNA 1 relates predominantly to the viral enhancer regions. The only cellular genes 
identified for which expression is up-regulated by EBNA 1 are Ragl and 2 (Kuhn- 
Hallek et al., 1995; Srinivas and Sixbey, 1995). One of the aims of this project was to 
examine the possible effects of EBNA 1 on the expression of key cellular genes in the 
B cell differentiation and proliferation pathways in vivo at the pre-tumour stage, 
using the transgenic mouse model (Wilson et al., 1992; 1996). The RNA expression 
level of different cellular genes in mouse tissues is variable depending on the 
developmental stage of the animal, the cell cycle point and the tissue that is analysed. 
A comparable study of cellular gene expression was therefore performed in age 
(siblings) and strain matched EpEBNA 1 positive and wt mice. It was important to 
collect tissues prior to the onset of neoplasia in this analysis to ensure that any 
observed effects were mediated by the EpEBNA 1 transgene and not by the 
secondary mutations that occur during tumourigenesis. In line 26, mice succumb to 
neoplasia at any age between 4 and 12 months. As such mice of 1 month (juvenile) 
and 2 month (young adults) were selected for this study. RNA samples were 
extracted from whole spleens and lymph nodes from EpEBNA 1 transgenic positive 
and wt sibling animals (see Methods section 2.4.5).
The spleen serves both a primary haemopoietic and lymphopoietic function 
in murine neonates but this is finished by 3-4 weeks o f age. The total lymphoid 
content reaches adult levels at 8-10 weeks of age. Mechanical disruption of the 
spleen yields about 5-15x107 cells including (about 2x l05 nucleated cells per mg fresh 
weight). The spleen is divided into red pulp and white pulp. The red pulp provides 
the emergency source of granulocytes and platelets. In addition it contains large 
numbers of macrophages, dendritic cells, scarce lymphocytes, endothelial cells and 
fibroblasts which usually act as accessory cells. The white pulp consists of 
lymphoid tissue, the periarteriolar lymphoid sheath, composed of T and B areas. T 
cells may be organised into either primary unstimulated follicles (surrounding 
aggregates of B cells) or secondary stimulated follicles, which possess a germinal 
centre (GC) (immature/naive B cell zone). Follicular dendritic cells and phagocytic 
macrophages are also found in germinal centres. Approximately 75% of the spleen 
cells are lymphocytes with about 50-55% being B cells and 25-30% T cells.
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Lymph nodes (LNs) are small but numerous within the mouse body. The LN 
consist of a B cell area (cortex), T cell area (paracortex) and a central medulla with 
cellular cords containing T cells (CD4+ and scarce CD8+), B cells, plasma cells and 
abundant macrophages. In the cortex, primary follicles consist o f mature resting B 
cells as well as macrophages and dendritic cells. In the secondary follicles germinal 
centres develop in response to antigenic stimulation and contain numerous large 
lymphocytes with phenotypic characteristics o f activated B cells. The mechanical 
disruption of LN in a young adult mouse yields about 5-10xl07 cells (without the 
mesenteric LN) (5x105 nucleated cells per mg wet weight). Approximately 75-80% 
of the lymphocytes is T cells and 20-25% B cells. Other cell types contribute in less 
than 1%.
The expression levels of several key cellular genes have been quantified by 
slot blotting total RNA samples from these tissues, probing and subsequent 
phosphoimaging analysis. Not knowing what expression level differences might be 
seen whole tissue was used as a first approach. Genes analysed in this approach 
include known B cell proto-oncogenes, apoptosis regulators and tumour suppressors. 
Due to the redundancy observed between EBNA 1 and Bcl2 in lymphomagenesis in 
transgenic cross-breeding experiments (see Introduction section 1.7) and the 
possibility that EBNA 1 could act through Bcl2 or another member of the Bcl2 gene 
family, the analysis started using probes for the Bcl2 family members. As a positive 
control indicator the Ragl and 2 genes involved in immunoglobulin loci rearrangement 
were also analysed. Certain additional genes were included in this screen, as detailed 
below.
4.2 Gene expression analysis in juvenile (1 month) tissues by slot blots
13 transgenic positive and 8 wt siblings at 1 month old from the EpEBNA 1 
line 26 mice were studied. Total RNA was extracted from whole spleen and LN and 
slot blots prepared using 5pg of RNA per slot. Four duplicate blots were prepared 
with batch samples. The blots were hybridised with 32P labelled probes generated by 
the random primed method from mouse-derived sequence plasmid cDNAs. The genes 
tested are listed in Table 4.1. Some tumour samples were also included in these slot 
blots as an indicator of over expression for certain transgenes. All slot blot signals 
were quantified by phosphoimage analysis. A representative slot blot autoradiogram 
is shown in Fig. 4.1 (phosphoimage values are given in Appendix 4.1); EpEBNA 1 
positive and wt RNA samples are listed. The background value was subtracted from 
the test values. The values were normalised (quantified for the RNA amount present 
in each slot) by re-probing the slot blots with the house-keeping gene glyceraldehyde
3-P dehydrogenase {GAPDH) and calculating the ratio of the test signal value over
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the quantitative signal value. In some cases there are only 1 or 2 samples in the group 
(such as the E[i-c-Myc, E \i-Piml and E\i-Bcl2 tumours), these can only give an 
indication o f expression levels without statistical relevance and were used only as 
expression controls.
In order to gauge whether the observed differences in the expression levels of 
the genes tested were significant, statistical analysis was performed using the Two- 
sample T-test. Statistical significance with 95% confidence intervals is reached when 
P<0.05. In order to visualise the data box plots are shown in Fig. 4.2. Statistically 
significant differences (P<0.05) between EpEBNA 1 transgenic positive and wt 
control samples were found in the expression levels of several genes. Graphical data 
is shown in Fig. 4.2 for those results displaying significant differences. The data are 
summarised in Table 4.1.
Of the genes tested in juvenile (1 month) spleen samples, from transgenic 
positive and wt mice, 4 displayed differential regulation. The expression levels of 
BclxL, Rag1 and Rag2 were found to be 1.3-fold higher in the EpEBNA 1 transgenic 
positives compared to wt controls, all to a significant degree. Pim l showed a lower 
expression level of 0.8-fold when compared to wt controls. This differs from the 
results obtained using LN samples where only the expression level of Bad (0.8x) was 
found to be significantly lower in the transgenic positive compared to the w t 
samples. This might be due to the different cellular compositions o f these tissues as 
described in the introduction.
These data demonstrate that presenting a ratio between mean values is not 
sufficient for meaningful results, and that statistical analysis is required to support 
conclusions. For example, Bax expression (Fig. 4.3) shows the largest difference of 
the means between positive and wt mice with a ratio of 1.8. However, this difference 
is not statistically significant as indicated by the box plot, in which the spread of the 
data in the EpEBNA 1 positives shows a different pattern to that seen in the wt ones 
(Appendix 4.1), and a P value of 0.3. Even discounting the outlying values does not 
bring the P value to significance. This is also evident in the bar graphs with the error 
bars in each group of data. In contrast to Bad, BclxL showed a smaller (1.3-fold) but 
statistically significant increase because the data spread within each group was 
smaller, shown in the box plot and by the error bars in the bar graph.
4.3 Gene expression analysis in young adult (2 month) tissues
The analysis was extended to pre-neoplastic young adult tissues using mice at 
2 months old. Whole spleen and LN total RNA samples from 8 EpEBNA 1 positive 
line 26 and 8 wt siblings were analysed using slot blots as described in section 4.2. 
EpEBNA 1 tumour samples from line 26 were also included within the slot blots (as
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described in section 4.2). Genes tested are listed in Table 4.2. The data obtained was 
analysed as described in section 4.2 and is summarised in Tables 4.2 and 4.3. 
Although some differences in the expression levels of some o f the genes were 
observed, none reached statistical significance. This might be due to the spread of the 
values in each group of samples. This is apparent in the differences in the examples 
shown (Fig. 4.4 and 4.5) which both include an outlying value in the data set. The 
number of samples included in each group may also contribute to the outcome of the 
results. An outlyer may be present within a group of data, which highly influences 
the result when the sample size is small. For example, in the case of Ragl expression 
in whole spleen RNA an outlyer value in the wt samples gives a result that does not 
show a statistically significant difference between positive and wt samples (See 
Appendix 4.II and Fig. 4.4). When the outlyer is excluded the values are less spread 
and the result is statistically significant as shown in Fig. 4.4b. Similarly, in the case 
of Mdm2 expression in the spleen an outlyer in the negative samples impacts the 
statistical analysis (Appendix 4.II). When the outlyer is excluded the result becomes 
significant as shown in Fig. 4.5a and b. The programme used for the statistical 
analysis considers as outlyer any value that is beyond 1.5-fold the inter-quartile range 
(the length o f the box in the box plot). When a value is further away from the bulk of 
the values the programme does not exclude it but instead it is depicted as an asterisk. 
A question arises here: is it valid to exclude an outlyer, just because it changes the 
result? It may be appropriate to exclude it when there is a scientific explanation to 
support it. In the case o f Ragl and Mdm2, since it is the same sample, it could be 
attributable to experimental error i.e. RNA sample extraction or poor hybridisation of 
this particular sample with GAPDH. Moreover, when one does this type of 
analysis, in vivo, variation in the samples is expected. This is because the analysis 
involves animals, which although grown under controlled conditions, they may differ 
as organisms especially in their immune reactions, behaviour (e.g. fighting) which 
impacts gene expression. However, because of the experimental approach e.g. 
animals grown in a controlled environment, same age, same protocols are used for 
RNA extraction and blot preparation and analysis, controllable variables are excluded.
4.4 Gene expression analysis in tumour samples
In order to investigate which genes are de-regulated in the EpEBNA 1 
transgenic tumours; RNAs from several tumour samples were analysed as described 
in section 4.2. It would be anticipated that any changes in expression patterns 
detected would reflect mutational changes in tumour progression as well as the result 
of EBNA 1-directed de-regulation.
Total RNA samples were derived from whole spleen and LN tissues from 6
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D F = 1 4  P O O L E D  S T D E V =  0 .0 5 6 2
Fig. 4.4 Box plot representation, with numerical values bellow, of Ragl expression results in 
2 month whole spleen total RNA from EpEBNA 1 positive (red) and wt (blue) mice. An 
outlyer in the group of the wt samples (represented by *) distorts the result and it renders it 
not statistically significant (a). When the outlyer is excluded the result becomes statistically 
significant (b).
a ) b)
0 . 4 —I
*  «  o . i -
0.0  -
Two-sample T for Mdm2 Spl Two-sample T for Mdm2 Spl
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D F = 1 4  P O O L E D  S T D E V =  0 .1 0 1
+ / -  N  M E A N  S T D E V  S E M E A N  
+  8 0 . 1 6 6 0  0 .0 7 2 8  0 .0 2 6
- 7  0 . 0 7 5 9  0 .0 4 4 8  0 .0 1 7
9 5 P C T  C l  F O R  M U +  - M U - : ( 0 .0 2 1 ,  0 .1 5 9 )  
T T E S T  M U  + = M U -  ( V S  N E ) : T = 2 .8 3  P = 0 .0 1 4  
D F = 1 3  P O O L E D  S T D E V =  0 .0 6 1 5
Fig. 4.5 Box plot representation, with numerical values bellow, of Mdm2 expression results in 
2 month whole spleen total RNA from EpEBNA 1 positive (red) and wt (blue) mice. An 
outlyer in the group of the wt samples (represented by *) distorts the result and it renders it 
not statistically significant (a). When the outlyer is excluded the result becomes statistically 
significant (b).
EpEBNA 1 mice with tumours in those tissues from line 26 and 5 EpLM Pl mice 
with tumours (line 39). The genes tested are listed in Table 4.3. A graph and a box 
plot o f significantly different expression results are shown in Fig. 4.6. It is difficult 
to select an appropriate control to evaluate gene expression de-regulation in tumour 
samples. Whereas the tumour sample might be composed of 50-90% malignant cells, 
normal tissues include several cell types and cells at different stages of development. 
Thus, a gene expressed at a higher level, for example in normal T cells, would obscure 
this comparison. Moreover, the percentage o f the tumour cells within the tissue 
varies between different tumours. As such, whole spleen, isolated splenocytes or 
selected B cells from wt control animals do not provide a cell type proportional 
control for tumour bearing tissue samples.
Initially, the line 26 tumour tissue samples were compared with 2 month old 
adult negative whole spleen or LN tissue. This data is summarised in Table 4.3. In 
the spleen tumours compared to wt young adult (2 month) whole tissues, a number 
of genes were found to be differentially expressed. Significantly higher expression 
levels were observed for Bad (3.2x), BclxL (4.7x), cMyb (4.65x), Mdm2 (x4.2), M ip la  
(2.7x) and Piml (xl.95). However, the results obtained from LN tumours compared 
to normal young adult (2 month) whole tissue RNA, only G fil (9.45x) and Ragl 
(29x) showed considerable and statistically significant higher expression levels in 
these tumour samples.
Due to the cell content differences between the normal and the tumour tissues 
a comparison was also made with EpLM Pl transgenic tumours from line 39. In this 
case the data will reflect a compound o f EBNA 1 and LMP 1 tumour progression 
characteristics, summarised in Table 4.4 and graphically depicted in Fig. 4.7. In the 
spleen EpEBNA 1 tumours from line 26 as compared to EpLM Pl tumours from line 
39, G fil (1.4x) and Rag2 (1.7x) were found statistically significantly higher in line 26 
(EpEBNA 1). In contrast, Bak (0.85x), Bax (0.73x), Bcl2 (x0.7) and Mdm2 (x0.865) 
were found statistically significantly lower in line 26 in comparison to line 39 
tumours. Quite different results were obtained with the LN EpEBNA 1 tumours 
(line 26) as compared to EpLM Pl tumours (line 39). In this case G fil (2.4x), 
GMCSF (2x), Mdm2 (1.25x) and M IPla  (2x) were found higher in EpEBNA 1 versus 
EpLM Pl tumours whereas Rag 1 (0.75x) was found lower in EpEBNA 1 tumours 
compared to EpLMPl tumours.
4.5 Discussion
4.5.1 Gene expression in pre-neoplastic tissues
Using the transgenic mouse model for EBV associated BL an attempt was 
made to identify genes that either mediate EBNA 1 action or may co-operate with it 
in the onset of tumourigenesis. As a transcriptional regulator EBNA 1 may directly
136
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effect the expression o f cellular proto-oncogenes and tumour suppressor genes. 
Therefore, the expression levels of several key cellular genes that are often found de­
regulated in lymphoid tumours were analysed.
The Rag genes are the only cellular genes suggested to be regulated by EBNA 
1 (Kuhn-Hallek et al., 1995; Srinivas and Sixbey, 1995). They were therefore 
included in this assay to investigate if this activity is present and measurable in vivo 
in murine cells and if so, to act as controls for this approach. Analysis o f the level of 
Ragl and 2 expression in RNAs from EpEBNA 1 transgenic positive and wt control 
sibling mice revealed a consistent Ragl and/or Rag2 up-regulation in EpEBNA 1 
expressing cells at all developmental stages tested. At 1 month, the juvenile mouse 
tissues are still immature and undergoing developmental changes. As was mentioned 
earlier (section 4.1) the composition of lymphoid tissues reaches adult proportions at 
8-10 weeks of age. Therefore, the Rag gene expression levels would be different 
according to the maturation stage of the cells. Rag expression is highly regulated 
during B lymphopoiesis. Ragl and 2 expression is primarily restricted to developing 
lymphocytes that are undergoing re-arrangement o f their antigen receptor genes (Fig. 
4.8). Ragl and 2 mRNA is first detected in pro-B cells but is down-regulated in early 
large B cells upon completion of IgH re-arrangements (Grawunder et al., 1995a). The 
Rag genes are then transcribed again in small pre-B cells to allow light chain gene re­
arrangements and later at Ig switching (Fig. 4.9). The fact that Rags were found up- 
regulated at the pre-tumour stage reflects that this in vivo approach is successful and 
useful in studying the mechanism of action of EBNA 1 as an oncogene.
In 1 month old whole spleen total RNA BclxL was found up-regulated in the 
EpEBNA 1 positive samples by 1.3 fold. Even though the ratio is low the result is 
significant, supported by the Rag control results which also showed a difference 1.3- 
fold. This result is consistent with observations from transgenic crossbreeding 
experiments between EpEBNA 1 and E \x-Bcl2 mice performed by M. Drotar and J. 
Coy in our laboratory. In this experiment Bcl2 was found redundant with EBNA 1 in 
lymphomagenesis (as described in the introduction). Thus, EBNA 1 could act in a 
similar way to Bcl2 or through a Bcl2 family member e.g. BclxL or Bad. However, 
this was not seen in the LN samples. Instead only Bad  was found down-regulated by 
0.8-fold. This difference may be due to the tissue composition e.g. spleen consists of 
more B cells and less T cells whereas LN have more T than B cells. Therefore, the 
effect of EBNA 1 on BclxL gene expression in B cells may be masked by the signal 
deriving from the T cells. The anti-apoptotic functions of BclxL are controlled in part 
by several interacting proteins such as Bad (an apoptosis promoter) which can 
heterodimerise with BclxL (Yang et al., 1995). Therefore EBNA 1 could either 
directly or indirectly deregulate the expression of Bel2 or other family members.
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Nevertheless, these results are not apparent at the 2 month stage from whole 
spleen and LN, as none of the genes tested showed statistically significant 
differences. However, no changes were observed in Rag 1 and 2 gene expression at 
this point.
This may be due to the different gene expression pattern in the spleen and LN 
from animals of different ages. In juvenile animals, which are still in the process of 
development, the immune system is not fully developed and therefore variation in 
gene expression would be expected. In contrast, the adult immune system is fully 
developed and unless there is an immunogenic factor that could trigger an immune 
reaction, gene expression is more stable.
The differences observed in the results obtained from the analysis of juvenile 
(1 month) and young adult (2 month) tissues may be attributable to age o f the animal 
and or maturation stage of the cells as well as the differences between spleen and LN 
tissues. This assumption is consistent with recent observations in the BclxL 
expression patterns during mouse development. Expression analyses have shown 
that BclxL is the dominant Bclx gene mRNA transcribed in embryonic and postnatal 
tissues including primary lymphoid organs (Gonzalez-Garcia et al., 1994; Fang et al, 
1994). BclxL is more abundant than Bcl2 in adult tissues with the highest levels in 
adult brain, thymus and kidneys and to a lesser extent in spleen and LN. In the 
mouse embryo, BclxL mRNA is detected at day 8.5 through to 12.5 of development. 
BclxL expression at day 15.5 is more restricted to heart, brain, thymus and kidney 
with the highest level in the liver the major site of haematopoiesis in the mouse 
embryo. During B cell development BclxL is expressed predominantly in pre-B cells 
and provides a survival signal for the maintenance of pre-B cells and activated mature 
B cells. Transgenic mice over-expressing BclxL exhibit accumulation of immature and 
mature B cells implying that BclxL supports maturation of pre-B cells into B cells 
(Grillot et al, 1996). However, in mature B cells BclxL expression is normally 
reduced. In addition BclxL protein has been detected at very low levels in pro-B 
cells, up-regulated in pre-B cells and down-regulated again in immature B cells (Fig. 
4.8 and Fig. 4.9) (Grillot et al., 1996). Interestingly BclxL and Rags are co-expressed 
during B cell development. Therefore, it can be postulated that EBNA 1 may act at a 
specific developmental stage, possibly resulting in de-regulation of these genes, 
indirectly.
c-Myc protooncogene expression levels were tested because c-Myc shows a 
co-operation with EBNA 1 in lymphomagenesis in transgenic cross-breeding 
experiments (introduction section 1.7). If EBNA 1 and c-Myc mutation/activation do 
co-operate in tumourigenesis, one would predict that EBNA 1 does not act through c- 
Myc. Consistent with this idea, no de-regulation of c-Myc by EBNA 1 was seen in 
the pre-tumour tissue.
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Piml is a protooncogene that has been shown to co-operate with cMyc in 
lymphomagenesis in transgenic cross-breeding experiments (reviewed in Introduction 
section 1.4). In the RNA expression analysis in pre-tumour tissues Pim l was found 
to be statistically significantly lower in the 1 month EpEBNA 1 positive spleens 
compared to wt controls. Pim l is predominantly expressed in T cells. Therefore, 
since EBNA 1 is expressed in B cells, it could be that EBNA 1 might effect B cells 
which subsequently could effect T cells.
Since BclxL acts to inhibit apoptosis in a similar manner to Bcl2 and is up- 
regulated in line 26, pre-tumour, EBNA 1 may act through BclxL (and/or Bad) to 
repress apoptosis. Therefore, EBNA 1 may act indirectly as an apoptosis regulator, 
factorial in oncogenesis. Moreover, EBNA 1 could act through de-regulation of Piml 
resulting in up-regulation of the genes inhibited by it. EBNA 1 may de-regulate gene 
expression by binding to the promoter or other regulatory elements. However, a 
database search revealed no EBNA 1 binding sites in the promoters o f any of the 
genes tested in this chapter. EBNA 1 was shown to bind the human cell protein 
P32/TAP which has been implicated in transcriptional regulation (see Introduction 
section 1.4). Thus, EBNA 1 could regulate gene expression by activating other 
transcription factors. However, a blast search needs to be undertaken to see if 
P3 2/TAP binding sites are present in the promoter o f the gene tested in the current 
analysis.
4.5.2 Gene expression in tumours
The analysis of EBNA 1 effects on cellular gene expression was extended to 
the tumour stage where a number of genes were found up- or down-regulated in 
comparison to wt control samples. Ragl expression was consistently up-regulated in 
line 26 EpEBNAl tumours by 29-fold (!) compared to wt controls and this change 
was statistically significant. In contrast, Ragl expression was significantly lower in 
EpEBNA 1 tumours (0.75x) when compared to EpLM Pl tumours which may 
suggest that Ragl is commonly up-regulated in human tumours, or also by LMP1. 
Rag2 expression on the other hand did not show statistically significant changes in 
EpEBNA 1 positive tumours versus wt type controls. However, Rag2 expression 
was statistically significant higher in the EpEBNA 1 positive tumours (1.7x) when 
compared to EpLMPl positive tumours suggesting that LMP1 (in contrast to EBNA 
1) down-regulates Rag2 expression.
Adding together the results from the pre-neoplastic and tumour Rag 1 and 2 
gene expression assays, it is tempting to speculate that the oncogenic action of 
EBNA 1 might be exerted through enhanced Rag expression giving rise to genome 
instability and aberrant translocations. However, karyotypic analysis of EpEBNA 1 
tumours showed that only approximately 10% of the tumours tested carried a
144
translocation (Wilson, JB personal communication). Translocations are not very 
common in mouse lymphomas compared to human lymphomas; instead mouse 
tumours more often display polysomy as was also seen in the EpEBNA 1 tumours.
Bcl2 family gene expression levels in the tumours were quite variable in 
comparison to the pre-neoplastic stage. In EBNA 1 positive spleen tumours BclxL 
and Bad expression were found to be significantly higher (4.6-fold and 3.2-fold 
respectively) in comparison to wt controls. In contrast, when compared to EpLM Pl 
tumours their expression, albeit higher, was not statistically significant. However, 
B ak( 1.2x) Bax (1.4x) and Bcl2 (1.43x) were found to be significantly down-regulated 
in line 26 tumours versus line 39 tumours which may suggest that LMP1 upregulates 
these genes. LMP1 has been shown to up-regulate Bcl2 (Henderson et al., 1991). 
Therefore, both EBNA 1 and LMP1 may influence the balance between the Bcl2 
family members by regulating their expression levels. The balance of the interaction 
of the Bcl2 family members is very sensitive and thus the slightest effects from 
EBNA 1 or LMP1 could lead to prolonged cell survival and subsequently tumour 
formation.
Statistically significantly higher expression levels o f Gfil (9.45-fold) were 
observed in EpEBNA 1 LN tumours as compared to wt controls. However, this 
upregulation was not apparent in the spleen tumours. G fil was also found higher in 
the EpEBNA 1 spleen and LN tumour samples when compared to EpLM Pl positive 
tumours. Thus, Gfil may be up-regulated in EBNA 1 tumours or comparatively 
down-regulated in the LMP1 tumours. However, as this de-regulation is not detected 
at the pre-tumour stage it might be a likely secondary mutation. Gfil encodes a 
nuclear zinc-fmger protein that carries a repressor domain, SNAG and functions as a 
position- and orientation-independent transcriptional repressor. Interestingly, it was 
recently demonstrated that Gfil down-regulates the expression of Bax and Bah 
(apoptosis promoters, Bcl2 family) in established cell lines and transgenic Gflil- 
positive primary cells (Grimes et al., 1996b). Therefore, Gfil may inhibit apoptosis 
by means o f its repression of multiple pro-apoptotic regulators. The antiapoptotic 
properties of Gfil may help to explain its strong collaboration with c-Myc during 
oncogenesis (Introduction section 1.4). Thus, if  EBNA 1 up-regulates G fil this could 
lead to down-regulation o f Bax or Bak in the EpENA 1 tumours. This assumption is 
consistent with the gene expression results in the line 26 tumours described in section 
4.4.
c-Myc is found to be de-regulated in BL tumours (discussed in Introduction 
sections 1.2 and 1.4). Preliminary data from our lab from transgenic cross-breeding 
experiments between EpEBNA 1 and E \i-c-Myc mice is suggestive of a co-operative 
action between EBNA 1 and c-Myc de-regulation in tumourigenesis. Moreover, 
karyotypic analysis has revealed that most of the tumours arising in these mice have
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trisomy of chromosome 15, the chromosome bearing c-Myc. If  EBNA 1 and c-Myc 
activation/mutation co-operate in tumourigenesis, one would predict that EBNA 1 
does not act through c-Myc. Consistent with this idea, no de-regulation of c-Myc by 
EBNA 1 was seen in the pre-tumour tissue and in tumours. This might be due to the 
wide variation in the level of c-Myc expression in transgenic and non-transgenic tissue 
(see Fig. 4.10 and Appendix 4.IV) regardless of tumour status which agrees with 
previous published work (van Lohuizen et a l, 1989). In addition, the variation in 
these samples could be due to the normal proliferative state o f the spleen and LN. 
Moreover, it is possible that c-Myc may be mutated in some tumours and not in 
others.
Pim l is another proto-oncogene that has been shown to co-operate with cMyc 
in transgenic cross-breeding experiments (reviewed in Introduction section 1.4). 
Although Piml was found to be down-regulated in the 1 month pre-neoplastic spleen 
samples in the spleen tumours Piml was found to be up-regulated. One possibility 
for this contrasting result could be that EBNA 1 may down-regulate Pim l, while, a 
secondary event in the tumours may overcome the EBNA 1 primary effect and 
upregulates Piml expression. Piml expression is highly induced by IL2, IL3 and 
GMCSF (Lilly et al, 1992; Sato et al., 1993; Buckley et al., 1995; Rohwer et al., 
1996). GMCSF was found significantly higher in transgenic positive spleen 
compared to wt controls. Therefore up-regulation o f GMCSF in these tumours could 
lead to up-regulation of Piml. Another factor contributing to the Pim l expression 
results could be the differences in the cell composition between the normal and 
tumour tissues.
Mdm2 expression was found to be significantly higher in EpEBNA 1 spleen 
tumours (x4.2) compared to wt controls (but not in the LN samples). Mdm2 was 
also found to be up-regulated (when outlyer is excluded) in the 2 month old RNAs. 
EBNA 1 could either directly or indirectly increase Mdm2 expression. Karyotypic 
analysis in our lab of EpEBNA 1 tumours showed a high percentage (56%) of 
trisomy for chromosome 10. A potentially important locus on this mouse 
chromosome is Mdm2 which negatively regulates p53. Mutated p53 has been found 
in some BL tumours (Farrell et al., 1991). Therefore, it can be postulated that 
upregulation of Mdm2 would lead to reduction o f p53 function. Nevertheless, 
although p53 gene expression analysis in EpEBNA 1 tumours showed no statistically 
significant changes of p53 RNA expression levels, this does not reveal what is 
happening at the protein level.
The RNA source is important in the experiments described in this chapter. 
The EpEBNA 1 transgene expression has been directed to the B cell compartment. 
Thus, the effects of EBNA 1 regulation on the expression o f cellular genes will be 
more obvious and the signals obtained more specific when the RNA samples are
146
c
.2* -»
■D
*C
<u>
c
.2"55
CO
o-
X
UQ
 — * -
Two-sample T for c-M yc Spl (1M  )
+/- N MEAN STDEV SEMEAN 
+ 13 4.942 0.816 0.23
8 5.377 0.826 0.29
95PCT Cl FOR MU+ -MU-:(-1.21, 0.34) 
TTEST MU +=MU- (VS NE):T=-1.18 P=0.25 
DF=19 POOLED STDEV= 0.820
Two-sample T for c-M yc Spl (2M)
+/- N MEAN STDEV SEMEAN
+ 8 0.166 0.117 0.041
- 8 0.1272 0.0720 0.025
95PCT Cl FOR MU+ -MU-:(-0.065, 0.143) 
TTEST MU +=MU- (VS NE):T=0.81 P= 0.43 
DF=14 POOLED STDEV= 0.0969
0.20-
0 .1 5 -
0.10_
0.00-
Two-sample T for c-M yc Spl Turn.
+/-
+
N MEAN STDEV SEMEAN
0.1272 0.072 0.025
- 5 0.233 0.122 0.055
95PCT Cl FOR MU+ -MU-:(-0.223, 0.012) 
TTEST MU +=MU- (VS NE):T=3.80 P=0.073 
DF=11 POOLED STDEV= 0.0935
0.09-
0.08-
0.07-
Two sample T for c-M yc LN (1M )
+/- N MEAN STDEV SEMEAN
+ 13 0.0917 0.0111 0.0031
- 8 0.0926 0.0111 0.0039
95PCT Cl FOR MU+ -MU-:(-0.0114, -0.0095) 
TTEST MU +=MU- (VS NE):T=-0.19 P=0.85 
DF=19 POOLED STDEV= 0.0111
2 -
1 -
0 -
Two-sample T for c-M yc LN (2M )
+/- N MEAN STDEV SEMEAN
+ 8 0.477 0.737 0.26
- 8 0.323 0.244 0.086
95PCT Cl FOR MU+ -MU-:(-0.44, 0.742) 
TTEST MU +=MU- (VS NE):T=0.56 P=0.59 
DF=14 POOLED STDEV= 0.549
0 .4 -
0.3 -
■0.2 -0.0-
Two-sam ple T for c-M yc LN Turn
N MEAN STDEV SEMEAN
+ 8 0.323 0.244 0.086
- 5 0.1077 0.0899 0.040
95PCT Cl FOR MU+ -MU-:(-0.038, 0.469) 
TTEST MU +=MU- (VS NE):T=1.88 P=0.088 
DF=11 POOLED STDEV= 0.202
Fig. 4.10 c-Myc expression levels in 1 month and 2 month EpEBNA 1 transgenic positive 
(red) versus wt (blue) spleen and LN and in EpEBNA 1 positive spleen and LN tumours versus 
2 month wt tissues.
extracted from selected B cells in comparison to total spleen or LN. For example, in 
the analysis of the cellular gene expression in juvenile (1 month) mice the RNA 
samples were extracted from total spleen and LN from line 26. Because the spleen is 
quite a heterogenous tissue consisting of many different cell types, the signal deriving 
from a gene that normally has higher expression in the T cells will mask the signal 
originating from the B cells. Therefore, the final observation may not reflect the 
actual effect of EBNA 1 action. However, the differences observed in the expression 
levels of BclxL, Bad, P im l, Ragl and 2 and Mdm2 may be due to EBNA 1 de­
regulation since they were found de-regulated in both pre-tumour and in tumour 
tissue.
The RNA samples used in the gene expression analysis in tumour samples 
derive from monoclonal B cell tumours from line 26. Such tumours consist 
predominantly of B cells and therefore the signal obtained from the cellular gene 
expression is more specific. However, as these tumours are monoclonal (inferring 
further cellular transforming events), the differences observed in tumour tissues may 
be partly, but not necessarily due to EBNA 1. The changes in the expression levels 
of Gfil, M IP la  and GMCSF may be secondary events in tumourigenesis as no 
significant differences were found in the pre-tumour samples. The high variation in 
gene expression in some tumour samples may be due to the fact that secondary 
mutations differ between tumours and therefore one may expect some higher values 
and some normal.
This kind of gene expression analysis, only reveals changes common to most 
or all tumours. Thus, comparing groups of data and doing statistics only give 
significance in the changes without specifying if the gene is de-regulated by EBNA 1 
or is a common secondary mutation. Therefore a more sensitive assay for c-Myc 
expression would be more useful. For example, in order to detect any c-Myc de­
regulation it would be more appropriate to compare c-Myc expression in cells (EBNA 
1 positive and wt cells) which are synchronised with respect to their cell cycle stage. 
In normal cells c-Myc expression is highly regulated (Marcu et al., 1992). Therefore, 
an assay which would assess cellular gene promoter usage in EBNA 1 induced 
tumours may be useful in detecting gene de-regulation.
Another factor, possibly contributing to the gene expression results in the 
tumours would be the controls that were used for the comparison. The problem is 
that we do not know what the percentage of each cell type is in the tumours as well 
as what the percentage of tumourous cells is. Therefore, the best solution to this 
problem would be to perform B cell selection from both tumour and normal tissues 
and then do a direct comparison of cell gene expression between the two sets of 
samples. Cell type purification and RNA extraction from pre-neoplastic tissues is 
described in Chapter 5.
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A combination of the BclxL expression pattern throughout murine life and the 
findings that BclxL and Rags are up-regulated in EBNA 1 pre-neoplastic and tumour 
tissues compared to wt would suggest that EBNA 1 may effect B cell survival and 
delay B cells in certain stages. Alternatively, EBNA 1 could simply induce aberrant 
expression of genes that are not normally co-expressed.
149
Chapter 5
Effects of EBNA 1 on cellular gene expression II: Differential 
expression
5.1 Introduction
An alternative approach to investigate the effects of EBNA 1 on cellular gene 
expression was used next, employing the “mouse Atlas expression array”, a 
comparative cDNA-based technique useful for profiling differential gene expression. 
This method can provide quantitative measurements of the expression levels of a 
large number of genes (588 genes in the array) in different samples. As such, levels 
may be compared between different samples, such as normal versus pathological 
tissues. Each Atlas array membrane contains 6 groups of genes encoding: a) 
oncoproteins, tumour suppressors and cell cycle regulators; b) stress response 
proteins, ion channel and transport proteins, intracellular signal transduction 
modulators and effectors; c) apoptosis-related proteins, DNA synthesis, repair and 
recombination proteins; d) transcription factors and general DNA binding proteins; e) 
receptors: growth factor and chemokine, interleukin and interferon, hormone and 
neurotransmitter, cell-surface antigens and cell adhesion proteins; f) growth factors, 
cytokines and chemokines, interleukins and interferons, cytoskeleton and motility 
proteins, protein turnover. The membranes also include some house-keeping genes 
and negative controls which serve as quantitative and qualitative controls. All genes 
included are listed in Appendix 5.1.
The assay as described here is more specific than those described in Chapter 4 
since the RNA used was derived from selected B cells from 2 month old mice instead 
of using whole spleen or splenocyte samples. However, as an approach in general, it 
should be used only as an indicator of which genes should be analysed further and not 
as evidence of gene de-regulation. This is because the data can only show the ratio of 
difference between two compared sets, without the possibility o f statistical analyses. 
Therefore, to test if any observed differential expression is real, by the criteria of 
statistical significance, the results obtained from the array must be confirmed. This 
was done here by returning to slot blot analyses.
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The analysis was extended to the protein level for some of the genes that 
showed (or were close) to statistically significant differential expression levels.
5.2 Gene expression analysis in selected B cells from young adult mouse 
spleens: Gene expression array
Splenocytes were isolated separately from 4 transgenic positive and 4 wt 
(sibling controls) 2 month old mice from the EjliEBNA 1 line 26. B cells were 
selected by a positive selection protocol employing the B220 (CD45R) antibody 
attached to magnetic beads. Total RNA was isolated from each of the 8 samples. 
30pg of RNA from each of the EpEBNA 1 positives were pooled and similarly for 
the wt, so that parameters measured for each sample represent a mean of 4 positives 
and 4 wt. The positive and the wt RNA pools were then polyA+ selected. 1 jug of 
polyA+RNA from each positive and wt RNA pool was used to make a cDNA probe 
for hybridisation to the mouse Atlas cDNA array membranes (see Methods section 
2.4.5). Hybridisation signal intensity depends on the abundance in each RNA sample 
of transcripts from each of the 588 genes displayed on the macroarray.
The images of the 2 mouse Atlas membranes, one hybridised with the 
EpEBNA 1 positive 2 month RNA and the other hybridised with the 2 month wt 
RNA, were scanned by phosphoimager and are shown in Fig. 5.1. The intensity of 
the images differed due to the small difference in the activity of the radioactive probes 
(the EpEBNA 1 positive cDNA was better labelled than the wt cDNA). Thus the 
membranes were normalised by adding the phospho-image values o f the house­
keeping genes (included on each array) on each blot and calculating the ratio of the 
positive blot over the wt blot house-keeping gene average value (correction factor = 
EpEBNA 1+ cDNA/ wt cDNA of house-keeping gene mean value). The obtained 
correction factor was 2.4. The values from the wt test samples were normalised by 
multiplying them by the correction factor. The differences between transgenic 
positive and wt values were calculated by the ratio o f the positive values compared 
to the corrected wt values (Ratio = EpEBNA 1+ cDNA value /wt corrected cDNA 
value).
The genes that showed the more obvious differential expression level are 
indicated by a number to the left or above the dots that represent each gene. Those 
genes showing differential levels of expression between EpEBNA 1 positive and wt
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RNAs are presented in Table 5.1. The genes were selected according to their ratio 
difference, usually >2 fold, with a couple o f exceptions because of their function. 
The transgenic positive and wt values before and after normalisation are also given. 
Those genes potentially up-regulated by EBNA 1, that is showing a higher level in 
the positive sample, include a number of transcription factors, several of which are 
proto-oncogenes, in contrast to those with a lower level which include a tumour 
suppressor gene, a lymphocyte differentiation antigen, a transcription factor inhibitor 
and an interferon pathway gene.
To support the above results the experiment was repeated using splenocyte 
RNA. Initially, total RNA was extracted from splenocytes o f 11 EpEBNA 1 
positive and 6 wt 2 month old mice from line 26. The total RNA samples were 
pooled and polyA+ mRNA was then extracted and radiolabelled cDNAs were then 
made. However, the large difference in the activity of the radiolabelled probes (as 
well as some areas of high background) made the data between positive and wt 
samples difficult to interpret. A similar problem was experienced when the 
experiment was repeated again using polyA+ mRNA from selected B cells of 1 
month old mice from line 26, at which point the membranes were no longer usable.
5.3 Testing the candidate de-regulated genes
5.3.1 Slot blot analysis using splenocyte RNA
Having found that several cellular genes appear to be differentially expressed 
at the RNA level in the splenic B cells between EpEBNA 1 transgenic mice and wt 
controls, this observation must be rigorously tested. It is possible to obtain a large 
quantity o f RNA from a mouse spleen, less from isolated splenocytes and a poor 
yield from selected B cells. The purity of B cells is in inverse proportion with the 
RNA yield. As a functional compromise, slot blots were prepared from total 
splenocyte RNA. The differentially expressed genes were quantified by a slot blot 
approach taking RNA samples from 5 positive and 5 negative (wt) mice for 
EpEBNA 1 line 26 (2 month old) and 3 positive and 3 negative (wt) mice for 
EpEBNA 1 line 59 (5-6 months old). 5 spleen tumours from line 26 transgenic 
positive animals were also assayed (mouse numbers are listed in Appendix 5.II).
Four duplicate slot blots were prepared simultaneously as described in 
Chapter 4. 5pg of total RNA was used per slot and the blots were hybridised with
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32P radio-labelled probes generated by the random primed method from mouse- 
derived sequence plasmid cDNAs. The blots were hybridised with all obtainable 
gene sequences, from the list in Table 5.1. In addition, BclxL sequence was included 
following the results obtained in Chapter 4. The slot blot signals were quantified by 
phospho-image analysis. The values were normalised by probing the blots with 
GAPDH  and subsequent calculation of the ratio of the test signal over the GAPDH  
signal value.
In determining whether the observed differences in the RNA expression levels 
of these genes were significant, statistical analysis was performed as described in 
Chapter 4. The results are summarised in Table 5.2 and representative graphs are 
shown in Fig. 5.2. In the 2 month splenocyte RNA samples from line 26 Egrl (2.5x) 
and BclxL (2.68x) showed statistically significant higher expression levels in the 
positive samples as compared to the wt control samples. Several of the other genes 
tested gave a ratio of means consistent with the Atlas results, showing 2-fold or 
greater elevation, but these did not reach statistical significance due to the high degree 
of variation between samples (see Appendix 5.II). Given that only 5 of each were 
tested, significance might be demonstrated if more samples were analysed.
In the tumours from line 26 as compared to wt 2 month splenocyte samples 
statistically significant higher expression was observed for cJun (2.45x), cFos (2.5x), 
EBF (3.25x), Ikaros (1.55x), Egrl (1.524x), Nras (2.62x), BclxL (2.0x), and Picl 
(3.3x). A statistically significant lower expression level was found for B2 (0.456x).
In the line 59 (slow tumour line) RNA sample slot blot analysis (EBNA 1 
positive compared to wt samples) cJun (1.2x), EBF (1.4x) and A ra f (2.56x) showed 
statistically significant higher expression levels. However, the small number of 
samples (only 3 samples) in each group compared reflect the outcome of these results 
as other genes such as Ikaros (1.3x), BclxL (2.12x) and B2 (0.83x) were close to 
significance (see Table 5.2 and Appendix 5.II). Thus, more line 59 samples need to 
be tested in order to determine the relevance of changes in gene expression of these 
genes in the assay for line 59.
5.3.2 Slot blot analysis using selected B cell RNA
Further slot blot analyses were conducted, this time using total RNA 
extracted from selected B cells. Despite the low yield of selected B cell RNA it was
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a) BclxL expression level in 2 month old splenocytes
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Fig. 5.2 Graphical and statistical illustration of statistically significant deregulated 
genes BclxL (a) and Egrl (b) in 2 month splenocyte total RNA. The histograms show 
the mean of the expression level in the spleen cells with standard deviation (bars) for 
E/<EBNA 1 transgenic positive line 26 ( r e d )  and wt siblings ( b l u e )  at 2 months old. 
These values are shown in box plot format on the right where wt siblings are denoted - 
and transgenic positive are depicted as + on the X axis. The ratio of means +/- and the 
P values of this ratio are given below.
decided to take the analysis to this high level of specificity. Total RNA was also 
extracted from the cells remaining after the B cell selection. These B cell depleted 
populations were used as controls in order to assess and compare the degree of the 
gene expression level contributing to the signal obtained from the total spleen and 
splenocyte RNA slot blots.
Total RNA was extracted from selected B cells from 8 EpEBNA 1 positive 
and 7 wt 2 month old control mice (line 26), 5 EpEBNA 1 positive and 5 wt 1 month 
old mice (line 26) and 11 EpEBNA 1 positive tumours from line 26 transgenic 
animals (the latter not B cell selected) (mouse numbers are listed in Appendix 5.III). 
Two duplicate slot blots were prepared simultaneously as described previously 
(Chapter 4). 5pg of each B cell selected and B cell depleted total RNA was used per 
slot and the blots were hybridised as above. The slot blot signals were quantified by 
phospho-image analysis and the values were normalised by GAPDH  hybridisation as 
previously. The genes tested in this analysis were those that showed differential 
regulation at (or close to) statistically significant levels in the previous slot blot 
analyses and are listed in Table 5.3. BclxL and Bad were included in this assay to 
confirm the previous slot blot results in the whole spleen and splenocyte total RNA. 
The Rag genes were also included to test if the observed changes in their expression 
level observed at the 1 month old stage extends to the 2 month old stage. Statistical 
analysis was performed in order to determine if the observed differences in the RNA 
expression levels of these genes were significant. The results are summarised in Table 
5.3.
Of the 13 genes tested, few were found to show statistically significant 
difference when comparing transgenic positives to wt controls. Again each group 
showed a high degree of variation between samples. Moreover, one of the EpEBNA 
1 2 month old positive samples (mouse no. 26.1318) was very different from the 
rest of the group and contributed highly to the degree of variation within this group 
of samples. Although this RNA sample was from an age matched mouse, the mouse 
was from a different litter and the RNA was extracted on a different day from the 
rest. This sample was used to increase the number of samples tested for the 
statistical analysis but as an outlyer for most o f the readings, it affected the results 
considerably. Nevertheless, as a set of valid data it must be included.
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When statistical analysis was performed at the 2 month old stage only BclxL (1.6- 
fold) was found to be statistically significantly up-regulated (Fig. 5.3). In contrast to 
all earlier results, Ragl showed statistically significant lower expression level (0.69x) 
in the transgenic B cells compared to wt cells but only when the outlyer was excluded 
(5.4a). In addition, EBF showed statistically significant lower expression level 
(0.75x) when an outlier was excluded (Fig. 5.4b and Appendix 5.III). At the tumour 
stage, Rag2 (0.5 lx), EBF (x0.57), Ikaros (0.6x) and hnRNPD (0.28x) showed 
statistically significant lower expression levels in line 26 tumours as compared to 2 
month old wt selected B cells.
Statistically significant increases in the expression levels were also found in 
the B cell depleted cells for BclxL (2.7x), Egrl (1.75x) and SATB1 (2x) in 1 month old 
mice, and hnRNPD (2x) in 2month old mice (data not shown). The flow through 
represents a mix of cells from the spleen, including T cells and all the B cells that 
were not isolated by the protocol. As such it is difficult to attribute these differences 
to any one cell type. However, if  these differences are due to the T cell expression 
patterns, it is possible that this is caused by B-T cell interactions. In vivo, a change 
in B cell phenotype or activity may well lead to changes in responsive T cells (and 
vice versa).
5.4 Analysis of protein function
While the slot blot and statistical analyses did not validate many of the 
observations made using the Atlas array, neither do they invalidate these results, 
indeed for several of the genes the 2-fold ratio was still apparent. In order to examine 
if the expression of a selection of these genes was affected at the protein or activity 
level, splenic protein extracts were assayed. For these studies, members of the API 
transcription factor group (Jun and Fos) were focused on due to their prominence in 
the Atlas array study. In addition, the DNA binding protein SATB1 was examined 
since it showed the highest expression ratio (4.1-fold).
Protein extracts from splenocytes and selected B cells of 2 month old 
transgenic positive and wt control siblings from mice of line 26 were examined for 
protein levels using Western blot analysis. In addition, DNA binding activity (where 
appropriate) was assessed by band-shift assay. The levels of detected proteins were
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F ig . 5 .4  Box plot representation with numerical values below o f  (a) Ragl and 
(b) EBF expression results in selected B cells from 2 month old mice. 
EpEBNA 1 transgenic positives represented by a + ( ed) and WT by a - (b lu e). 
An outlyer ( ) in the group o f  positive samples distorts the results and renders 
it not statistically significant (blue box plot). When the outlyer is excluded the 
result becomes statistically significant (green box plot).
measured by densitometry of the autoradiographs. Finally, for those genes encoding 
kinases (i.e. JNK, MAPK), levels of active (phosphorylated) kinases were examined.
5.4.1 DNA/protein interactions: API
In order to examine API components in splenocytes, whole cell protein 
extracts were prepared from primary splenocytes from 2 positive and 2 wt control 2 
month old mice using a modification of the protocol of Marais et al., (1993) in the 
presence o f protease and phosphatase inhibitors. Protein concentration was then 
measured using the BioRad protein assay.
5|ng of total protein from each sample was analysed in gel retardation assays 
using an oligonucleotide containing the TPA-responsive element (TRE or API site) 
from the collagenase gene promoter (colTRE; Angel et al., 1987). A positive control 
sample (sample 34, chicken fibroblast cell line protein extract) was included in all 
assays. However, the standard protocol for protein extraction and DNA binding had 
been optimised using cell lines. The bands obtained from the primary cell extracts 
were numerous and less well resolved giving smeary tracks making the results less 
clear. To demonstrate the specificity of the API band corresponding to the one from 
the positive control, non-labelled double stranded TRE-oligonucleotide was added to 
the binding reactions (at a 50-fold molar excess over the probe) as a competitor for 
binding to the labelled probe. In the presence of competitor oligonucleotide the API 
band was competed, demonstrating the specificity o f the band (not shown).
To investigate the composition of the API complex/band, antibody addition 
gel retardation analysis was performed on whole cell extracts from EpEBNA 1 
transgenic positive and wt splenocytes. Under these conditions a specific 
interaction, between the test antiserum and a component o f the DNA-binding 
complex is signified by disruption and/or further electrophoretic retardation 
(supershifting) of the complex. Supershift assays were conducted using antibodies 
for cFos, cJun, JunB, JunD, FosB and Fral. Again the results were not very clear 
due to the numerous bands and smeary tracks in the lanes. Nevertheless, in a 
supershift assay using cFos, cJun, JunB, JunD, FosB and Fral antibodies, 
oligonucleotide retardation to the top of the gel was observed in the presence of cJun 
and JunD antibodies in both positive and negative samples suggesting that cJun and 
JunD are API components in these cells (data not shown).
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However, in general, in these first sets of experiments, band smearing, poor 
competition with specific cold competitor and poor resolution in antibody supershift 
assays may be due to several reasons. For example, splenocyte-derived samples 
contained red blood cells (RBC) as well as lymphocytes. Although RBCs do not 
have a nucleus they have cytoplasmic organelles with proteins such as NfE2, a 
haematopoietic factor, which can react with API.
In order to try and optimise the conditions using primary cells, several 
modifications in the protein extraction buffers and DNA binding reaction buffers 
were tried. The nuclear protein extraction buffer used [modified from Schreiber et al., 
(1989)] was tested with or without Triton-XlOO and with or without glycerol. The 
DNA binding buffer [modified from Marais et al, (1993)] was tested with or without 
glycerol. Glycerol is usually used to aid subsequent gel loading, however, it was 
found that it interfered with the reaction and thus was excluded from the subsequent 
protein samples. Triton-XlOO is used as a detergent to lyse the cells and as it did not 
interfere with the reaction it remained as one of the buffer components. It was also 
found that increasing the dldC (non-specific competitor) concentration to 
2pg/reaction was more effective in reducing the non-specific binding.
The experiment was repeated using nuclear protein extracts obtained from 
splenocytes from 5 EpEBNA 1 positive and 5 wt control mice 2 month old using the 
newly modified nuclear protein extraction protocol. 10pg of nuclear protein from 
each sample was analysed in a gel retardation assay using the TRE oligonucleotide 
probe.
The API binding activity in some of these samples is illustrated in Fig. 5.5. 
In Fig. 5.6 only a pair of transgenic and wt samples is shown. The addition of the 
col-TRE competitor in Fig. 5.6a lanes 2, 5, 6 effectively competed the API band 
showing high specificity of the probe used.
In the presence of cJun and Jun D antisera (and less for JunB) a shift o f the 
API band was observed in both EpEBNA 1 positive and wt samples. This was 
consistent in four different experiments using different pairs of transgenic positive 
and wt samples. As shown in Fig. 5.6b much of the API complex/band was 
disrupted and supershifted by the cJun (lanes 3 and 4) and JunD (lanes 7 and 8) 
antisera but it was unaffected by cFos, FosB, Fral and Fra2 antisera (Fig. 5.5a/b). 
(In lane 2 of Fig. 5.6b, the band at the top of the gel was due to leak from lane 3
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Fig. 5.5 Gel retardation assay of DNA/protein complex for API band specificity. 
Nuclear extracts of splenocytes from transgenic positive (lanes 3-4,7-8) or wt mice 
(lanes 5, 6) or extracts of chicken fibroblasts (lanes 1-2, used as control) were 
mixed with radiolabelled oligonucleotide comprising a TRE sequence. In lanes 
2,4,6,8 the unlabelled col-TRE oligo was added as a specific competitor for API 
binding at 50-fold molar excess over probe.
Fig. 5.6. EMSA of TRE oligonucleotides with EBNA 1 transgenic positive or wt tissue 
extracts and antibodies directed against Jun and Fos proteins. Nuclear cell extracts of 
splenocytes recovered from transgenic positive or wt mice, or extracts of chicken 
fibroblasts (5.6a/b lanes 1-2, used as controls) were mixed with radiolabelled 
oligonucleotides comprising a TRE sequence. Cold competitor oligonucleotides were 
added as a control (competitor 50x, lanes 2, 5, 6 in 5.6a and lane 2 in 5.6b). 
Alternatively, antibodies directed against either Fos (all), FosB, cFos, cJun, JunB, JunD, 
Fral or Fra2 were added to detect the presence of these factors as components o f the 
API complex in these cells. Pre-immune serum (PI) was added as a non-specific binding 
control (lanes 7, 8). EB1= protein extract from EpEBNA 1 transgenic positive mouse 
(26.1475) and WT= protein extract from a transgenic negative mouse (26.1476). The 
API complex is indicated by an arrow to the left o f the image. The bands supershifted 
by antisera to cJun, JunB and JunD are indicated by arrows to the right o f the image.
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during loading). These results indicate that the API complex in these splenocytes 
consists o f a cJun component, a JunD component and possibly a minor JunB 
component. What the Jun partners might be (homo- or heterodimers) is not clear. 
However, in general, the intensities of the bands containing the protein-DNA-binding 
complexes appeared similar between transgenic positive and wt control samples. 
Since the API band contains many different proteins, subtle changes in the level or 
activity of one component could be masked.
5.4.2 Steady state protein levels
To examine if any potential differential expression between EpEBNA 1 
transgenic and wt samples is apparent at the protein level, protein extracts from 
selected B cells of transgenic positive and wt controls were assayed by western blot. 
Line 26 tumour extracts were also analysed. The levels of selected proteins were 
measured by densitometry of the autorads.
Whole cell protein extracts were prepared from selected B cells and the B cell 
depleted cells from 7 EpEBNA 1 mouse spleens and 7 wt controls 2 month old. 
Protein extracts from each group were made after cells were pooled together to 
increase the protein available for each “sample” and to give an overview of the 
protein levels in EpEBNA 1 positive as compared to the wt control tissues.
Duplicate western blots were prepared by using lOOpg of protein/lane. A 
representative western blot against BclxL is shown in Fig. 5.7. The antisera used 
were against BclxL, cJun, SATB1 and cFos.
Protein levels were measured by densitometry of the autoradiographs and 
they were normalised against non-specific bands from the compared samples. 
However, since no positive control was included, because no pre-immune sera or 
blocking peptide were available, an assumption of the correct band was made based 
on size. After calculating the ratio of the intensities of the BclxL bands, it was found 
that the protein level was higher in the positive B cells as compared to the wt 
controls by 1.2-fold. If this is indeed BclxL, this result is consistent with the RNA 
results described previously (Chapters 4 and 5).
Western blots of selected spleen B cell protein extracts (as described above) 
were probed with cJun and cFos antisera but these results were inconclusive (data 
not shown).
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Fig. 5.7. Steady state BclxL protein level. Western blot analysis o f BclxL in total cell 
extracts of selected B cells from 2 month old mice (line 26). Lane 1: EpEBNA 1 
transgenic positive protein extracts (EB1), lane 2: wt protein extract (WT). The 
suspected BclxL band is indicated with an arrow. lOOpg of total protein from selected 
spleen B cells was loaded per track. Rabbit anti-BclxL was used at a concentration of 
0.3pg/ml and the secondary HRP-conjugated anti-Rabbit IgG at 1:2000 dilution. The 
detection system used was the luminol system ECL(Amersham # RNP2106).
SATB1 levels were also analysed. The previous blots were stripped using 
MENS A buffer and probed with the SATB1 antiserum (see Materials and Methods 
section 2.4.7). Although these are preliminary results and need further confirmation 
there was no difference in the protein level between positive and wt samples. SATB1 
staining gave the expected size band of 85.9KDa which appeared as a doublet in both 
B cell enriched and depleted fractions (albeit fainter in the former) (not shown). 
However, since no positive and negative controls were included, it was not possible 
to say with certainty which band was the correct one and if there was an actual 
EBNA 1 effect on the protein level.
In line with the examination of Jun and Fos proteins, the activation status of 
SAPK and MAPK pathway members ERK and JNK was examined by western blot 
assay of the active, phosphorylated forms. No differences were found between 
transgenic positive and wt samples (not shown).
5.5 Discussion
To investigate the effects of EBNA 1 on cellular gene expression, a differential 
display approach was employed using the mouse Atlas cDNA expression array. 
Using this method the researcher can quantitate the expression levels of a large 
number of genes in two different samples in one experiment. The size of these arrays 
range from 588 (which was used here) up to 1200 genes with the new macroarray, or 
even more with microarrays either on glass or chips. The arrays also include different 
house-keeping genes which serve as quantitative/qualitative controls. This makes the 
normalisation easier, because subsequent hybridisation with a house-keeping gene (as 
in the slot blots) is not needed. However, because polyA+ RNA is used to make the 
cDNA probe there is a possibility that other, perhaps important mRNA messages 
will be lost during the purification and therefore may affect the final result.
As an approach, array analyses should not be used as absolute evidence of 
gene de-regulation but only as an indicator of which genes should be analysed further. 
This is because the data can only show the ratio o f difference between two compared 
sets without the possibility of statistical analysis. However, this indication of gene 
expression may sometimes be misleading, and many genes that showed higher or 
lower expression in the Atlas, did not show any difference in the subsequent slot blot 
analysis or vice versa. For example, neither BclxL or Rags were selected candidates in
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the Atlas approach but they showed statistically significant differential regulation in 
all o f the slot blots. Moreover, subtle differences, such as the 1.3x, first observed for 
BclxL and Rags, may be easily disregarded in an array approach. Another negative 
feature of this approach is that the membranes are very sensitive to extensive 
handling and can only be used the maximum 2 or 3 times for the macroarrays and 
only once for the microchip arrays.
Analysis of the effects o f EBNA 1 on cellular gene expression using the Atlas 
cDNA expression array has identified a number o f genes which may be differentially 
expressed between the EpEBNA 1 positive splenic B cells and wt controls. Those 
showing higher expression levels in EpEBNA 1 positive samples (approximately 2- 
fold or more) include several Jun and Fos family members, and a number of B cell 
oncogenes and transcription factors such as EBF, Egrl and Pax5. Those showing 
lower expression levels include kinases such as haemopoietic cell kinase (HCK), 
MAPKK1, JAK3 and the tumour suppressor PML. Interestingly, while cRel was 
amongst those genes showing higher expression levels, its inhibitor, I kB  was amongst 
the most suppressed ones. Slot blot analysis was used to test the candidate gene 
expression in more samples.
Slot blot analysis using either splenocyte or selected B cell RNA in most 
cases did not confirm the differential regulation. However, although the slot blots did 
not confirm the Atlas results, this differential regulation may still be real since a lack 
of statistical significance in small sample numbers cannot refute this possibility. One 
of the reasons for the outcome of these results may be the large variation within the 
datasets. This variation is a characteristic of approaches using in vivo samples 
because unlike cell lines these samples derive from tissues consisting o f different cell 
types that are not clonal. Different genes have different expression patterns at 
different cell cycle points and even more between different cell types and therefore 
this may contribute to the variation in these results. Alternatively, factors that effect 
the immune responses of the animals could also effect the outcome o f the results. 
These mice derive from the same strain and they have the same genetic background. 
Therefore, one would expect that any changes at the genetic level would be similar. 
However, although these mice are kept in a controlled environment and treated in the 
same way, this environment is not completely free of pathogens. Thus, the presence 
o f pathogens would trigger immune responses, different in each individual mouse.
171
Another factor influencing immune responses is aggressive behaviour (usually 
observed in male mouse cages). Consequently, since an immune response can be 
triggered by many factors the relative changes at the molecular level would be 
different. For example, different pathways would be triggered and therefore gene 
expression would be differentially affected in each case.
In conclusion, if the differential regulation observed in the Atlas approach is 
real, it may need many more samples to show statistical significance. As such, all the 
genes identified remain candidates for differential regulation, but further experiments 
are required to definitely support or refute the possibility. Implications regarding 
each candidate gene are considered below.
5.5.1 API
One third, 6 o f the 20 genes that showed higher expression levels in the 
positive samples as compared to the wt controls are API components (cJun, JunB, 
JunD, cFos, FosB and Fral). This itself is strongly suggestive that these genes may 
be valid targets of de-regulation. This result is intriguing since these genes have been 
classified as immediate-early response genes, that is those genes that are induced in 
the absence of de novo protein synthesis and show an immediate change in their 
expression after cell stimulation. These genes serve as nuclear couplers o f early 
cytoplasmic events to long term alterations in gene expression (Herschman, 1991). 
However, in subsequent slot blot analyses using RNA extracted from splenocytes or 
selected B cells, none of these genes showed any statistically significant differences in 
their expression levels between EpEBNA 1 positive and wt controls in pre­
neoplastic tissues even though (for the genes tested) the increased ratio (of 2-fold) 
was still evident in the mean values derived from splenocytes. Nevertheless, two of 
these genes (cJun and cFos) showed statistically significant higher expression levels 
in line 26 tumours (by 2.4-fold and 2-fold respectively) as compared to the wt 
splenocyte RNA controls. However, cJun expression was later found statistically 
significant lower (1.45-fold or 0.69x) in the line 26 tumours when compared to the 2 
month wt selected B cell RNA.
API/DNA binding assay revealed the presence of cJun, JunD and JunB in the 
API complex in spleen cell nuclear protein extracts o f both transgenic positive and 
wt controls while the Fos family members were not evident. Because band intensity
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in bandshift assays varies considerably depending on the quality of the extract, 
densitometry is quite difficult. In addition, these results were much more ambiguous 
because protein was extracted from primary cells (comprising many different cell 
types and cell stages). Therefore this assay did not reveal information concerning the 
activity levels of these components in this system and was not examined further.
O f the 6 genes only cJun and cFos were tested for any differences at the 
protein level between EpEBNA 1 positive and wt samples. However, these results 
were inconclusive and further analyses of steady state protein might be informative.
API is a transcription factor complex involved in cell growth, differentiation 
and stress signalling pathways (Angel and Karin, 1991; Karin and Hunter, 1995; 
Whitmarsh and Davis, 1996). API consists o f various combinations of Jun, Fos, 
ATF2, and possibly other, family members that dimerise via a leucine zipper domain 
and bind to DNA via an adjacent basic region (Gentz et a l, 1989; Kouzarides and 
Ziff, 1989). The Jun family consists of three gene products (cJun, JunB and JunD) 
while the Fos family consists of four gene products (cFos, FosB, Fral and Fra2). 
Jun proteins form heterodimers with Fos family proteins (Hai and Curran, 1991) and 
ATF2 and also form functional homodimers, although with reduced stability 
(Halazonetis et al., 1988; Rauscher et al., 1988). Fos proteins form heterodimers 
with Jun and ATF family proteins (Hai and Curran, 1991). API binds to a specific 
target DNA sequence TGAC/GTCA, called TRE (tetradecanoyl phorbol acetate- 
responsive element, Angel and Karin, 1991) which was used as a probe in the band 
shift assay. The binding activity for a given TRE is determined by three main 
factors. Firstly, by the different combinations and the context o f the surrounding 
sequences (Halazonetis, et al., 1988; Ryseck and Bravo, 1991; Hawker et al., 1996). 
Secondly, the expression of Jun/Fos proteins is temporarily co-ordinated in response 
to various stimuli with the result that the composition o f API may change in the cell 
depending on the cell cycle time point and stimulus (Curran and Morgan, 1987; 
Cohen et al., 1989; Kovary etal., 1991; 1992; Lallemand etal., 1997). Thirdly, some 
Jun and Fos proteins possess transcriptional transactivation domains which are 
regulated by phosphorylation and thus different dimer combinations may exhibit 
different transactivation properties (Kouzarides and Ziff, 1989).
Some of these later phosphorylation events are catalysed by serine/threonine 
protein kinases activated via the MAP kinase and Jun kinase pathways.
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Interestingly, the Atlas cDNA expression array analyses of EpEBNA 1 positive B 
cells indicated lower expression levels of MAPKK1 (which has pleiotropic effects).
TRE is found in the promoter of many genes including cell cycle regulators 
such as cyclin D1 and autocrine growth factors such as heparin-binding epidermal 
growth factor (HB-EGF) (Herber et al., 1994; Albanese et a l, 1995; McCarthy et al, 
1997). Thus, if EBNA 1 does upregulate the API group, one could expect the 
expression levels of genes regulated by API components to be affected. Such genes 
include those involved in stress response, proliferation and differentiation. This 
could explain the cell proliferative advantage observed in the EpEBNA 1 positive 
bone marrow cell cultures in comparison to the wt ones, described in Chapter 3.
5.5.2 Other B cell transcription factors
The zinc finger transcription factor early growth response 1 (Egrl) is another 
immediate early response gene (Dinkel et al., 1998) that was identified using the 
cDNA expression array approach. Its expression was higher in the EpEBNA 1 
positive RNA by 2.3-fold in comparison to the wt controls. In subsequent slot blot 
analysis, using 2 month old splenocyte total RNA, Egrl up-regulation was 
consistent and statistically significant in both pre-tumour (2.5-fold) and tumour (1.5- 
fold) samples as compared to the 2 month old wt type splenocyte RNA controls. 
However, in the selected B cell slot blot although Egrl expression was still higher in 
the transgenic positive samples it was not statistically significant, possibly due to the 
high variation in this data set. These results in part support the array observation 
that Egrl is up-regulated by EBNA 1.
Egrl transient expression in mature B cells is rapidly activated upon 
stimulation by B cell receptor (BCR) cross-linking (Seyfert et al., 1989; McMahon 
and Monroe, 1995) whereas signals resulting from Fc receptor crosslinking inhibit 
induction (Klaus et al, 1993; Gottschalk et al., 1994). Little is known about the 
expression and function of Egrl during the early steps of B cell differentiation. 
However, it was recently reported that Egrl expression can be detected in pro-B and 
pre-B (B220+/sIgM-) cells isolated from BM and foetal liver-derived pre-B cell 
cultures (Dinkel et al., 1998). Thus it can be suggested that Egrl might also have a 
regulatory function in early stages of B cell lymphopoiesis (Fig. 5.8 and 5.9). In the
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same report, using transgenic mice, it was also demonstrated that overexpression of 
Egrl appears to promote entry into the mature B cell stage even in the absence of 
Rag2 activity. Therefore if EBNA 1 does upregulate Egr 1 then perhaps EBNA 1 
would also promote B cell maturation. This could explain the flow cytometry results 
in Chapter 3 in which the percentage of slg + B cells in the EpEBNA 1 positive 
spleens and BM was approximately 2-fold higher than that of the wt spleen and B M 
cells.
The early B cell factor (EBF) is a B cell specific transcription factor that was 
also identified in the mouse cDNA Atlas approach, showing 2.65-fold higher levels in 
EpEBNA 1 positive B cells. Its expression was further found to be statistically 
significantly higher in the tumour samples by 3.25-fold in comparison to the 2 month 
old wt splenocyte sample controls. Its expression was also found to be 3.7-fold 
higher (the highest difference of all genes tested) in the transgenic positive 
splenocytes versus wt ones, but this result was not statistically significant. 
However, the selected B cell results do not confirm the up-regulation. Although EBF 
is also expressed in other non-lymphoid tissues (Wang and Reed, 1993), experiments 
involving knockout EBF +l' or EBF '/‘ mice suggested that EBF plays a specific and 
important role in the transcriptional control o f B cell differentiation at a stage before 
Ig gene rearrangement but after commitment of cells to the B lymphoid lineage 
(transition of pro-B to pre-B cells). These mice lacked transcripts from Ragl and 2 
genes as well as other B cell specific genes such as Pax5, mb-1, VpreB and DJH- 
rearranged // gene (Lin and Grosschedl, 1995; O'Riordan and Grosschedl, 1999). 
Thus, EBF  is required at an earlier stage of B lymphopoiesis than Pax5 and Rags and 
possibly regulates their expression. Interestingly, it was recently reported that EBF 
directly binds and activates the Pax5 promoter (O'Riordan and Grosschedl, 1999). If 
EBNA 1 does upregulate EBF then this could result in up-regulation o f EBF target 
genes such as Pax5 and possibly Rags which would promote B cell Ig rearrangements 
and maybe genomic instability that could ultimately lead to tumour.
Pax 5/BSAP expression level was also found higher in the EpEBNA 1 positive 
cDNA in the Atlas expression array by 1.5-fold versus the wt cDNA. However, 
although its expression was also higher in the splenocyte slot blot analysis (2-fold) it 
was not statistically significant. Pax5 is a member o f the Pax family of transcription 
factors, which is expressed primarily in B cells, central nervous system (CNS) and
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testis (Busslinger and Urbanek, 1995). Pax5 is found in all stages o f B cell 
development, except plasma cells (Fig. 5.8 and 5.9). Knockout mice for Pax5 lack 
pre-B, B and plasma B cells. VHDJH recombination is also significantly reduced, 
suggesting an important role in B cell maturation and differentiation (Busslinger et al., 
1996). Several B cell specific genes have been implicated as targets for Pax5 
activation including CD 19, VpreB, X5 and m bl and the germline IgH Ce promoter 
(Fitzsimmons et al., 1996; Nutt et al., 1997 and references therein) . It was recently 
reported that Pax5 binds to a conserved sequence in the Rag2 promoter, critical for 
its activity (Lauring and Schlissel, 1999). Interestingly, many of these Pax5 regulated 
genes have multiple transcription start sites and lack a TATA box. This suggests 
that Pax5 may play a role in recruiting the basal transcription machinery to TATA- 
less promoters in B cells. In addition Pax5 has been suggested to act as a repressor at 
the heavy-chain 3' a  enhancer (Singh and Birshtein, 1993; Neurath et al., 1994), the k 
light chain 3' enhancer (Roque et al., 1996; Shaffer et al., 1997) and the J chain 
promoter (Rinkenberger et al., 1996). Therefore, if EBNA 1 leads to the up- 
regulation of Pax5 then it could affect B cell sub-population numbers in both spleen 
and BM by promoting B cell maturation. Since Pax5 binding sites exist within the 
Rag2 promoter sequence, then up-regulation of Pax5 by EBNA 1 could lead to 
increased recombination and genomic instability.
Ikaros, another lymphocyte specific transcriptional regulator, expression was 
found higher in the mouse Atlas expression array EpEBNA 1 positive RNA by a 2.8- 
fold in comparison to the wt control RNA. Slot blot analysis using either splenocyte 
or selected B cell RNA (2 month old) did not support the Atlas result. However, 
Ikaros expression was statistically significantly higher in the line 26 tumours versus 
wt controls. Thus, there is less evidence supporting Ikaros as a target o f EBNA 1 
de-regulation because its up-regulation was not supported by the slot blots. The 
Ikaros gene encodes a set of proteins, generated by alternative mRNA splicing, that 
contain kruppel-like zinc fingers organised in two functional domains, one for DNA 
binding and the other for dimerisation (Hahm et a l, 1994; Molnar and Georgopoulos 
1994; Georgopoulos et al., 1997). Ikaros is primarily expressed in haematopoietic 
tissues and its mRNA is present throughout B cell development. Ikaros gene 
expression appears to increase as B cells mature, but the relevance of absolute versus 
relative levels of Ikaros proteins is not understood (Georgopoulos et al., 1997).
178
Ikaros null mutant mice lack foetal lymphocytes and adult B cells. The B cell 
developmental block is very early- prior to the pro-B cell stage (Wang et al, 1996). 
Ikaros binding sites have been described in promoters of a number of genes including 
Ragl and 2, IL2 receptor, Iga, VpreB, X5 and TdT  (Georgopoulos et al., 1997). 
Interestingly, in pre-B cells VpreB and X5 receptor, along with IgH expression is 
required for pre-B cells to avoid negative selection. Therefore, up-regulation of 
Ikaros by EBNA 1 would affect the expression of Ikaros target genes and thus affect 
B cell maturation and differentiation.
The above findings are very interesting and consistent with Ragl and 2 
regulation by EBNA 1 (Kuhn-Hallek et a l,  1995; Srinivas and Sixbey, 1995). As 
previously discussed in Chapter 4, analysis of the level of Ragl and 2 expression in 
RNAs from EpEBNA 1 transgenic positive and wt control sibling mice revealed a 
consistent Ragl and/or Rag2 up-regulation in EBNA 1 expressing cells at all 
developmental stages tested. Based on the above it can be suggested that Rag gene 
expression appears to be regulated by a number of different transcription factors that 
are possibly regulated by EBNA 1. Therefore, it can be suggested that EBNA 1 may 
regulate Rag expression possibly through direct regulation o f one of the above genes 
such as Egrl or other genes acting upstream of those tested. In addition, the fact that 
these genes were found de-regulated may suggest a B cell developmental stage at 
which EBNA 1 acts.
5.5.3 Proto-oncogenes
Other genes that were found up-regulated in the mouse Atlas expression array 
include the Ets2, cRel and the proto-oncogenes Nras and Araf. Nras de-regulation at 
2 month stage was not supported by slot blots, but it was statistically significantly 
higher in the tumours by 2.65-fold versus wt splenocyte RNA. A ra f was found up- 
regulated in both pre-tumour samples and in tumours but this change was not 
statistically significant.
Ets2 expression was 2.2-fold higher in the EpEBNA 1 transgenic versus wt 
array. Ets2 is a nuclear protooncogene and is member o f a large family of 
transcription factors known as the Ets family. Ets2 expression correlates with cell 
proliferation and differentiation and development (Bhat et al., 1987; Boulukos et al., 
1990; Maroulakou et al., 1994). It was recently demonstrated that Ets2 inhibits
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apoptosis through binding to the BclxL promoter and upregulates its expression 
(Sevilla et a l, 1999). Therefore, since BclxL was up-regulated in the EBNA 1 positive 
samples, yet no EBNA 1 binding sites have been found in the BclxL promoter, it can 
be postulated that EBNA 1 may upregulate BclxL via Ets2. However, due to lack of 
probe availability Ets2 expression results were not examined further.
cRel belongs to the NFicB/Rel family of transcription factors. There are at 
least 5 Rel family members that are involved in B cell development. These include 
RelA (p65), RelB, cRel, N F kB I  (pl05) and NFkB2  (P100). The latter two are 
processed by proteolytic cleavage to generate the p50 and p52 subunits respectively, 
which can generate hetero- and homodimers. NFKB/rel dimers are located in the 
cytoplasm where they associate and are regulated by IkB proteins (Baeuerle and 
Henkel 1994; Siebenlist et al, 1997; Thanos and Maniatis, 1995; Verma et al, 1995). 
Interestingly, while cRel was expressed at a higher level in the EBNA 1 cDNA array, 
I kB (its opposing factor) was expressed at a lower level (3.3x reduced), suggesting a 
concerted action. However, due to the lack of plasmid probe availability the 
observed changes in the expression of both cRel and I kB  cannot be confirmed at 
present. Nevertheless, it can be suggested that the changes in the expression of both 
these genes are not a coincidence and could be due to EBNA 1 action. In order to see 
if these changes are definitely due to EBNA 1 regulation, further expression analysis 
at the RNA and protein level should be pursued using material from selected B cells.
NFkB was originally characterised as a pre-B cell inducible transcription 
factor. Moreover, it is constitutively activated in mature B cells (Sen and Baltimore, 
1986). A hierarchy of NFkB dimers during B cell development has been suggested; 
pre-B cells primarily have p50/p65 dimers, mature cells have cRel/p50 dimers and 
plasma cells have p52/RelB dimers (Fig. 5.8 and 5.9) (Liou et al, 1994; Miyamoto et 
al, 1994). Recent experiments in which a dominant-negative, non-degradable form of 
IkB was overexpressed in pre-B cells indicated that the NFKB/Rel proteins are 
necessary for B cell differentiation (Scherer et al., 1996). In addition to the regulation 
of gene expression of genes important for immune and inflammatory responses, 
Rel/NFKB also controls the transcription o f genes that confer resistance to death- 
inducing signals. These genes include those encoding the caspase inhibitors cl API 
and cIAP2 and the TNF receptor-associated factors TRAF1 and TRAF2 (Wang et 
al, 1998a). Interestingly, it was recently demonstrated that cRel upregulates BclxL
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expression through binding and activating the bclx promoter (Chen et a l, 2000). 
These results are consistent with the increased expression of BclxL and cRel in the 
EpEBNA 1 transgenic positive samples. Therefore, if  EBNA 1 upregulates cRel and 
down-regulates I kB  then this would affect downstream targets of cRel transcriptional 
activation which would lead to increased cell survival and immunoglobulin gene 
rearrangement and possibly promote B cell differentiation. Increased Ig 
rearrangement in B cells at an earlier than usual, stage could cause these cells to be 
positively selected and lead to the accumulation o f these cells in the spleen or other 
lymphoid tissues.
5.5.4 SATB1
The gene showing highest levels of expression (4.1-fold) in the EpEBNA 1 
positive samples in comparison to wt controls in the cDNA array is SATB1. 
However, in the slot blot analysis using splenocyte RNA (2 month old) from pre­
neoplastic and tumour tissues, SATB1 de-regulation was not statistically significant. 
In the slot blot containing the 2 month old selected B cell RNA, SATB1 expression 
was higher in the transgenic positive samples, but only close to statistical significance 
(with 26.1318 included, and statistically significant when this mouse is not included). 
This could be attributable to the high variation in the obtained values but also due to 
cell heterogeneity in the tissue. SATB1 is predominantly expressed in T cells. 
Therefore, it can be postulated that EBNA 1 upregulates SATB1 in B cells, but the 
signal originating from the T cells may be stronger and obscures that from the B cells. 
Alternatively, this result may be a false positive due to the very low expression of 
SATB1 in B cells, where any small variation might show a significant difference. The 
results from the SATB1 protein level analysis were unclear since a positive SATB1 
control (for the mammalian SATB1) was not included in the assay. For further 
experiments, since SATB1 is predominantly expressed in thymocytes, protein 
extracts from wt mouse thymocytes could provide the appropriate mammalian 
SATB1 positive protein control. Alternatively, in vitro expressed purified 
mammalian SATB1 protein could be used as positive control in this assay.
SATB1 is a cell type specific nuclear matrix or scaffold (MAR/SAR)- 
associated DNA-binding protein (Dickinson et al., 1992). Experiments in transgenic 
mice and in transfected cells suggest that SATB1 generally exerts a negative
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regulatory effect on gene expression (Kohwi-Shigematsu et al., 1997; Liu et al., 1997). 
Interestingly, the regulatory regions of several genes including ^-globin, CD8, Xlr 
nuclear protein and the long terminal repeat (LTR) of mouse mammary tumour virus, 
have been shown to contain matrix attachment regions (MARs) that bind SATB1 
(Cunningham et al., 1994; Banan et al., 1997; Liu et al., 1997; Escalier et al., 1999). 
The nuclear matrix is an insoluble structural network of proteins within the nucleus 
and is involved in DNA replication, steroid hormone binding, gene transcription and 
hnRNA processing. Specific regions of cell DNA are attached to the nuclear matrix 
and called matrix attachment regions (MARs). The cell DNA located between the 
MAR sites form chromatin loops or domains representing functional units of 
replication or transcription (Nelson et al., 1986; Bodnar, 1988).
Interestingly, EBNA 1 has been implicated in the nuclear matrix attachment 
(ori¥ is contained within or is immediately adjacent to a high affinity MAR) and also 
has a negative regulatory effect on gene transcription (see Introduction sections 
1.3.Ill and 1.3.IV).
If EBNA 1 really upregulates SATB1 this may have important secondary 
effects. Increased SATB1 expression may result in down-regulation o f expression of 
genes responsive to S ATB1. If some of these genes encode proteins that normally 
restrict expansion of B cells, this could partially explain the oncogenic role of EBNA 
1 observed in the transgenic lines.
hnRNPD was included in this assay because it is a component (along with 
nucleolin) o f the LR1 protein, another nuclear matrix binding protein. It is thought 
that LR1 binds near the c-Myc promoter and has roles in the transformation and 
regulation o f c-Myc in B cell lymphomas (Brys and Maizels, 1994). It has also been 
shown to regulate EBNA 1 from the Fp promoter (Bulfone-Paus et al., 1995). 
However, hnRNPD expression results were confusing. In the slot blots with the 2 
month old splenocyte RNAs, hnRNPD showed a higher ratio, but was not 
statistically significant, in both pre-neoplastic tissues and in tumours. Moreover, in 
the slot blots with the selected B cell RNA, hnRNPD had still higher expression in 
the transgenic pre-neoplastic tissues but statistically significantly lower expression in 
the tumours. Down-regulation of hnRNPD may be a post-transformation event not 
necessarily mediated by EBNA 1.
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5.5.5 BclxL confirmation
Table 5.4 BclxL RNA and protein expression results
RNA level Protein level
Gene Pre-Tumour stage
1M Spleen 2M spleen 2M Splenocytes 2M selected
B cells
Ratio Ratio Ratio Ratio
Spleen
Tumour
Ratio
2M Selected 
B cells
Ratio
BclxL 1.3 (0.011) 1.5 2.68 (0.018) 1.6 (0.033) 4.7 (0.0009) 1.2
Analysis of the expression levels of the anti-apoptotic gene BclxL (a Bcl2 
family member) showed an up-regulation of BclxL RNA which was supported at the 
protein level. These results are summarised in Table 5.4, where the ratios and the 
statistically significant P values are given (the latter in brackets). At the RNA level, 
in both 2 month old splenocyte and selected B-cell RNA, BclxL expression was 
consistently higher in the EpEBNA 1 positive samples when compared to the wt 
controls. The result from 2 month old spleen gave a 1.5 ratio without significance. 
This difference may be due to the specificity o f the RNA used. Because BclxL is 
expressed in many different cell types in addition to B cells, the signal from the other 
cell types (e.g. T cells) might interfere with that from the B cells. In contrast, in the 
case o f the splenocyte and selected B cell RNA the B cell signal is more enriched and 
the result more reliable. Interestingly, BclxL up-regulation was consistent at the 
tumour stage as well. Moreover, in addition to the RNA level, BclxL up-regulation 
was extended to the protein level by 1.2-fold, at a level comparable to that observed 
in the RNA studies. However, since there was no BclxL positive control included in 
the western blot it was difficult to say with certainty, which was the BclxL band. As 
control one could have used the peptide epitope that was used to produce the 
antibody for BclxL to block the antibody interaction. Alternatively, a recombinant 
BclxL expressed in transfected cells could have provided a positive control. 
However, neither the peptide or such a construct were available at the time the 
western blots were prepared.
These results strongly support the previous suggestion that EBNA 1 may act 
in the same way as Bcl2 and exerts its oncogenic action at least in part through up- 
regulation of BclxL. E\x-BclxL transgenic mice show accumulation of immature and 
mature B cells, suggesting that BclxL supports the maturation of pre-B cells to 
mature B cells. Therefore, there is a possibility that EBNA 1 may upregulate BclxL
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expression and drive cells into a more mature stage. This hypothesis is supported by 
the increased percentage of slg+ B cells in the EBNA 1 transgenic positive samples.
5.5.6 Genes expressed at lower levels in EBNA 1 samples
A number of cellular genes showed lower expression levels in the mouse Atlas 
expression array including a tumour suppressor gene and several kinases. However, 
results were not confirmed in slot blot analysis for several of these genes in the 
cDNA array due to restriction o f probe availability.
The human haemopoietic cell kinase (HCK) is a member of the Src family of 
protein tyrosine kinases. HCK  expression was found to be 5-fold lower in the Atlas 
array probed with EpEBNA 1 positive cDNA. In the subsequent slot blot analysis 
in splenocyte and selected B cell RNA samples, HCK  expression difference was not 
statistically significant. In tumours, HCK  expression was found to be lower when 
compared to either 2 month old splenocyte (0.78x) or selected B cell (0.856x) wt 
controls, but again with no statistical significance. Therefore the Atlas finding was 
not confirmed. HCK is expressed in cells o f the granulocytic and monocytic lineage 
and at low levels in B lymphocytes and NK cells. Its expression is regulated at the 
level of transcription and increases during myeloid differentiation of normal and 
leukaemic haemopoietic cells. Spl appears to play an essential role in the regulation 
o f the differential gene expression of the HCK  gene. Therefore, since HCK 
expression is normally low in B cells, the slightest variation in its expression level 
would appear quite dramatic as in the mouse Atlas. Moreover, in the slot blot 
analysis the high variation in the samples and also the heterogeneity in the cell 
population of the tissues from which the RNA was extracted, could also be 
responsible for the result.
The PML tumour suppressor gene expression level was found to be 5.7-fold 
lower in the EpEBNA 1 transgenic positive when compared to wt RNA by the 
mouse Atlas assay. This was not confirmed in the subsequent slot blot analyses. In 
the splenocyte 2 month old and tumour RNA, PML expression was found slightly 
higher (albeit not to statistical significance) in the transgenic positives. These 
contrasting results could be due to the difference in the RNA source. Again the 
presence of other cell types in the splenocyte samples may affect the results. 
Therefore, the signal originating from other cells may be stronger than that of B cells
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and thus distort the final result. However, as PML expression was not tested in the 
selected B cell slot blots these results still need to be extended and therefore it is not 
possible to draw any final conclusions.
PML is a phosphoprotein associated with the nuclear matrix and is localised 
to the nuclear bodies (NB), (Dyck et al., 1997). PML has been regarded as a growth 
regulator and shares many properties with tumour suppressors (Mu et al, 1994; 
Guiochon-Mantel et al., 1995; Liu et al., 1995; He et al., 1997). PML is expressed in 
most tissues, but its expression is regulated during normal haematopoiesis in a 
differentiation and lineage specific manner. PML is required in early haematopoiesis 
and erythropoiesis (Wang et al., 1998b; Labbaye et al., 1999). PML controls genes 
(LMP-2, LMP-7, TAP-1 and TAP-2) involved in MHC class I antigen presentation 
(Zheng et al, 1998). This function is consistent with previous findings that PML 
expression is low in normal tissues with low levels of MHC class I (Gambacorta et 
al, 1996) but also in tumours with reduced cell surface MHC class I molecules due to 
defective antigen presentation (Korkolopoulou et al., 1996). Down-regulation of 
PML occurs in invasive and metastatic lesions in a large collection of tumours (Koken 
et a l, 1995; Gambacorta et al., 1996) possibly due to disruption o f the nuclear bodies 
in the tumour cells. Disruption of PML nuclear bodies is also caused by 
cytomegalovirus (Ahn and Hayward, 1997), herpes virus (HSV1) (Everett and Maul 
1994; Everett et al., 1997) and adenovirus infection (Rotem-Yehudar et al., 1996), as 
a consequence of the interaction of viral proteins with PML NB protein complexes 
(Ahn et a l, 1998). Therefore, down-regulation of PML may enable a tumour or a 
virus to evade the immune defence of its host. Interestingly, EBNA 1 avoids immune 
recognition through its Gly-Ala repeat (Introduction section 1.3) which was shown 
to inhibit in cis the presentation of MHC class I restricted cytotoxic T cell epitopes 
probably by interfering with ubiquitin/proteasome-dependent protein degradation 
(Levitskaya et a l, 1995; 1997). If EBNA 1 downregulates PML this effect could lead 
to down-regulation of the genes devoted to MHC class I antigen presentation 
resulting in reduced expression of MHC class I molecules on the cell surface. Thus it 
can be suggested that EBV may have developed an additional route o f escaping the 
host immune recognition through transcriptional regulation function of EBNA 1.
STAT3 is a member of the signal transducers and activators o f transcription 
family of proteins and its expression level was lower in the EBNA 1 positive array in
185
comparison to the wt array. STAT3 is usually constitutively activated in cells 
transformed by oncogenic tyrosine kinases like Src and by human tumour viruses 
such as HTLV-1 (Migone et al., 1995; Yu et al., 1995). It was recently reported 
thatSTAT3 is constitutively activated in BM myeloma cells and that it contributes to 
this pathogenesis by preventing apoptosis through a BclxL-dependent mechanism 
(Catlett-Falcone et al., 1999). However, since there was no probe fragment available, 
the analysis of STAT3 expression did not proceed further.
The rest of the genes that showed lower expression levels in the differential 
mouse Atlas expression array were not tested by the slot blot approach. Therefore, 
it is not clear at present if these are truly differentially regulated or if  they are false 
positives from the Atlas.
5.5.7 Conclusions and future experiments
In general, the results from selected B cell RNA slot blots contrasted with the 
results from either the Atlas or splenocyte or total spleen RNA slot blots. Since the 
Rags did not show any statistically significant differences in these blots, this 
particular assay may have suffered from technical problems. Specifically, the blots 
were used at least 4 times each before hybridisation with the Rag probes, whereas 
BclxL was the first probe used. Therefore, it is possible that much of the RNA may 
have been lost, giving less reliable ratios. Thus, repeating hybridisation with certain 
probes on new slot blots using selected B cell RNA may be required to confirm the 
gene expression ratios obtained here.
There are cases where a gene may be up-regulated pre-tumour and down- 
regulated in the tumours and vice-versa. It can be postulated that certain events may 
occur pre-tumour to promote proliferation or cell survival but no longer be needed 
after secondary events have taken place because they may have been superseded by 
the latter. Thus an EBNA 1 effect pre-tumour could be masked by a secondary event 
in the tumour leading to the observed results.
Several observations suggest that EBNA 1 drives cells through development 
and differentiation by promoting, either directly or indirectly, the expression of genes 
involved in these pathways. In addition, it can be postulated that EBNA 1 may hold 
cells at a particular “normal” B cell phenotype. If these cells were normally 
negatively selected and destroyed by the host immune system, EBNA 1 may have
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assisted these to escape negative selection and allow accumulation in the lymphoid 
tissues.
An alternative protocol to identify genes which may be de-regulated by 
EBNA 1 is subtractive hybridisation. In this method there is no restriction to the 
number of genes tested in contrast to the cDNA expression array where a fixed 
number of genes are tested. In this technique known or even novel genes may be 
isolated and identified which could be targets for EBNA 1 regulation. However, in 
this approach subtle changes are unlikely to be selected. Subsequent analysis will 
involve assays to examine if any de-regulated genes are direct or indirect targets of 
EBNA 1 action. This can be tested by transfection o f B cells with a construct 
containing the promoter region of the gene of interest upstream of a reporter gene and 
a second construct expressing EBNA 1. Genes identified in this assay could be 
tested for steady state protein expression as well as protein activity by western blot 
and EMSAs respectively.
Alternatively, for example in the case of BclxL, protein localisation using 
FACS would be useful in assessing in which subtype o f B cells BclxL expression is 
up-regulated.
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Chapter 6
Final discussion and future directions
The occurrence of lymphoma in two different transgenic mouse lines for 
EBNA 1 is strong evidence that EBNA 1 is an oncogene in vivo. These mice 
develop monoclonal B cell lymphomas (Wilson et al, 1992; 1996) indicating that 
although EBNA 1 predisposes cells to tumour formation it is insufficient for 
lymphoma development and that secondary events are required.
EBNA 1 is a DNA binding protein and (at least in the viral genome) 
functions as a transcriptional transactivator and under some circumstances, as a 
transcriptional repressor. Furthermore it also binds to RNA and may regulate post- 
transcriptional events.
While EBNA 1 can act as an oncogene in vivo, the mechanism(s) by which 
EBNA 1 assists in the transformation of B cells is unclear. It has been the aim o f this 
body of work to begin to address the role of EBNA 1 in lymphomagenesis by 
assessing the ability of EBNA 1 to modify gene expression in pre-tumour B cells, 
and thereby to modify the B cell phenotype. These phenomena have been addressed 
by a number of different approaches.
Differential expression analyses revealed that EBNA 1 up-regulates BclxL, 
Ragl and R a g 2 gene expression at both the pre-tumour stage and in tumours 
(Chapters 4 and 5). Results from a differential display cDNA expression array 
suggest that EBNA 1 possibly deregulates the expression o f Egrl, Ikaros, EBF, 
Pax5, and A P I  family members amongst others (Chapter 5). Flow cytometric 
analysis o f splenic and BM cells from EpEBNA 1 transgenic mice revealed that the 
percentage of slg+ (and possibly CD23+) cells was statistically significantly higher 
(73.3% versus 54% in the spleen and 64.5% versus 46.65% in the BM) when 
compared to the control littermates. Moreover, EpEBNA 1 transgenic positive BM 
cells have a statistically significant higher proliferation/ survival rate than the wt BM 
cells, as was shown by a cell survival/proliferation assay (Chapter 3).
BclxL de-regulation by EBNA 1 is consistent with our earlier observation that 
EBNA 1 is redundant with Bcl2 in a tumour latency assay and therefore it could act
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through the Bcl2 family members to exert its oncogenic effects. The fact that these 
particular genes are (possibly) deregulated by EBNA 1 is very interesting because 
they are normally expressed during particular “windows’ through B cell development 
and differentiation. BclxL  is highly expressed in pre-B and germinal centre (GC) 
cells but it is down regulated as B cells mature (Fang et al., 1996; Grillot et al., 
1996).
EBNA 1 as a transcriptional transactivator could up-regulate BclxL 
expression by direct action at the promoter of BclxL (by binding directly or via an 
adaptor protein). However, EBNA 1 binding sites are not evident in the BclxL  
promoter. Alternatively, EBNA 1 could indirectly up-regulate BclxL expression by 
up-regulating transcription factors, which then increase expression of BclxL.
BclxL expression is regulated at the transcriptional level, yet only three 
transcription factors (Ets2, Stat3 and cRel) have been shown to specifically activate 
this promoter. Recently Sevilla et al., showed that the Ets2 transcription factor could 
inhibit apoptosis upon growth factor deprivation through transactivating BclxL 
(Sevilla et al., 1999). Interestingly, Ets2 expression was found to be higher by 2.2- 
fold in the EpEBNA 1 positive versus wt array. However, due to lack o f probe 
sequence its expression was not analysed further. Catlett-Falcone et al., (1999) 
showed that constitutive activation o f Stat3 signalling by IL6 confers resistance to 
apoptosis in myeloma cells by induction o f BclxL expression. However, the Stat3 
expression level was lower (0.3x) in the EpEBNA 1 positive compared to the wt 
Atlas expression array. Furthermore, IL6 in EpEBNA 1 transgenic and wt culture 
experiments supported both cultures equally (Chapter 3). Interestingly, it was 
recently demonstrated that cRel up-regulates BclxL expression by directly binding to 
the Bclx promoter (Chen et al., 2000). cRel expression was found to be higher (2x) 
and the inhibitor I kB  lower (3.3x) in the EpEBNA 1 positive Atlas array as 
compared to the wt array. Thus, Ets2 and/or NFkB (cRel) but probably not Stat3 
may be possible candidates for indirect BclxL regulation by EBNA 1.
Ragl and Rag2 expression are primarily restricted to developing lymphocytes 
that are undergoing rearrangement o f their antigen receptor genes (Fig. 4.8). Ragl 
and Rag2 mRNA is first detected in pro-B cells but is down-regulated in early large 
B cells upon completion of IgH rearrangements (Grawunder et al., 1995a). The Rag 
genes are then transcribed again in small pre-B cells to allow light chain gene 
rearrangements (Fig. 4.9) (Grawunder et al., 1995b). It was more recently
189
demonstrated that Ragl, 2 are re-expressed in activated mature B cells both in vivo 
(in GCs) and in vitro (Hikida et al., 1996).
E grl expression is detected in pro-B and pre-B (B220+/sIgM‘) cells isolated 
from BM and foetal liver-derived pre-B cell cultures (Dinkel et al., 1998). Ikaros 
gene expression seems to increase as B cells mature (Georgopoulos et al., 1997). 
EBF  is expressed at the very early stages of B cell development. Finally, Pax5  is 
expressed in all stages of B cell development except plasma cells.
The fact that all these genes were found deregulated in the EpEBNA 1 
transgenic positive samples is very important and may indicate a particular B cell 
developmental stage at which EBNA 1 acts.
In vitro (Kuhn-Hallek et al., 1995; Srinivas and Sixbey, 1995) and now in 
vivo (Chapter 4) Rag gene expression was found to be up-regulated by EBNA 1. 
Rag gene expression is regulated by different transcription factors that are possibly 
regulated by EBNA 1. Ikaros binding sites have been described in the promoters o f a 
number o f genes including Ragl and Rag2 (Georgopoulos et al., 1997). Moreover, 
Pax5 binding sites are found within the Rag2 promoter and this binding is critical for 
its function (Lauring and Schlishel, 1999). Thus, EBNA 1 could up-regulate the Rag 
genes through up-regulation of either Ikaros or Pax5. However, Pax5 expression is 
in turn regulated by EBF (O’Riordan and Grosschedl, 1999). Therefore, a cascade is 
formed consisting of EBF-»Pax5—»Ragl, 2, through which EBNA 1 could either 
directly or indirectly regulate Rag gene expression.
As a transcriptional regulator EBNA 1 may directly effect the expression of 
cellular proto-oncogenes and tumour suppressor genes. This could be achieved by 
DNA binding, EBNA 1 may bind to the cellular gene promoters. Alternatively, 
EBNA 1 may interact with cellular proteins that regulate gene expression. These 
possibilities can be addressed by the use of transient assay systems that are based on 
the use o f reporter genes. In addition, as the EBNA 1 binding consensus is not 
absolute, and alternatively EBNA 1 may not directly interact with a given promoter, 
but perhaps with cellular proteins that do interact with the DNA sequence, potential 
interactions could be examined by mobility shift assays or the yeast 2-hybrid system.
Another approach in determining if  EBNA 1 acts in a particular B cell 
subtype would be to test EBNA 1 expression levels in B cell fractions. The 
EpEBNA 1 transgene contains the IgH enhancer (Ep), which should direct EBNA 1 
expression in most B cells (after the pre-B cells stage). However, the Ep activity in
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each B cell compartment may differ and therefore EBNA 1 may be expressed more 
in a particular B cell type and less in another (and hence more effective in a 
particular B cell subtype). Protein extraction from sorted B cells and western 
blotting would help to detect EBNA 1 expression in the different B cell 
compartments.
Given that BclxL  is up-regulated in EpEBNA 1 transgenic mice it is 
worthwhile comparing the phenotype results of EpEBNA 1 mice with Ep-BclxL and 
Ep-Bcl2 transgenic mice. Both EpEBNA 1 and E p -Bcl2 transgenic mice develop 
tumours whereas tumour development in E\i-BclxL transgenic mice has not been 
reported. Tumour incidence differs with EpEBNA 1 developing tumours at 4-12 
(sometimes earlier) months and Ep-Bcl2 mice with a later onset, usually o f over 8 
months. The difference in tumour incidence makes a direct comparison between 
EpEBNA 1 and E\i-Bcl2 transgenic mice difficult because there are many factors 
that need to be considered. For example, although both transgenes contain the IgH 
enhancer Ep, we are not sure about the relative expression levels o f the transgenes. 
EpEBNA 1 mice develop monoclonal tumours as do E\i-Bcl2 transgenic mice, which 
present a polyclonal hyperplasia, that then develops into monoclonal lymphoma 
(McDonnell and Korsmeyer, 1991). Both Ep -Bcl2 and Ep-BclxL transgenic mice 
show modest splenomegaly at approximately 5 months o f age (Fang et al., 1996; 
McDonnell et al., 1989). In this study mice were examined at 2 months of age when 
most did not show splenomegaly. The occasional EpEBNA 1 mouse with 
splenomegaly was excluded from the pre-tumour studies.
Splenomegaly in the E p -Bel2 and E\i-BclxL  transgenic mice was due to 
enlargement o f the B cell compartment which was found to be due to a survival 
advantage conferred to the cells by the over-expression o f either Bcl2 or BclxL. In 
the wt mice while Bcl2 plays a critical role in the survival o f mature lymphocytes 
(Nakayama et al., 1993), BclxL is important for the survival o f immature 
lymphocytes and GC cells (Motoyama et al., 1995). Thus, since EBNA 1 is 
redundant with Bcl2 in lymphoma onset and up-regulates BclxL it might be predicted 
that EpEBNA 1 transgenic cells would survive much better than the wt cell cultures. 
Ep -BclxL transgenic explant B cell cultures and Ep -Bcl2 transgenic positive explant 
or primary cell cultures showed survival advantage over the control cells upon serum 
starvation (McDonnell et al., 1989; Fang et al., 1996; Takahashi et al., 1999). In 
contrast, EpEBNA 1 transgenic positive cultures showed no difference to the wt
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cultures under any conditions tested. An apoptosis assay using AnnexinV-FITC/PI 
staining showed similar results. Nevertheless, since culture conditions between the 
E \i-BclxL or E \x-Bcl2 and EpEBNA 1 cells as well as the age of the mice were 
different, a direct comparison would not be appropriate. Whilst the E\x-BclxL 
cultures consisted of selected B cells, the EpEBNA 1 cell cultures contained other 
cells such as T cells which would have undergone apoptosis and therefore any 
evidence of survival or delay in apoptosis of B cells may have been obscured. 
Therefore, to eliminate factors that may influence the B cell response to growth 
factors or FCS concentration and cell survival, a B cell selection and/or sorting prior 
to culture should be undertaken. Alternatively, cell sorting could be done on the cell 
cultures to analyse which B cell population EBNA 1 supports/effects. TUNEL assay 
on spleen cells or spleen sections from transgenic and control mice would be useful 
to determine if  EBNA 1 inhibits apoptosis o f B cells since it up-regulates BclxL  or 
possibly by acting in the same way as Bcl2.
These approaches could also be performed on older animals. The cells tested 
in the experiments described in the previous chapters derived from 1 month and 2 
month old mice. These mice are predisposed to tumours by EBNA 1 with a tumour 
incidence between 4-12 months. Thus there is a period between 2 and 4 months 
(some times more than 4 months) when mice may still be free o f tumours. Thus, 
there is a possibility that changes in gene expression and hence cell phenotype due to 
EBNA 1 effect, may be more obvious in the older mice of this group. In this way a 
direct comparison with the E \i-BclxL and E \x-Bcl2 (6 months old) would be possible.
Based on the redundancy between EBNA 1 and Bcl2 shown by transgenic 
crossbreeding, up-regulation o f BclxL by EBNA 1 and the expression patterns of 
BclxL (Fig. 4.8 and 4.9), it can be postulated that EBNA 1 may increase B cell 
survival but nevertheless support B cell differentiation. This could explain the 
increase in the slg+ B cell population in the EpEBNA 1 transgenic mouse spleens 
and the BM. In the BM, B cells are present up to naive cell stage (IgM+) recognised 
by slg antibodies. In addition, plasma cells may return to the BM, but these would 
express low slg or are negative for slg. As the slg antibody recognises surface IgM, 
IgG and IgA, individual antibody staining for these markers is required to further 
characterise the increase in the sIg+B220+ cell population in both the EpEBNA 1 
spleen and BM.
In contrast to Ep -Bel2 and E\x-BclxL transgenic mice with a 2 to 3-fold
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increase o f IgM+/B220+ B cells, the percentage o f these cells were comparable 
between EBNA1 positive and wt sibling mice. Similar results were obtained for 
IgM+/IgD+ B cells in EBNA 1 and wt control mice in contrast to the 3 to 4-fold 
increase observed in the E \i-Bcl2 mice. However, by examining older EpEBNA 1 
transgenic mice we may also see increase in the B cell number.
The increased IgM+/IgD+ B cell population in the Ep-Bcl2 transgenic spleen 
suggested that Bcl2 supports B cell differentiation. This was supported by the 2-fold 
increase in the serum Ig levels for IgG and IgA while IgM levels were comparable to 
those in normal littermates (McDonnell et al, 1989). In contrast, BclxL seemed to 
support antibody producing cells (APCs) but did not alter antibody production since 
serum Ig levels were comparable between Ep-BclxL  transgenics and wt controls 
(Takahashi et al., 1999). Thus, by immunisation o f the animals with a specific 
antigen and subsequent measurement of the secreted IgG in the serum by ELISA it 
would be possible to monitor if  EBNA 1 effects B cell maturation and antibody 
production.
As mentioned earlier, BclxL is re-expressed in GC B cells with expression 
confined to the centrocyte subset in which (antigenic) selection is thought to occur 
(Tuscano et al., 1996). Apoptotic cell death in GCs o f Ep -BclxL transgenic mice 
was significantly reduced and led to the persistence o f many B cells carrying VDJ 
rearrangements that would normally be negatively selected (Takahashi et al., 1999). 
Since EBNA 1 up-regulates BclxL it might be predicted to see a similar effect on the 
GC development and antibody responses of the EpEBNA 1 transgenic spleens. 
These could be tested initially by immunisation o f the animals with an antigen 
followed by immunocytochemistry during the reactive period. Also looking at VDJ 
re-arrangements it would be possible to see if EpEBNA 1 transgenic positive cells 
have increased VDJ recombination. Increased VDJ recombination/hypermutation 
and increased survival might lead to decreased negative selection, retention of high 
(or even low) affinity B cells and accumulation of these “inappropriately” selected B 
cells in the GC. This is because GCs are sites where cells which are not positively 
selected undergo apoptosis and become phagocytosed. Therefore, since EBNA 1 
upregulates BclxL the EpEBNA 1 positive cells will survive longer and accumulate 
in these compartments.
Ep-BclxL B cells displayed some evidence of increased proliferation (using a 
BM cell culture assay) whereas Ep-Bcl2 cells were not tested (McDonell et al., 1989;
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Takahashi et al., 1999). Similarly to E \i-BclxL cells, EpEBNAl transgenic BM cell 
cultures (grown in methylcellulose medium supplemented with IL-7 for selective 
growth) showed a statistically significant proliferative advantage over the wt control 
BM cell cultures (Fig. 3.16). However, the proliferating cell populations still need to 
be characterised. This can be done by pooling the methylcellulose colonies together 
and doing a FACS analysis using B cell surface markers. In addition, analysis of the 
morphology of the cells within the colonies would be informative. In addition the 
proliferative activity o f the spleen GC compartments of both transgenic and control 
animals could be tested by BrdU incorporation in vivo followed by FACS. BrdU 
will only be incorporated into proliferating cells.
Based on the above observations and assumptions the diagram in Fig. 6.1 
represents a possible model o f EBNA 1 action which may lead to tumour 
development. A combination of the Bcl2 and BclxL  expression pattern throughout 
mouse life and the findings that EBNA 1 is redundant with Bcl2 and that BclxL and 
Ragl, 2 are up-regulated in EBNA 1 pre-neoplastic and tumour tissues, as compared 
to the wt ones, would suggest that EBNA 1 may effect B cell maturation. 
Particularly, BclxL and Ragl, 2 genes apart from immature B cells (in both BM and 
spleen) are re-expressed in the germinal centres where B cell maturation takes place. 
In addition Egrl is expressed in both pre-B cells but also in mature/differentiated B 
cells. Therefore it can be postulated that EBNA 1 may drive cells through 
development and differentiation possibly indicated by the increased percentage of 
slg+ B cells in both EpEBNA 1 transgenic spleen and BM. Alternatively, EBNA 1 
may support the survival/proliferation o f immature B cells supported by the 
methycellulose colony numbers and then drives them to differentiate and survive 
leading to increased slg. However, the increased percentage of slg may not be due to 
increased B cell differentiation per se but instead EBNA 1 may effect antibody 
production via the upregulation of the Ragl,2 genes.
Alternatively, EBNA 1 could simply induce aberrant expression of genes that 
do not normally co-express or repress the expression o f genes responsible for the 
control of immune response e.g. interferon responsive genes including those coding 
for JAKs and STATs. JAK3 and STAT 3 both showed lower expression levels in the 
EpEBNA 1 positive Atlas array. Binding o f IFNcc/por IFNy to their specific 
receptors, activates different sets of kinases within the JAK family which then leads 
to activation of different combinations of STAT proteins which then transactivate
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downstream genes. Interferons are produced upon viral infection and prevent viruses 
from spreading efficiently, allowing the adaptive immune response enough time to 
develop and eliminate the virus. Particularly, IFNy was found to inhibit both B cell 
proliferation and infection by EBV (Lotz et al., 1985). Therefore, by down- 
regulating IFN pathway genes (i.e. those coding for JAKs/STATs) or by up- 
regulating their inhibitors (Hoey and Schindler, 1998; Leonard and O ’Shea, 1998), 
EBNA 1 could counteract the anti-proliferative action o f INFy as well as weaken the 
host’s immune response, therefore facilitating EBV maintenance in the B cells.
Moreover, EBNA 1 avoids immune recognition through its Gly-Ala repeat 
which was shown to inhibit in cis the presentation o f MHC class I restricted 
cytotoxic T cell epitopes probably by interfering in the ubiquitin/proteasome- 
dependent protein degradation (Levitskaya et al., 1995; 1997). Interestingly, PML a 
regulator of genes devoted to MHC class I antigen presentation, is possibly down- 
regulated by EBNA 1 (Chapter 5) and if  this is true it could result in reduced 
expression of MHC molecules on the cell surface. Thus, it can be suggested that 
EBV may have developed an additional route o f escaping the host immune 
recognition through EBNA 1 transcriptional regulation function.
Based on the results discussed in this thesis which are suggestive of an 
apoptosis inhibition function by EBNA 1 and the possibility that EBNA 1 may 
decrease negative selection in the GCs through BclxL up-regulation, it can be 
suggested that the virus takes advantage o f the host cell environment in order to 
survive. By extending the survival of the virally infected cells and reducing the 
immune response to virally infected cells the virus can persist. EBNA 1 alone may 
perform many other functions.
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Chapter 4 APPENDIX I
1 1
Pim-1 1 month Spleen RNAs
Animal No. Spleen + GAPDH Ratio Animal No. Spleen - GAPDH Ratio
26815 2277 311 7.3215 26818 4060 516 7.868
816 2475 329 7.5228 821 1598 178 8.978
817 6507 997 6.5266 823 1760 208 8.462
819 2769 485 5.7093 825 5375 660 8.144
820 1893 371 5.1024 826 3066 469 6.537
822 2581 454 5.685 828 2103 394 5.338
824 2686 539 4.9833 832 1516 269 5.636
827 1943 390 4.9821 835 4857 766 6.341
829 3657 600 6.095
830 5864 968 6.0579
831 2127 350 6.0771
833 4155 642 6.472
834 1073 202 5.3119
Bad 1 month LN RNAs
Animal No. LN + GAPDH Ratio Animal No. LN- GAPDH Ratio
26815 494 988 0.5 26818 1383 1678 0.824
816 530 964 0.5498 821 542 733 0.739
817 558 872 0.6399 823 830 1440 0.576
819 483 598 0.8077 825 535 586 0.913
820 879 1058 0.8308 826 270 362 0.746
822 476 654 0.7278 828 802 1088 0.737
824 260 394 0.6599
00 568 805 0.706
827 537 984 0.5457 835 476 614 0.775
829 267 635 0.4205
830 225 543 0.4144
831 300 601 0.4992
833 239 490 0.4878
834 358 635 0.5638
Ragl 1 month Spleen RNAs
!
Animal No. Spleen+ GAPDH Ratio j Animal No. Spleen - GAPDH Ratio
26815 773 382 2.02361 26818 1236 757 1.633
816 943 480 1.9646 821 512 326 1.571
817 938 i 678 1.3835 823 593 342 1.734
819 i 1178 677 1.74' 825 940 621 1.514
820
822
833 494 1.68621 826 820 502 1.633
1114 547 2.0366 i 828 556 428 1.299
824i 1297 771 1.6822| 832 578 386 1.497
827! 315 391 0.8056! 835 885 617 1.434
829i 1128 517 2.1818!
8301 1666! 582 2.8625!
831 962, 366 2.6284
833! 1322 522 2.5326
COoo 402 233 1.7253
j !
I  i i
Rag2 lmonth spleen RNAs1
i
Animal No. i Spleen+ GAPDH: Ratio Animal No. Spleen - GAPDH Ratio
26815! 484 202 2.3961 26818 994 718 1.384
816 795 288 2.7604 821 382 305 1.252
817 1392 790 1.762! 823 320 250 1.28
819! 906 652 1.3896! 825 995 572 1.74
820 524l 364 1.4396! 826 530 333! 1.592 
1.7038221 727! 408 1.7819 828 504 296
824
827’
732' 407 1.7985; 832! 426 253 1.684
422: 147| 2.8707! 835 i 863 440 1.961
829 6901 379j 1.8206:
83 0_____ 1176_____ 541 ■ 2.1738;
831 f 476 244 j 1.9508'
833 649, 309i 2.1003
834 228 112* 2.0357;
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BclxL 1 month Spleen RNAs
Animal No. Spleen+ GAPDH Ratio Animal No. Spleen - GAPDH Ratio
26815 93 353 0.2635 26818 95 589 0.161
816 60 400 0.15 821 31 227 0.137
817 120 601 0.1997 823 29 236 0.123
819 80 511 0.1566 825 76 412 0.184
820 72 345 0.2087 826 58 335 0.173
822 97 447 0.217 828 56 269 0.208
824 90 385 0.2338 832 30 261 0.115
827 53 272 0.1949 835 70 534 0.131
829 80 442 0.181
00 o 110 583 0.1887
831 59 325 0.1815
833 72 448 0.1607
834 42 180 0.2333
Bax 1 month Spleen RNAs
Animal No Spleen + GAPDH Ratio Animal No Spleen GAPDH Ratio
26815 0 202 0 26818 179 718 0.249
816 0 288 0 821 0 305 0
817 59 790 0.0747 823 0 250 0
819 638 652 0.9785 825 255 572 0.446
820 135 364 0.3709 826 414 333 1.243
822 319 408 0.7819 828 23 296 0.078
824 306 407 0.7518 832 0 253 0
827 206 147 1.4014 835 45 440 0.102
829 110 379 0.2902
830 120 541 0.2218
831 172 244 0.7049
833 94 309 0.3042
834 21 112 0.1875
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Ragl 2 month Spleen RNA
Animal No. Spleen+ GAPDH Ratio Animal No. Spleen- GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908 392 1638 0.23932 26911 239 1095 0.218 26569 322 1305 0.25
909 331 2800 0.11821 913 208 2105 0.099 26572 189 920 0.21
910 121 632 0.19146 915 82 1336 0.061 26574 142 862 0.16
912 170 4640 0.03664 919 79 877 0.09 26583 113 999 0.11
916 106 756 0.14021 920 150 2305 0.065 26584 67 1084 0.06
917 69 485 0.14227 923 49 674 0.073
921 94 1050 0.08952 924 67 861 0.078
927 110 879 0.12514 926 68 714 0.095
Ragl 2 month LN RNA
Animal No LN + GAPDH Ratio Animal No. LN- GAPDH Ratio Animal No. LN Turn GAPDH Ratio
26908 415 5351 0.07756 26911 289 2220 0.13 26569 282 249 1.13
909 442 4726 0.09353 913 307 5713 0.054 26572 501 131 3.82
910 406 5727 0.07089 915 226 2707 0.083 26574 301 176 1.71
912 560 4601 0.12171 919 234 2508 0.093 26583 458 147 3.12
916 563 4553 0.12365 920 209 3384 0.062 26584 298 258 1.16
917 65 1081 0.06013 923 210 3492 0.06
921 263 4355 0.06039 924 258 4756 0.054
927 256 4236 0.06043 926 174 2864 0.061
Mdm2 2 month Spleen RNA
Animal No. Spleen+ GAPDH Ratio Animal No. Spleen- GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908 236 780 0.30256 26911 121 299 0.405 26569 139 249 0.56
909 210 1570 0.13376 913 238 1244 0.191 26572 107 131 0.82
910 83 577 0.14385 915 98 829 0.118 26574 67 176 0.38
912 254 4159 0.06107 919 63 526 0.12 26583 67 147 0.46
916 87 534 0.16292 920 100 1929 0.052 26584 57 258 0.22
917 57 243 0.23457 923 20 525 0.038
921 88 660 0.13333 924 20 545 0.037
927 56 360 0.15556 926 22 626 0.035
c-Myb 2 month Spleen RNA
Animal No. Spleen+ GAPDH Ratio Animal No. Spleen- GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908 1011 780 0.12949 26911 59 299 0.197 26569 85| 249 0.34
909 146 1570 0.09299 913 148 1244 0.119 26572 127! 131 0.97
910 107, 577 0.18544 915 94 829 0.113 26574 841 176 0.48
912 208j 4159 0.05001 919 99 526 0.188 26583 92j 147 0.63
916, 153| 534i 0.28652 920 190 1929 0.098 26584 90| 258 0.35
917| 97; 243' 0.39918 923 40 5251 0.076 1 ------
921; 138' 660. 0.20909; 924 39 545, 0.072
927! ' 104' 360 0.28889: 926 55 626 0.088!
1 i
c-Myb 2 month LN RNA ! 1 ' !| 1 ~T " i | 1
Animal Noj LN + jGAPDH jRatio Animal No. LN- GAPDH Ratio Animal No. LN Turn GAPDH Ratio
26908 164! 1094: 0.14991 26911 118 209 0.565 26569 931 418 0.22
909: 161: 748! 0.21524 913 201 18131 0.111 26572 581 728 0.08
910! 126; 1345! 0.09368! 915 181 3911 0.463 26574! 1341 2264 0.06
912' 114! 1431! 0.07966 919 119 397 0.3 26583 145; 6032 i 0.02
916; 139! 1393| 0.09978 920 111! 1108' 0.1 26584 64! 1373 0.05
917;
921
9i 22110.040721 9231 721 989! 0.073!
110 1580! 0.06962 9241 125 10731 0.116! 1 !
927 61 1651 0.03695! 9261 107| 666i 0.161! ! !
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Gfil 2 month LN RNA
Animal No LN + GAPDH Ratio Animal No. LN- GAPDH Ratio Animal No. LN Turn GAPDH Ratio
26908 99 5351 0.0185 26911 233 2220 0.105 26569 167 282 0.59
909 160 4726 0.03386 913 262 5713 0.046 26572 274 501 0.55
910 287 5727 0.05011 915 174 2707 0.064 26574 281 301 0.93
912 2156 4601 0.46859 919 190 2508 0.076 26583 322 458 0.7
916 2444 4553 0.53679 920 202 3384 0.06 26584 206 298 0.69
917 68 1081 0.0629 923 240 3492 0.069
921 297 4355 0.0682 924 340 4756 0.071
927 322 4236 0.07602 926 274 2864 0.096
BclxL 2 month Spleen RNA
Animal No. Spleen + GAPDH Ratio Animal No. Spleen - GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908 174 780 0.22308 26911 68 299 0.227 26569 249 514 0.48
909 160 1570 0.10191 913 117 1244 0.094 26572 131 572 0.23
910 43 577 0.07452 915 71 829 0.086 26574 176 276 0.64
912 38 4159 0.00914 919 107 526 0.203 26583 147 621 0.24
916 84 534 0.1573 920 59 1929 0.031 26584 258 429 0.6
917 70 243 0.28807 923 16 525 0.03
921 42 660 0.06364 924 27 545 0.05
927 72 360 0.2 926 21 626 0.034
Bad 2 month Spleen RNA
Animal No. Spleen + GAPDH Ratio Animal No. Spleen - GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908 467 780 0.59872 26911 345 299 1.154 26569 278 249 1.12
909 500 1570 0.31847 913 412 1244 0.331 26572 218 131 1.66
910 204 577 0.35355 915 248 829 0.299 26574 210 176 1.19
912 288 4159 0.06925 919 253 526 0.481 26583 130 147 0.88
916 223 534 0.4176 920 237 1929 0.123 26584 186 258 0.72
917 230 243 0.9465 923 97 525 0.185
921, 195 660 0.29545 924 30 545 0.055
927 148 360 0.41111 926 104 626 0.166
j
,
MIP1 a 2 month Spleen RNA \
i
Animal No.iSpleen + GAPDH Ratio Animal No. Spleen - GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908 124 780 0.15897 26911 109 299 0.365 26569 129 249 0.52
909] 92 1570 0.0586 913 113 1244 0.091 26572 91 131 0.69
910! 45 577 0.07799 915 69 829 0.083 26574 50 176 0.28
___912
916
69 4159 0.01659 919 73 526 0.139 26583 29 147 0.2
47 534 0.08801 920 77 1929 0.04 26584 32 258 0.12
917 37 243 0.15226 923 69 525 0.131
921i 64 660! 0.09697 924 52 545 0.095
927 72 360! 0.2 926 85 626 0.136
i
, | i
Pirn 1 2 month Spleen RNA i l
i i .i. . .
Animal No.|Spleen + GAPDH Ratio Animal No. Spleen - GAPDH Ratio Animal No. Spleen Turn GAPDH Ratio
26908i 153 1776 0.08615 26911 187 1330 0.141 26569 205 1481 0.14
909| 1511 3530 0.04278 913 176 2794 0.063 26572 77 750 0.1
9101 481 1075 0.04465 915 61 1937 0.031 26574 204 1332 0.15
912 72| 6076 0.01185 919 84! 1385 0.061 i 26583| 128 1731 0.07
916 97' 1187 0.08172 920 108j 2644 0.041i 26584| 90 i 1608 0.06
917 36 859 0.04191 923 32 997! 0.032, j i
921 42| 1173 0.03581 924 42 1119! 0.038; I
i !927 46, 1236 0.037221 926 30! 1281! 0.023■
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Chapter 5 Appendix I
Genes on the Atlas Mouse cDNA Expression 
Array
Oncogenes & Tumor Suppressors 
Tumor Suppressors & Related Proteins
- A P C ;  A d e n o m a t o u s  P o l y p o s i s  C o l i  p r o t e in  
- B R C A 1 ;  B r e a s t / o v a r i a n  c a n c e r  s u s c e p t i b i l i t y  lo c u s  1 
p r o d u c t  B R C A 2 ;  B r e a s t  c a n c e r  s u s c e p t i b i l i t y  lo c u s  2  
p r o d u c t
- D C C ;  n e t r i n  r e c e p to r ;  i m m u n o g lo b u l in  g e n e  
s u p e r f a m i l y  m e m b e r ;  f o r m e r  t u m o r  s u p p r e s s o r  p r o t e in  
c a n d i d a t e
- E B 1 A P C - b i n d i n g  p r o t e in
- E z r i n ;  V i l l i n  2 ;  N F - 2  ( m e r l i n )  r e l a t e d  f i l a m e n t /p l a s m a
m e m b r a n e  a s s o c i a t e d  p r o t e in
- M a d r l ;  m S m a d l ;  M o th e r s  a g a i n s t  d p p  p r o te in  ( M a d )
m u r i n e  h o m o l o g u e ;  T G F - b e t a  s i g n a l i n g  p r o t e i n - 1 ( b s p -
1 ); c a n d i d a t e t u m o r  s u p p r e s s o r  g e n e
- M d m 2 ;  p 5 3 - r e g u l a t i n g  p r o t e in
- N F 2 ;  M e r l i n  ( m o e s i n - e z r i n - r a d i x i n - l i k e  p r o t e in ) ;
s h w a n n o m i n ,  m u r i n e  n e u r o f i b r o m a t o s i s  t y p e  2
s u s c e p t i b i l i t y  p r o t e in
- p i 0 7 ;  R B L 1 ;  R e t i n o b l a s t o m a  g e n e  p r o d u c t - r e l a t e d  
p r o t e i n  p i 0 7  ( c e l l  c y c l e  r e g u l a to r )
- p i 3 0 ;  R e t i n o b l a s t o m a  g e n e  p r o d u c t - r e l a t e d  p r o t e in  
R b 2 / p l 3 0  ( c e l l  c y c l e  r e g u l a t o r )
- p 5 3 ;  t u m o r  s u p p r e s s o r ;  D N A - b i n d i n g  p r o te in  
- R b ;  p p l 0 5 ;  R e t i n o b l a s t o m a  s u s c e p t i b i l i t y - a s s o c i a t e d  
p r o t e i n  ( t u m o r  s u p p r e s s o r  g e n e ;  c e l l  c y c le  r e g u l a to r )  
- T S G 1 0 1  t u m o r  s u s c e p t i b i l i t y  p r o t e in  
- T u m o r  s u p p r e s s o r  m a s p i n
- V H L ;  V o n  H i p p e l - L i n d a u  t u m o r  s u p p r e s s o r  p r o t e in  
- W T 1 ;  W i l m s  tu m o r  p r o t e in ;  t u m o r  s u p p r e s s o r  
- Z O - 1 ;  T i g h t  j u n c t i o n  p r o t e in ;  d i s c s - l a r g e  f a m i ly  
m e m b e r ,  p a r t i a l l y  h o m o l o g o u s  to  a  d l g - A  tu m o r  
s u p p r e s s o r  in  D r o s o p h i l a
Proto-Oncogenes & Transcription Factor-Related 
Oncogenes
- A - m y b  p r o t o - o n c o g e n e ;  m y b - r e l a t e d  p r o te in  A  
- B - m y b  p r o t o - o n c o g e n e ;  m y b - r e l a t e d  p r o te in  B  
- c - E r b A  o n c o g e n e ;  th y r o i d  h o r m o n e  r e c e p to r  
- c - F o s  p r o t o - o n c o g e n e ;  t r a n s c r i p t i o n  f a c t o r  A P -1  
c o m p o n e n t ,  f o s  c e l l u l a r  o n c o g e n e  
- c - J u n  p r o t o - o n c o g e n e  ( t r a n s c r i p t i o n  f a c t o r  A P -1  
c o m p o n e n t ) ,  R N A  p o l y m e r a s e  I t e r m in a t io n  f a c t o r  T T F -  
1
- c - m y b  p r o t o - o n c o g e n e  p r o t e in  
- c - m y c  p r o t o - o n c o g e n e  p r o te in  
- c - r e l  p r o t o - o n c o g e n e  
- E a r - 2 ;  v - e r b A  r e l a t e d  p r o t o - o n c o g e n e  
-E lk - 1  e t s - r e l a t e d  p r o t o - o n c o g e n e  
-F l i - 1  e t s - r e l a t e d  p r o t o - o n c o g e n e  
- F o s - B ;  c - f o s - r e l a t e d  p r o t e i n  f o s  B  
- F r a - 2  ( f o s - r e l a t e d  a n t ig e n  2 )
- G l i  o n c o g e n e ;  z i n c  f i n g e r  t r a n s c r i p t i o n  f a c to r
- J u n - B ;  c - j u n - r e l a t e d  t r a n s c r i p t i o n  f a c t o r
- J u n - D ;  c - j u n - r e l a t e d  t r a n s c r i p t i o n  f a c t o r
- L - m y c  p r o t o - o n c o g e n e  p r o t e in
- N e t ;  e t s  r e l a t e d  t r a n s c r i p t i o n  f a c t o r ;  a c t iv a t e d  b y  R a s
- N - m y c  p r o t o - o n c o g e n e  p r o te in
Serine/Threonine Protein Kinase Oncogenes
- A - R a f  p r o t o - o n c o g e n e
- B - R a f  p r o to - o n c o g e n e
- C o t  p r o t o - o n c o g e n e
- C a s e i n  k i n a s e  II ( a l p h a  s u b u n i t )
- P im - 1  p r o to - o n c o g e n e
Tyrosine Protein Kinase Oncogenes: Receptor 
Protein Tyrosine Kinase Oncogenes
- c - F m s  p r o t o - o n c o g e n e  ( m a c r o p h a g e  c o l o n y  s t im u la t in g  
f a c t o r  1 ( C S F - 1 )  r e c e p to r )
- c - K i t  p r o t o - o n c o g e n e  ( m a s t / s t e m  c e l l  g r o w th  f a c t o r  
r e c e p t o r  t y r o s i n e  k in a s e )
- M e t  p r o t o o n c o g e n e
- P D G F R a ;  p l a t e l e t - d e r i v e d  g r o w t h  f a c t o r  a l p h a - r e c e p t o r  
- R e t  p r o t o - o n c o g e n e  ( P a p i l l a r y  th y r o i d  c a r c in o m a -  
e n c o d e d  p r o t e i n )
- S k i  p r o t o - o n c o g e n e
- S k y  p r o t o - o n c o g e n e  ( T y r o 3 ;  R s e ;  D tk )
- T i e - 2  p r o t o - o n c o g e n e
- V e g f r l ;  V a s c u l a r  e n d o t h e l i a l  g r o w t h  f a c t o r  r e c e p to r  
1 /F m s - r e l a t e d  t y r o s i n e  k i n a s e  1 ( F l t l )
Tyrosine Protein Kinase Oncogenes: Non-Receptor
Tyrosine-Protein Kinases
- c - A b l  p r o t o - o n c o g e n e
- c - F e s  p r o t o - o n c o g e n e
- c - F g r  p r o t o - o n c o g e n e
- c - S r c  p r o t o - o n c o g e n e
- L y m p h o c y t e - s p e c i f i c  t y r o s i n e - p r o t e i n  k in a s e  L C K  
Intracellular Signal Transduction-Related 
Oncogenes
- c - C b l  p r o t o - o n c o g e n e  ( A d a p t o r  p r o t e in )
- H - r a s  p r o t o - o n c o g e n e ;  t r a n s f o r m i n g  G - p r o t e i n  
- L f c  p r o t o - o n c o g e n e
- N - r a s  p r o t o - o n c o g e n e ;  t r a n s f o r m i n g  G - p r o t e i n
- S h e  t r a n s f o r m i n g  a d a p t o r  p r o t e in ;  S r c  h o m o l o g y  2
( S H 2 )  p r o t e in ,  S H B - r e l a t e d
Growth Factor-Related Oncogenes
- C S F - 1 ;  M - C S F ;  c o l o n y  s t i m u l a t i n g  f a c to r -1
- I n t - 3  p r o t o - o n c o g e n e ;  N O T C H  f a m i ly  m e m b e r ;
N O T C H 4
- P r e p r o g l u c a g o n
- B e t a - p r o t a c h y k i n i n  a
Non-Tyrosine Kinase Receptor Oncogenes
- c - M p l ;  t h r o m b o p o i e t i n  r e c e p to r ;  h e m a to p o i e t i c  g r o w th
f a c t o r  r e c e p t o r  s u p e r f a m i l y  m e m b e r
-  M a s  p r o t o - o n c o g e n e  ( G - p r o t e i n  c o u p l e d  r e c e p to r )
Other Oncogenes & Related Genes
- I G F B P - 2 ;  i n s u l i n - l i k e  g r o w th  f a c t o r  b in d i n g  p r o t e in  2 ;
a u t o c r in e  a n d / o r  p a r a c r i n e  g r o w th  p r o m o t e r
- T ia m - 1  in v a s i o n  in d u c in g  p r o t e in ;  G D P - G T P
e x c h a n g e r - r e l a t e d
Cell Cycle Regulators
Cyclins
- C y c l in  A  ( G 2 / M - s p e c i f l c )
- C y c l in  A 1  ( G 2 /M - s p e c i f i c )
- C y c l in  B 1  ( G 2 / M - s p e c i f i c )
- C y c l in  B 2  ( G 2 / M - s p e c i f i c )
- C y c l in  C  ( G 1 - s p e c i f i c )
- C y c l in  D 1  ( G l / S - s p e c i f i c )
- C y c l in  D 2  ( G l / S - s p e c i f i c )
- C y c l in  D 3  ( G l / S - s p e c i f i c )
- C y c l in  E  ( G l / S - s p e c i f i c )
- C y c l in  F  ( S / G 2 / M - s p e c i f i c )
- C y c l in  G  ( G 2 / M - s p e c i f i c )
- C y c l in  G 2  ( G 2 / M - s p e c i f i c )
Cell Cycle-Regulating Kinases
- C d k 4 ;  c y c l i n - d e p e n d e n t  k i n a s e  4
- C d k 5 ;  c y c l i n - d e p e n d e n t  k i n a s e  5
- C d k 7 ;  M O  1 5 ; c y c l i n - d e p e n d e n t  k in a s e  7  ( h o m o l o g u e  o f
X e n o p u s  M O  15 c d k - a c t i v a t i n g  k in a s e )
- p 5 8 /G T A ;  g a l a c t o s y l t r a n s f e r a s e  a s s o c i a t e d  p r o t e in  
k in a s e  ( c d c 2 - r e l a t e d  p r o t e in  k in a s e )
Cdk Inhibitors
- p l 8 i n k 4 ;  c d k 4  a n d  c d k 6  i n h i b i to r
- p l 9 i n k 4 ;  c d k 4  a n d  c d k 6  i n h i b i to r
- p 2 1 / C i p l / W a f l ;  c d k - i n h i b i t o r  p r o te in  1
- p 2 7 k i p l ;  G 1  c y c l i n - C d k  p r o t e in  k in a s e  in h i b i to r ,  p 2 1 -
r e l a te d
C h a p ter  5 A p p e n d ix  I
- p 5 7 k i p 2 ;  c d k - i n h i b i t o r  k ip 2  ( c y c l i n - d e p e n d e n t  k in a s e
i n h i b i t o r  I B )  m e m b e r  o f  t h e  p 2 1 C I P l  - C d k  i n h i b i to r
f a m i ly ,  c a n d i d a t e  t u m o r  s u p p r e s s o r  g e n e
- W e e l / p 8 7 ;  c d c 2  t y r o s i n e  1 5 - k in a s e
Other Cell Cycle-Regulating Proteins
- C d c 2 5  p h o s p h a t a s e ;  g u a n i n e  n u c l e o t i d e  r e l e a s in g
p r o t e i n
- C d c 2 5 a ;  c d c 2 5 M l ;  M P I 1  ( M - p h a s e  in d u c e r  
p h o s p h a t a s e  1)
- C d c 2 5 b ;  c d c 2 5 M 2 ;  M P I 2  ( M - p h a s e  i n d u c e r  
p h o s p h a t a s e  2 )
- M y e l o b l a s t i n ;  t r y p s i n - c h y m o t r y p s i n  r e l a t e d  s e r in e  
p r o t e a s e
- P r o t h y m o s i n  a l p h a
- T o b  a n t i p r o l i f e r a t i v e  f a c t o r ;  i n t e r a c t s  w i th  p l 8 5 e r b B 2
Stress Response Proteins
- H S P 2 7 ;  h e a t  s h o c k  2 7 k D  p r o t e i n  1
- H S P 6 0 ;  h e a t  s h o c k  6 0  k D a  p r o t e in  1 ( c h a p e r o n in ,
G r o E L  h o m o l o g u e ) ;  m i to c h o n d r i a l  m a t r ix  p r o t e in  P I
- H S P 8 4 ;  h e a t  s h o c k  8 4 k D  p r o t e in
- H S P 8 6 ;  h e a t  s h o c k  8 6 k D  p r o te in
- M T J 1 ;  D n a J - l i k e  h e a t - s h o c k  p r o t e in  f r o m  m o u s e  t u m o r
- O s p 9 4  o s m o t i c  s t r e s s  p r o t e in ;  A P G - 1; h s p 7 0 - r e l a t e d
- M D R 1 ;  P - g l y c o p r o t e i n ;  m u l t i d r u g  r e s i s t a n c e  p r o te in ;
e f f l u x  p u m p
- H M G 1 - r e l a t e d  V D J  r e c o m b i n a t i o n  s ig n a l  b i n d i n g  
p r o t e in
- M m M r e l  l a  p u t a t i v e  e n d o / e x o n u c le a s e
- C 3 H  c y t o c h r o m e  P 4 5 0 ;  C y p l b l
- E R p 7 2  e n d o p l a s m i c  r e t i c u l u m  s t r e s s  p r o t e in ;  p r o t e in
d i s u l f i d e  i s o m e r a s e - r e l a t e d  p r o t e in
- E t o p o s i d e  i n d u c e d  p 5 3  r e s p o n s i v e  ( E I 2 4 )  m R N A
- G l u c o s e  r e g u l a t e d  p r o t e in ,  7 8 k D ;  G r p 7 8
- O x i d a t i v e  s t r e s s - i n d u c e d  p r o t e i n  m R N A
- P - 1 - 4 5 0 ;  d io x i n - i n d u c i b l e  c y t o c h r o m e  P 4 5 0
Ion Channel & Transport Proteins
- A T P - b i n d i n g  c a s e t t e  8 ;  A B C 8 ;  h o m o l o g  o f  D r o s o p h i l a
w h i t e  C C H B 3 ;  c a l c iu m  c h a n n e l  ( v o l t a g e - g a t e d ;
d ih y d r o p y r i d i n e - s e n s i t i v e ;  L - t y p e )  b e t a - 3  s u b u n i t )
- G o l g i  4 - t r a n s m e m b r a n e  s p a n n i n g  t r a n s p o r t e r ;  M T P
- G l u c o s e  t r a n s p o r t e r - 1, e r y t h r o c y te ;  G l u t l
- V o l t a g e - g a t e d  s o d iu m  c h a n n e l
Intracellular Signal Transduction Modulators &
Effectors
Receptors & Cell Surface Proteins
- B 7 - 2 ;  T  ly m p h o c y te  a c t i v a t io n  a n t ig e n  C D 8 6 ;  C D 2 8  
a n t ig e n  l i g a n d  2 ,  B 7 - 2  a n t ig e n ;  a l t e r n a t i v e  C T L A 4  
c o u n t e r - r e c e p t o r
- B S T - 1 ;  ly m p h o c y te  d i f f e r e n t i a t i o n  a n t ig e n  C D 3 8  
- C - C  C K R - 1 ;  C C R - 1 ;  C - C  c h e m o k in e  r e c e p t o r  t y p e  1, 
m a c r o p h a g e  i n f l a m m a to r y  p r o t e i n - 1 a l p h a  r e c e p to r ;  
M I P - l a l p h a - R ;  R A N T E S - R  
- C f 2 r ;  c o a g u la t i o n  f a c t o r  I I  ( t h r o m b in )  r e c e p to r  
- E p h 3  ( N u k )  t y r o s in e - p r o t e in  k in a s e  r e c e p to r  
- E t k l  ( M e k 4 ;  H E K )  ty r o s i n e - p r o t e i n  k i n a s e  r e c e p to r  
H E K
- F r i z z l e d - 3 ;  D r o s o p h i l a  t i s s u e  p o la r i t y  g e n e  f r i z z le d
h o m o l o g u e  3 ; d i s h e v e l l e d  r e c e p to r
- H e k 2  m u r i n e  h o m o l o g u e ;  M d k 5  m o u s e  d e v e lo p m e n t a l
k in a s e ;  E p h  - r e l a t e d  t y r o s i n e - p r o t e i n  k in a s e  r e c e p to r
- H tk ;  M d k 2  m o u s e  d e v e lo p m e n t a l  k in a s e ;  E p h  - r e l a te d
t y r o s i n e - p r o t e i n  k i n a s e  r e c e p to r
- I F N g R 2 ;  i n t e r f e r o n - g a m m a  r e c e p t o r  s e c o n d  ( b e t a )
c h a in ;  i n t e r f e r o n  g a m m a  r e c e p t o r  a c c e s s o r y  f a c t o r - 1
( A F - 1 )
- I n t e r l e u k i n - 6  r e c e p t o r  b e t a  c h a in ;  m e m b r a n e  
g ly c o p r o t e i n  g p  1 3 0
- L C R - 1 ;  C X C R - 4 ;  C X C  ( S D F - 1 )  c h e m o k in e  r e c e p t o r  4 ; 
H I V  c o r e c e p t o r  ( f u s in ) ;  G  p r o t e in - c o u p le d  r e c e p to r  
L C R 1  h o m o l o g u e
- L F A 1 - a l p h a ;  in t e g r in  a l p h a  L ;  l e u k o c y te  a d h e s i o n  
g l y c o p r o t e i n  L F A - 1  a l p h a  c h a in ;  a n t ig e n  C D 1 1 A  ( p i 8 0 )  
- P r o s t a g l a n d i n  E 2  r e c e p t o r  E P 4  s u b ty p e  
- T ie - 1  t y r o s i n e - p r o t e i n  k in a s e  r e c e p t o r  
- T r a n s f e r r i n  r e c e p t o r  p r o t e in  ( p 9 0 ,  C D 7 1 )
- u P A R l ;  u r o k i n a s e  p l a s m i n o g e n  a c t iv a t o r  s u r f a c e  
r e c e p t o r  ( C D 8 7 )
- V e g f r 2 ;  K D R / f l k l  v a s c u l a r  e n d o t h e l i a l  g r o w th  f a c t o r
ty r o s i n e  k i n a s e  r e c e p t o r
Transcription Factors
- B e t a 2 - R A R ;  r e t i n o i c  a c i d  r e c e p t o r  b e t a - 2
- C R E - B P 1 ;  c A M P  r e s p o n s e  e l e m e n t  b in d i n g  p r o t e i n  1
- I - k a p p a  B  a l p h a  c h a in
- I - k a p p a  B  b e t a
- N F - k a p p a - B  t r a n s c r i p t i o n  f a c t o r  p 6 5  s u b u n i t ;  r e l -  
r e l a t e d  p o l y p e p t i d e
- P m l ;  M u r in e  h o m o l o g u e  o f  t h e  l e u k e m i a - a s s o c i a t e d  
P M L  g e n e
- R X R - b e t a  c i s - 1 1- r e t i n o i c  a c id  r e c e p t o r  
- S t a t l ;  s i g n a l  t r a n s d u c e r  a n d  a c t i v a t o r  o f  t r a n s c r i p t i o n  
- S t a t 3 ;  A P R F ;  a c u t e  p h a s e  r e s p o n s e  f a c t o r  
- S t a t 5 a ;  m a m m a r y  g l a n d  f a c t o r
- S t a t 6 ;  s i g n a l  t r a n s d u c e r  a n d  a c t i v a t o r  o f  t r a n s c r i p t i o n  6 ; 
I L - 4  S ta t ;  S T A 6
- T A N K ;  I - T R A F ;  T R A F  f a m i ly  m e m b e r  a s s o c i a t e d  N F -  
k B  a c t iv a t o r
- T r a n s c r i p t i o n  f a c t o r  A 1 0  
- T r a n s c r i p t i o n  f a c t o r  T F I I D  
- T r i s t e t r a p r o l i n e
- R e c e p t o r - A s s o c i a t e d  P r o t e i n s  &  A d a p to r s
- C a s ;  C r k - a s s o c i a t e d  s u b s t r a t e ;  f o c a l  a d h e s i o n  k in a s e
s u b s t r a t e
- C r k  a d a p t o r  p r o t e in
- C s k ;  c - S r c - k i n a s e  a n d  n e g a t i v e  r e g u l a to r  
- F y n  p r o t o - o n c o g e n e ;  S r c  f a m i ly  m e m b e r  
- H c k  t y r o s i n e - p r o t e i n  k in a s e
- S L A P ;  s r c - l i k e  a d a p t e r  p r o t e in ;  E c k  r e c e p to r  ty r o s in e  
k in a s e - a s s o c i a t e d
- S y k  t y r o s i n e - p r o t e i n  k i n a s e  ( a c t i v a t e d  p 2 1 c d c 4 2 H s  
k in a s e  [ a c k ] )
- S y p ;  S H - P T P 2 ;  a d a p t o r  p r o t e i n  ty r o s in e  p h o s p h a ta s e  
Intracellular Kinase Network Members
- C a m K  I V ; C a 2 / c a l m o d u I  i n - d e p e n d e n t  p r o te in  k in a s e  
IV  ( c a t a ly t i c  c h a in )
- c A M P - d e p e n d e n t  p r o t e in  k i n a s e  t y p e  I - b e t a  r e g u l a to r y  
c h a in
- E r k l ;  e x t r a c e l l u l a r  s i g n a l - r e g u l a t e d  k in a s e  1; p 4 4 ;  E r t2  
- I n h ib i to r  o f  t h e  R N A - a c t i v a t e d  p r o te in  k in a s e ,  5 8 - k D a  
- J a k 3  ty r o s i n e - p r o t e i n  k in a s e ;  J a n u s  k in a s e  3 
- J n k  s t r e s s - a c t i v a t e d  p r o t e i n  k in a s e  ( S A P K )
- L I M K ;  L I M  s e r i n e / t h r e o n i n e  k in a s e  
- M A P K ;  M A P  k in a s e ;  p 3 8
- M A P K A P K - 2 ;  M A P  k i n a s e - a c t i v a t e d  p r o te in  k in a s e ;  
M A P K A P  k i n a s e  2
- M A P K K 1 ;  M A P  k in a s e  k i n a s e  3 ( d u a l  s p e c i f i c i t y )  
( M K K 1 )
- M A P K K 3 ;  M A P  k in a s e  k in a s e  3 ( d u a l  s p e c i f i c i t y )  
( M K K 3 ,  M E K 3 )
- M A P K K 4 ;  M A P  k in a s e  k i n a s e  4 ; J n k  a c t iv a t in g  k in a s e  
1; ( J N K K 1 ;  S E K 1 ;  M K K 4 )
- M A P K K 6 ;  M A P  k i n a s e  k i n a s e  6 ( d u a l  s p e c i f i c i t y )  
( M K K 6 )
- P K C - a lp h a ;  p r o t e in  k i n a s e  C  a l p h a  ty p e
- P K C - b e ta ;  p r o t e i n  k i n a s e  C  b e t a - I I  t y p e
- P K C - d e l t a ;  p r o t e in  k i n a s e  C  d e l t a  t y p e
- P K C - t h e t a ;  p r o t e in  k in a s e  C  t h e t a  ty p e
- R s k ;  r i b o s o m a l  p r o t e in  S 6  k in a s e
Non-Protein Kinase Effectors
- P I 3 - K  p i  1 0 ; p h o s p h a t i d y l i n o s i t o l  3 - k in a s e  c a t a ly t i c
s u b u n i t
C h ap ter  5 A p p e n d ix  I
- P I 3 - K  p 8 5 ;  p h o s p h a t i d y l i n o s i t o l  3 - k i n a s e  r e g u l a to r y  
s u b u n i t ;  p h o s p h o p r o t e i n  p 8 5 ;  P D G F  s i g n a l i n g  p a t h w a y  
m e m b e r
- P L C  b e t a ;  p h o s p h o l i p a s e  C  b e t a  3 
- P L C  g a m m a ;  p h o s p h o l i p a s e  C  g a m m a  
G-Proteins
- G - a lp h a - 1 3  g u a n i n e  n u c l e o t i d e  r e g u l a t o r y  p r o te in  
- G e m ;  in d u c e d ,  im m e d i a t e  e a r l y  p r o t e in ;  R a s  f a m i ly  
m e m b e r
- R a b - 2  r a s - r e l a t e d  p r o t e in  
- R a c l  m u r i n e  h o m o l o g u e
- R - r a s  p r o t e in ,  c l o s e ly  r e l a t e d  t o  r a s  p r o t o - o n c o g e n e s
- T r a n s d u c i n  b e t a - 2  s u b u n i t
- V a v ;  G D P - G T P  e x c h a n g e  f a c t o r ;  p r o t o - o n c o g e n e
Other Related Proteins
- 1 4 - 3 - 3  p r o t e i n  e t a
- C o r t a c t i n ;  p r o t e i n  t y r o s i n e  k i n a s e  s u b s t r a t e
- D v l2 ;  d i s h e v e l l e d - 2  t i s s u e  p o l a r i t y  p r o t e in
- G a p I I I ;  G T P a s e - a c t i v a t i n g  p r o t e in
- I R F 1 ;  i n t e r f e r o n  r e g u l a to r y  f a c t o r  1
- P T P R G ;  p r o t e i n - t y r o s i n e  p h o s p h a t a s e  g a m m a
- W B P 6 ;  p S K - S R P K l ;  W W  d o m a in  b i n d i n g  p r o t e in  6
s e r in e  k i n a s e  f o r  S R  s p l i c in g  f a c t o r s
- Z y x i n ;  L I M  d o m a in  p r o t e in ;  a l p h a - a c t i n i n  b in d i n g
p r o t e in
Apoptosis-Related Proteins 
Cysteine Proteases
- C a s p a s e - 1 1 ; I C H - 3  c y s t e i n e  p r o t e a s e ;  u p s t r e a m  
r e g u l a t o r  o f  I C E
- C a s p a s e - 3 ;  N e d d 2  c y s t e in e  p r o t e a s e  ( p o s i t i v e  r e g u l a t o r  
o f  p r o g r a m m e d  c e l l  d e a th  I C H - 1  h o m o l o g u e )  
- C a s p a s e - 7 ;  L i c e 2 ;  I C E - L A P 3  c y s t e in e  p r o t e a s e  
Bcl-2 Family
- B a d ;  h e t e r o d i m e r i c  p a r t n e r  f o r  B c l - X L  a n d  B c l - 2 ;  
p r o m o t e s  c e l l  d e a th
- B A G - 1 ;  b c l - 2  b in d i n g  p r o t e i n  w i th  a n t i - c e l l  d e a th  
a c t iv i ty
- B a k  a p o p t o s i s  r e g u l a to r ;  B c l - 2  f a m i ly  m e m b e r  
- B a x ;  B c l - 2  h e t e r o d i m e r i z a t i o n  p a r t n e r  a n d  h o m o l o g u e  
- B c l - 2 ;  B  c e l l  l y m p h o m a  p r o t e i n  2 ,  a p o p t o s i s  i n h i b i t o r  
- B c l - W  a p o p t o s i s  r e g u l a to r ;  B c l - 2  f a m i ly  m e m b e r  
- B c l - x L  a p o p t o s i s  r e g u l a t o r  ( b c l - x  l o n g ) ;  B c l - 2  f a m i ly  
m e m b e r
- B I D ;  a p o p t i c  d e a th  a g o n i s t
Glutathione Peroxidases, Transferases, etc.
- G l u t a t h i o n e  p e r o x i d a s e  ( p l a s m a  p r o t e in ) ;  s e l e n o p r o t e i n  
- G l u t a t h i o n e  r e d u c t a s e  
- G lu t a th io n e  S - t r a n s f e r a s e  A  
- G lu t a th io n e  S - t r a n s f e r a s e  ( m i c r o s o m a l )
- G l u t a t h i o n e  S - t r a n s f e r a s e  M u  1 
- G l u t h a t h i o n e  S - t r a n s f e r a s e  ( t h e t a  t y p e l ) ;  p h a s e  II  
c o n j u g a t i o n  e n z y m e
- G S T  P i 1; g l u t a t h i o n e  S - t r a n s f e r a s e  P i  1; p r e a d i p o c y te
g r o w th  f a c t o r
Other
- A 2 0  z i n c  f i n g e r  p r o te in ;  a p o p t o s i s  i n h i b i to r
- A d e n o s in e  A I M  r e c e p to r
- A d e n o s i n e  A 2 M 2  r e c e p to r
- A d e n o s i n e  A 3  r e c e p to r
- A L G - 2 ;  c a l c i u m  b in d i n g  p r o te in  r e q u i r e d  f o r
p r o g r a m m e d  c e l l  d e a th
- B lk ;  B  l y m p h o c y te  k in a s e ;  S r c  f a m i ly  m e m b e r  
- c - A k t  p r o to - o n c o g e n e ;  R a c - a lp h a ;  p r o t e in e  k in a s e  B  
( P K B )
- C D 2 7 ;  l y m p h o c y t e - s p e c i f i c  N G F  r e c e p t o r  f a m i ly  
m e m b e r
- C D  3 0 L  r e c e p t o r  ( L y m p h o c y te  a c t i v a t io n  a n t i g e n e  C D  
3 0 , K .i-1 a n t ig e n e )
- C D 4 0 L ;  C D 4 0  l i g a n d
- C h o p  1 0 ; m u r i n e  h o m o l o g u e  o f  G a d d i  5 3  ( g r o w t h  a r r e s t  
a n d  D N A - d a m a g e - i n d u c i b l e  p r o t e in )
- C lu s t e r in ;  c o m p l e m e n t  ly s i s  in h i b i to r ;  t e s t o s t e r o n e -  
r e p r e s s e d  p r o s t a t e  m e s s a g e  2 ;  a p o l i p o p r o t e i n  J ;  s u l f a t e d  
g l y c o p r o t e i n - 2
- C R A P 1 ;  T N F  r e c e p t o r  ( C D 4 0  r e c e p t o r )  a s s o c i a t e d
f a c t o r ;  T R A F - r e l a t e d
- D A D - 1 ;  d e f e n d e r  a g a i n s t  c e l l  d e a th  1
- F A F 1 ;  F a s - a s s o c i a t e d  p r o t e i n  f a c t o r ,  a p o p t o s i s  a c t i v a t o r
- F a s l  r e c e p t o r  ( F a s  a n t ig e n ,  A p o - 1  a n t ig e n )
- F a s l ;  F a s  a n t i g e n  l i g a n d ;  g e n e r a l i z e d  
ly m p h o p r o l i f e r a t i o n  d i s e a s e  g e n e  ( g ld )  in  m i c e  
- F L I P - L ;  a p o p t o s i s  i n h i b i to r ;  F L I C E - l i k e  in h i b i to r y  
p r o t e in
- F m s - r e l a t e d  t y r o s i n e  k i n a s e  3  F l t 3 / F l k 2  l i g a n d  
- G a d d 4 5 ;  g r o w t h  a r r e s t  a n d  D N A - d a m a g e - i n d u i b l e  
p r o t e i n
- I G F R I I ;  i n s u l i n - l i k e  g r o w t h  f a c t o r  r e c e p t o r  I I ,  c a t io n -  
i n d e p e n d e n t  m a n n o s e - 6 - P  r e c e p to r ;  e l e v a t e d  in  W i lm s 's  
tu m o r  c e l l s
- I G F - I - R  a l p h a ;  i n s u l i n - l i k e  g r o w t h  f a c t o r  I  r e c e p to r  
a l p h a  s u b u n i t
- iN O S l ;  n i t r i c  o x i d e  s y n t h a s e  ( i n d u c i b l e )
- I n t e r l e u k i n - 1 r e c e p t o r
- N A D P H - c y t o c h r o m e  P 4 5 0  r e d u c t a s e
- N e u r o n a l  d e a th  p r o t e i n
- N m 2 3 - M 2 ;  n u c l e o s i d e  d i p h o s p h a t e  k i n a s e  B ;
m e t a s t a s i s - r e d u c i n g  p r o t e in ;  c - m y c - r e l a t e d  t r a n s c r i p t i o n
f a c t o r
- N u r 7 7  e a r l y  r e s p o n s e  p r o t e in ;  t h y r o i d  h o r m o n e  ( T R 3 )  
r e c e p to r
- p 5 5 c d c ;  c e l l  d iv i s i o n  c o n t r o l  p r o t e i n  2 0
- P D - 1  p o s s i b l e  c e l l  d e a th  in d u c e r ;  I g  g e n e  s u p e r f a m i ly
m e m b e r
- P r o t e i n  t y r o s i n e  p h o s p h a t a s e
- P S - 2 ;  h o m o l o g u e  o f  t h e  A l z h e i m e r 's  d i s e a s e  g e n e
- R e l a x in
- R I P  c e l l  d e a t h  p r o t e in ;  F a s /A P O - 1  ( C D 9 5 )  in t e r a c t o r ,
c o n t a in s  d e a th  d o m a in
- S ik ;  S r c - r e l a t e d  i n t e s t i n a l  k in a s e
- S P I 3 ;  s e r p in ;  s i m i l a r  t o  h u m a n  p r o t e i n a s e  i n h i b i to r  6
( p l a c e n ta l  t h r o m b i n  in h i b i to r )  s e r i n e  p r o t e i n a s e  i n h i b i to r
- S T A M ;  s ig n a l  t r a n s d u c i n g  a d a p t o r  m o l e c u l e
- S t r o m e l y s i n - 3 ;  m a t r ix  m e t a l l o p r o t e i n a s e - 1 1 ( M M P - 1 1 )
- T D A G 5 1 ;  c o u p l e s  T C R  s i g n a l i n g  t o  F a s  ( C D 9 5 )
e x p r e s s i o n
- T N F  5 5 ;  t u m o r  n e c r o s i s  f a c t o r  1 ( 5 5 k d )
- T R A I L ;  T N F - r e l a t e d  a p o p t o s i s  i n d u c in g  l i g a n d ;  A p o - 2  
l i g a n d
- T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  1; T N F R - 1
DNA Synthesis, Repair & Recombination Proteins
- A c t i v a t o r  -1  1 4 0  K D  s u b u n i t  ( r e p l i c a t i o n  f a c t o r  C  
1 4 0 K D )
- A P  e n d o n u c l e a s e ;  a p u r i n i c / a p y r i m i d i n i c  e n d o n u c le a s e  
( A p e x )
- A tm ;  a t a x i a  t e l a n g i e c t a s i a  m u r i n e  h o m o l o g u e  
- A T P - d e p e n d e n t  D N A  h e l i c a s e  I I 7 0  k D a  s u b u n i t ;  
t h y r o i d  K u
- ( p 7 0 / p 8 0 )  a u t o a n t i g e n  p 7 0  s u b u n i t ;  p 7 0  K u )  
- A T P - d e p e n d e n t  D N A  h e l i c a s e  I I  8 0  k D a  s u b u n i t ;  
t h y r o i d  K u  ( p 7 0 / p 8 0 )  a u t o a n t i g e n  p 8 0  s u b u n i t ;  p 8 0  K u )  
- D N A  l i g a s e  I 
- D N A  l i g a s e  I I I
- D N A  p o l y m e r a s e  a l p h a  c a t a l y t i c  s u b u n i t  ( p i 8 0 )
- D N A  t o p o i s o m e r a s e  I ( T o p  I)
- D N A  t o p o i s o m e r a s e  II  ( T o p  I I )
- P A 6  s t r o m a l  p r o t e in ;  R A G 1  g e n e  a c t i v a t o r  
- D N A - p o l y m e r a s e  d e l t a  c a t a l y t i c  s u b u n i t  
- D N A s e  I
- E R C C - 1 ;  D N A  e x c i s io n  r e p a i r  p r o t e in
C h a p te r  5 A p p e n d ix  I
- E R C C 3  D N A  r e p a i r  h e l i c a s e ;  D N A - r e p a i r  p r o t e in  
c o m p l e m e n t i n g  X P - B  c e l l s  ( X P B C )
- E R C C 5  e x c i s io n  r e p a i r  p r o t e in ;  D N A - r e p a i r  p r o t e i n  
c o m p l e m e n t i n g  X P - G  c e l l s  ( X P G )
- G T B P ;  G / T - m i s m a t c h  b i n d i n g  p r o t e in ;  M S H 6
- H R 2 1 s p A ;  p r o t e i n  i n v o l v e d  in  D N A  d o u b l e - s t r a n d
b r e a k  r e p a i r ;  P W 2 9 ;  c a l c i u m - b i n d i n g  p r o t e in
- M H R 2 3 A ;  R a d 2 3  U V  e x c i s i o n  r e p a i r  p r o te in
h o m o l o g u e ;  x e r o d e r m a  p i g m e n t o s u m  g r o u p  C  ( X P C )
r e p a i r  c o m p l e m e n t i n g  p r o t e in
- M H R 2 3 B ;  R a d 2 3  U V  e x c i s i o n  r e p a i r  p r o t e in
h o m o l o g u e ;  x e r o d e r m a  p i g m e n t o s u m  g r o u p  C  ( X P C )
r e p a i r  c o m p l e m e n t i n g p r o t e i n
- M L H 1  D N A  m i s m a tc h  r e p a i r  p r o t e in ;  M u tL
h o m o l o g u e
- M m L i m l 5 ;  R e c A - l i k e  g e n e ;  D M C 1  h o m o l o g u e ;  
m e i o s i s - s p e c i f i c  h o m o l o g o u s  r e c o m b i n a t i o n  p r o t e i n  
- M m R a d 5 1 ;  y e a s t  D N A  r e p a i r  p r o t e in  R a d 5 1  a n d  E  c o l i  
R e c A  h o m o l o g u e
- M m R a d 5 2 ;  y e a s t  D N A  r e p a i r  p r o t e i n  R a d 5 2  
h o m o l o g u e
- M S H 2  D N A  m i s m a tc h  r e p a i r  p r o t e in ;  M u tS  h o m o l o g u e  
2
- P C N A ;  p r o l i f e r a t i n g  c e l l  n u c l e a r  a n t ig e n ;  p r o c e s s i v i t y  
f a c t o r
- P h o t o l y a s e / b l u e - l i g h t  r e c e p t o r  h o m o l o g u e  
- P M S 2  D N A  m i s m a tc h  r e p a i r  p r o t e in ;  y e a s t  P M S 1  
h o m o l o g  2
- P u r - a l p h a  t r a n s c r i p t i o n a l  a c t i v a t o r ;  s e q u e n c e - s p e c i f i c  
s s D N A - b i n d in g  p r o t e in  
- R a d 5 0 ;  D N A  r e p a i r  p r o t e in  
- R A G - 1 ;  V ( D ) J  r e c o m b i n a t i o n  a c t iv a t in g  p r o t e in  
- R A G - 2 ;  V ( D ) J  r e c o m b i n a t i o n  a c t i v a t i n g  p r o te in  
- S h c C  a d a p to r ;  S h c - r e l a t e d ;  b r a i n - s p e c i f i c  
- T r a n s l in ;  r e c o m b i n a t i o n  h o t s p o t  b in d i n g  p r o te in  
- U b i q u i t i n - c o n j u g a t i n g  e n z y m e ,  y e a s t  R a d 6  h o m o l o g u e ;  
m u r i n e  H R 6 B
- U n g l ;  u r a c i l - D N A  g l y c o s y l a s e
- X P A C ;  x e r o d e r m a  p i g m e n t o s u m  g r o u p  A  c o r r e c t i n g
p r o te in
- X R C C 1  D N A - r e p a i r  p r o t e in ,  a f f e c t i n g  l i g a t i o n  
Transcription Factors & General DNA Binding 
Proteins
- A b lp h i l in - 1  ( a b i - 1 )  s i m i l a r  to  H O X D 3  
- A c t i v a t i n g  t r a n s c r i p t i o n  f a c t o r  4  ( m A T F 4 )
- A d ip o c y t e  d i f f e r e n t i a t i o n - a s s o c i a t e d  p r o te in  
- A T  m o t i f - b i n d i n g  f a c t o r  A T B F 1  
- B a s i c  d o m a i n / l e u c i n e  z i p p e r  t r a n s c r i p t i o n  f a c t o r  
- B r a i n  f a c t o r  1 ( H f h b f l )
- B r a i n  s p e c i f i c  t r a n s c r i p t i o n  f a c t o r  N U R R - 1  
- B m - 3 .2  P O U  t r a n s c r i p t i o n  f a c t o r  
- B u ty r a t e  r e s p o n s e  f a c t o r  1 
- C A C C C  B o x -  b i n d i n g  p r o t e i n  B K L F  
- C C A A T -  B in d i n g  t r a n s c r i p t i o n  f a c t o r  ( C /  E B P )
- C a u d a l  t y p e  H o m e o b o x  1 ( C d x l )
- C a u d a l  t y p e  H o m e o b o x  2  ( C d x 2 )
- S im  t r a n s c r i p t i o n  f a c t o r  
- E a r l y  B  c e l l  f a c t o r  ( E B F )
- E n g r a i l e d  p r o t e in  ( E n - 1 )  h o m o l o g
- E n g r a i l e d  p r o t e in  ( E n - 2 )  h o m o l o g
- E r y t h r o id  t r a n s c r i p t i o n  f a c t o r  N F - E 2
- D N A - b in d i n g  p r o t e in  S A T B 1
- D N A - b in d i n g  p r o te in  S M B P 2
-D P -1  ( D R T F - p o l i p e p t i d e  1) c e l l  c y c l e  r e g u l a to r y
t r a n s c r i p t i o n  f a c t o r
- E 2 F - 5  t r a n s c r i p t i o n  f a c t o r
-E g r -1  Z n - f i n g e r  r e g u l a to r y  p r o te in
-E lf -1  E ts  f a m i ly  t r a n s c r i p t i o n  f a c t o r
- E p i d e r m a l  g r o w th  f a c t o r  r e c e p t o r  k in a s e  s u b s t r a t e  E P S 8
-E R A - 1  P r o te in  ( E R A - 1 - 9 9 3 )
- E r f  ( E t s - r e l a t e d  t r a n s c r i p t i o n  f a c t o r )
- E r y t h r o id  k r u p p e l - l i k e  t r a n s c r i p t i o n  f a c t o r
- E t s - r e l a t e d  p r o t e i n  P E A  3
- E t s - 2  t r a n s c r i p t i o n  f a c t o r
- E t s - r e l a t e d  p r o t e i n  S a p  1A
- G A  b i n d i n g  p r o t e i n  b e t a - 2  c h a in
- G A T A  b i n d i n g  t r a n s c r i p t i o n  f a c t o r  ( G A T A - 4 )
- G A T A - 3  t r a n s c r i p t i o n  f a c t o r  
- G b x  2
- G l ia l  c e l l s  m i s s i n g  g e n e  h o m o l o g  ( m G C M l )  
- G u t - s p e c i f i c  K r u p p e l - l i k e  f a c t o r  G K L F  
- H e a t  s h o c k  t r a n s c r i p t i o n  f a c t o r  2  ( H S F  2 )
- H e p a t o c y t e  n u c l e a r  f a c t o r  3 / f o r k h e a d  h o m o l o g  8  ( H F H -  
8)
- H M G - b o x  t r a n s c r i p t i o n  f a c t o r  f r o m  t e s t i s  ( M u s S o x l 7 )  
- H M G - 1 4  n o n  h i s t o n e  c h r o m o s o m a l  p r o t e in  
- H o m e o  B o x  p r o t e i n  1.1 ( H o x - 1 .1 )
- H o m e o  B o x  p r o t e i n  2 .1  ( H o x - 2 . 1)
- H o m e o  B o x  p r o t e i n  2 .4  ( H o x - 2 .4 )
- H o m e o  B o x  p r o t e i n  2 .5  ( H o x - 2 .5 )
- H o m e o  B o x  p r o t e i n  3 .1  ( H o x - 3 . 1)
- H o m e o  B o x  p r o t e i n  4 .2  ( H o x - 4 .2 )
- H o m e o  B o x  p r o t e i n  7 .1  ( H o x - 7 . 1)
- H o m e o  B o x  p r o t e i n  8  ( H o x - 8 )
- H o m e o b o x  p r o t e i n  H O X D - 3  
- I k a r o s  D N A  b in d i n g  p r o t e in  
- S p 4  z i n c  f i n g e r  t r a n s c r i p t i o n  f a c t o r  
- I n t e r f e r o n  in d u c ib l e  p r o t e i n  1 
- I n t e r f e r o n  r e g u l a t o r y  f a c t o r  2  ( I R F  2 )
- K r u p p e l - l i k e  f a c t o r  L K L F  
- L b x  1 t r a n s c r i p t i o n  f a c t o r
- M p h - 1  n u c l e a r  t r a n s c r i p t i o n a l  r e p r e s s o r  f o r  h o x  g e n e s  
- M R E - b i n d i n g  t r a n s c r i p t i o n  f a c t o r  
- M y o c y t e  n u c l e a r  f a c t o r  ( M N F )
- M y o g e n i c  f a c t o r  5
- N e u r o n a l  h e l i x - l o o p - h e l i x  p r o t e i n  N E X - 1  
- N F - 1 B  p r o t e in  ( t r a n s c r i p t i o n  f a c t o r )
- N F - k a p p a  B  b i n d i n g  s u b u n i t  ( n u c l e a r  f a c t o r )  ( T F D B 5 )  
- N u c l e a r  f a c t o r  r e l a t e d  t o  P 4 5  N F - E 2  
- N u c l e a r  h o r m o n e  r e c e p t o r  R O R - A L P H A - 1  
- N u c le o b i n d in
- O c t a m e r  b i n d i n g  t r a n s c r i p t i o n  f a c t o r  ( O c t  3 )
- P A X - 8  ( p a i r e d  b o x  p r o t e in  P A X  8 )
- S p l i t  h a n d / f o o t  g e n e  
- S R Y - b o x  c o n t a i n i n g  g e n e  3 ( S o x 3 )
- P A X - 5  ( B  c e l l  s p e c i f i c  t r a n s c r i p t i o n  f a c t o r )
- P A X - 6  ( p a i r e d  b o x  p r o t e i n )
- P O U  d o m a in ,  c l a s s  2 ,  a s s o c i a t e d  f a c t o r  1 
- P S D - 9 5 / S A P 9 0 A
- R e t in o i c  a c id  b i n d i n g  p r o t e i n  I I  c e l l u l a r  ( C R A B P - I I )  
- R e t in o i c  a c id  r e c e p t o r  R X R -  g a m m a  
- R e t i n o i d  X  r e c e p t o r  i n t e r a c t i n g  p r o t e in  ( R I P  1 5 )  
- T - l y m p h o c y t e  a c t i v a t e d  p r o t e in  
- T r a n s c r i p t i o n  f a c t o r  1 f o r  h e a t  s h o c k  g e n e  
- T r a n s c r i p t i o n  f a c t o r  B A R X 1  ( h o m e o d ia n  t r a n s c r i p t i o n  
f a c t o r )
- T r a n s c r i p t i o n  f a c t o r  C  1
- T r a n s c r i p t i o n  f a c t o r  C T C F  (1 1  z in c  f in g e r s )
- T r a n s c r i p t i o n  f a c t o r  L IM -1
- T r a n s c r i p t i o n  f a c t o r  L R G  - 21
- T r a n s c r i p t i o n  f a c t o r  N F A T  1, i s o f o r m  a lp h a
- S R Y - b o x  c o n t a i n i n g  g e n e  4
- T r a n s c r i p t i o n  f a c t o r  R e l B
- T r a n s c r i p t i o n  f a c t o r  S - I I  ( t r a n s c r i p t i o n  e l o n g a t i o n
f a c t o r )
- T r a n s c r i p t i o n  f a c t o r  S E F 2
- T r a n s c r i p t i o n  f a c t o r  S P 1 P  ( P O U  d o m a in  t r a n s c r i p t i o n  
f a c to r )
- T r a n s c r i p t i o n  f a c t o r  S P 2  
- T r a n s c r i p t i o n  f a c t o r  U B F
C h a p te r  5 A p p e n d ix  I
- T r a n s c r i p t i o n a l  e n h a n c e r  f a c t o r  1 ( T E F - 1 )
-Y B 1  D N A  b i n d i n g  p r o t e i n  
-Y Y 1  ( U C R B P )  t r a n s c r i p t i o n a l  f a c t o r  
- Z i n c  f i n g e r  K r u p p e l  t y p e  Z f p  9 2  
- Z i n c  f i n g e r  t r a n s c r i p t i o n  f a c t o r  R U 4 9  
- Z i n c  f i n g e r  X - c h r o m o s o m a l  p r o te in  ( Z F X )
Growth Factor & Chemokine Receptors 
- A c t i v i n  t y p e  I r e c e p t o r  
- O r p h a n  r e c e p t o r
- B o n e  m o r p h o g e n e t i c  p r o t e i n  r e c e p to r
- C - C  c h e m o k i n e  r e c e p t o r  ( M o n o c y te  c h e m o a t t r a c t a n t
p r o t e i n  1 r e c e p t o r  ( M C P - I R A )
- C D 4  r e c e p t o r  ( T  c e l l  a c t i v a t i o n  a n t ig e n e )
- C D  4 0 L  r e c e p t o r  ( T N F  r e c e p t o r  f a m i ly )
- C 5 A  r e c e p t o r
- C o r t i c o t r o p i n  r e l e a s i n g  f a c t o r  r e c e p to r  
- b  r e c e p t o r  [ E d n r b ]
- G r a n u l o c y t e  c o l o n y - s t i m u l a t i n g  f a c t o r  r e c e p t o r  
- M o n o t y p e  c h e m o a t t r a c t a n t  p r o t e in  3 
- D - F a c t o r / L I F  r e c e p t o r
- E R B B - 2  r e c e p t o r  ( c - n e u ,  H E R 2  p r o t e in  t y r o s in e  
k in a s e )
- E R B B - 3  r e c e p t o r
- E r y t h r o p o i e t i n  r e c e p t o r
- F i b r o b l a s t  g r o w t h  f a c t o r  r e c e p t o r  4
- F i b r o b l a s t  g r o w t h  f a c t o r  r e c e p t o r  B a s i c  ( b  F G F - R )
- G - p r o t e i n - c o u p l e d  r e c e p t o r
- G r a n u l o c y t e - m a c r o p h a g e  c o l o n y - s t i m u l a t i n g  f a c t o r
r e c e p t o r
- G r o w t h  f a c t o r  r e c e p t o r  
- L i m p h o t o x i n  r e c e p t o r  ( T N F R  f a m i ly )
- M a c r o p h a g e  m a n n o s e  r e c e p t o r  
- P r e - p l a t e l e t - d e r i v e d  g r o w t h  f a c t o r  r e c e p to r  
- s n o N ;  s k i - r e l a t e d  o n c o g e n e  
- T G F - b e t a  r e c e p t o r  t y p e  1 
Interleukin & Interferon Receptors 
- I n t e r f e r o n  a l p h a - b e t a  r e c e p t o r  
- I n t e r f e r o n - g a m m a  r e c e p t o r  
- I n t e r l e u k i n - 1 r e c e p t o r  t y p e  II  
- I n t e r l e u k i n - 10  r e c e p to r  
- S o m a t o s t a t i n  r e c e p t o r  2  
- I n t e r l e u k i n - 2  r e c e p to r  g a m m a  c h a in  
- I n t e r l e u k i n - 3  r e c e p t o r
- I n t e r l e u k i n - 4  r e c e p t o r  ( m e m b r a n e - b o u n d  f o r m )
- I n t e r l e u k i n - 5  r e c e p to r
- I n t e r l e u k i n - 7  r e c e p to r
- I n t e r l e u k i n - 8  r e c e p to r
- I n t e r l e u k i n - 9  r e c e p to r
Hormone Receptors
- A n d r o g e n  r e c e p t o r
- C a l c i t o n i n  r e c e p t o r  l b
- E s t r o g e n  r e c e p t o r
- G l u c o c o r t i c o i d  r e c e p t o r  f o r m  A
- G r o w t h  h o r m o n e  r e c e p t o r
- I n s u l in  r e c e p t o r
- I n s u l i n  r e c e p t o r  s u b s t r a t e - 1 ( I R S - 1 )
- P r o l a c t in  r e c e p t o r  P R L R 2  
- L o w  d e n s i t y  l i p o p r o t e i n  r e c e p t o r  
Neurotransmitter Receptors
- 5 - H y d r o x y t r y p t a m i n e  r e c e p t o r  [ S e r o to n i n  r e c e p t o r  ty p e  
2  ( 5 H T 2 ) ]
- 5 - H y d r o x y t r y p t a m i n e  ( s e r o t o n i n )  r e c e p to r  l b  
- 5 - H y d r o x y t r y p t a m i n e  ( s e r o t o n i n )  r e c e p to r  1c 
- 5 - H y d r o x y t r y p t a m i n e  ( s e r o t o n i n )  r e c e p to r  l e  b e t a  
- 5 - H y d r o x y t r y p t a m i n e  ( s e r o t o n i n )  r e c e p to r  2 c  
- 5 - H y d r o x y t r y p t a m i n e  ( s e r o t o n i n )  r e c e p to r  3 
- 5 - H y d r o x y t r y p t a m i n e  ( s e r o t o n i n )  r e c e p to r  7  
- A c e t y l c h o l i n e  r e c e p to r  d e l t a  s u b m i t  
- A d r e n e r g i c  r e c e p to r ,  b e t a  1 
- C a n n a b i n o i d  r e c e p to r  1 ( b r a i n )
- C a n n a b i n o i d  r e c e p t o r  2  ( m a c r o p h a g e ,  C B 2 )
- D o p a m i n e  r e c e p t o r  4
- G - p r o t e in  c o u p l e d  r e c e p to r
- G A B A - A  r e c e p t o r  a l p h a - 1 s u b m i t
- G A B A - A  t r a n s p o r t e r  1
- G A B A - A  t r a n s p o r t e r  3
- G A B A - A  t r a n s p o r t e r  4
- G lu t a m a t e  r e c e p t o r ,  i o n o t r o p ic  A M P A  1
- G lu ta m a t e  r e c e p t o r ,  i o n o t r o p ic  N M D  A 2 A  ( e p s i l o n  1)
- G lu t a m a t e  r e c e p t o r ,  i o n o t r o p ic  N M D A 2 B  ( e p s i l o n  2 )
- N ic o t in i c  a c e t y l c h o l i n e  r e c e p t o r
Cell-Surface Antigens & Cell Adhesion Proteins
- P - s e l e c t in  ( g l y c o p r o t e i n  l i g a n d - 1)
- C a t e n in  a l p h a
- C D  18  a n t ig e n  b e t a  s u b u n i t  ( l e u k o c y t e  a d h e s i o n  L F A - 1 )  
( C D 3 ,  P 1 5 0 ,  9 5 )
- C D 2  a n t ig e n
- C D 2 8  ( r e c e p t o r  f o r  B 7 1 )
- C D 3  a n t ig e n ,  d e l t a  p o l y p e p t i d e
-C D 3 1  ( P l a t e l e t  e n d o t h e l i a l  c e l l  a d h e s i o n  m o l e c u l e  1 )
- C D 4 4  a n t ig e n
- C D 4 5  a s s o c i a t e d  p r o t e in  ( C D  4 5 - a p ,  L S M - 1 )
- C D 7  a n t ig e n  
- C D  14  a n t ig e n  
- C D 2 2  a n t ig e n
- C e l l  s u r f a c e  g ly c o p r o t e i n  M A C - 1  a l p h a  s u b u n i t  
- D e s m o c o l l i n  2  
- D y s t r o g l y c a n  1
- G lu t a m a t e  r e c e p t o r  c h a n n e l  s u b u n i t  g a m m a  
- I n t e g r i n  a l p h a  2  ( C D 4 9 b )
- I n t e g r i n  a l p h a  4  
- I n t e g r i n  a l p h a  5  ( C D 5 1)
- I n t e g r i n  a l p h a  6  
- I n te g r i n  a l p h a  7  
- D ip e p t id y l  p e p t i d a s e  IV  
- I n t e g r i n  b e t a  
- I n t e g r i n  b e t a  7  s u b u n i t  
- I n t e r c e l l u l a r  a d h e s i o n  m o l e c u l e - 1 
- L a m im in  r e c e p t o r  1 
- N e u r o n a l - c a d h e r i n  ( N - c a d h e r i n )
- N e u r o n a l  c e l l  s u r f a c e  p r o t e in  F 3  
- V a s c u la r  c e l l  a d h e s i o n  p r o t e in  1 
- V L A - 3  a l p h a  s u b u n i t
Growth Factors, Cytokines & Chemokines
- B a s i c  F i b r o b l a s t  g r o w th  f a c t o r  ( b - F G F )
- B o n e  m o r p h o g e n e t i c  p r o t e in  1
- B o n e  m o r p h o g e n e t i c  p r o t e in  2  ( B M P - 2 )  ( T G F - b e ta
f a m i ly )
- B o n e  m o r p h o g e n e t i c  p r o t e in  4  ( B M P - 4 )  ( T G F - b e t a  
f a m i ly )
- B o n e  m o r p h o g e n e t i c  p r o t e in  7  ( B M P - 7 )  ( o s t e o g e n ic  
p r o te in  1)
- B o n e  m o r p h o g e n e t i c  p r o t e in  8 a  ( B M P - 8 a )  ( T G F - b e t a  
f a m i ly )
- C e k  5 r e c e p t o r  p r o t e in  t y r o s i n e  k in a s e  l i g a n d  
- C e k  7  r e c e p t o r  p r o t e in  t y r o s i n e  k in a s e  l i g a n d  
- E n d o t h e l i a l  l i g a n d  f o r  L - s e l e c t i n  ( G L Y C A M  1) 
- E p i d e r m a l  g r o w t h  f a c t o r  ( E G F )
- F ib r o b la s t  g r o w t h  f a c t o r  9  
- F o l l i s t a t i n
- G a m m a  in t e r f e r o n  in d u c e d  m o n o k i n e  ( M I G )
- G l ia l  c e l l  l i n e - d e r iv e d  n e u r o t r o p h ic  f a c t o r  
- G r a n u lo c y t e  c o l o n y - s t i m u l a t i n g  f a c t o r  ( G - C S F )  
- G r o w t h / d i f f f e r e n t i a t i o n  f a c t o r  1 ( G D F - 1 )  ( T G F -  b e t a  
f a m i ly )
- G r o w t h /  d i f f f e r e n t i a t i o n  f a c t o r  2  ( G D F - 2 )  
- H e p a r i n - b i n d i n g  E G F - l i k e  g r o w th  f a c t o r  ( D ip h th e r i a  
to x i n  r e c e p to r )
- H e p a to c y te  g r o w th  f a c t o r  ( h e p a p o i t e i n )
- H e p a to m a  t r a n s m e m b r a n e  k in a s e  l ig a n d
C h ap ter  5 A p p e n d ix  I
- I n h i b i n  a l p h a  s u b u n i t
- I n h i b i n  b e t a  A  s u b u n i t  ( T G F  b e t a  f a m i ly )
- I n s u l i n - l i k e  g r o w t h  f a c t o r  b i n d i n g  p r o t e in  - 6  ( I G F B P  6 )  
- I n s u l i n - l i k e  g r o w t h  f a c t o r  b i n d i n g  p r o t e i n - 1 ( I G F B P - 1) 
- I n s u l i n - l i k e  g r o w t h  f a c t o r  b i n d i n g  p r o t e in - 3  ( I G F B P - 3 )  
- I n s u l i n - l i k e  g r o w t h  f a c t o r  b i n d i n g  p r o t e in - 4  ( I G F B P - 4 )  
- I n s u l i n - l i k e  g r o w t h  f a c t o r  b i n d i n g  p r o t e in - 5  ( I G F B P - 5 )  
- I n s u l i n - l i k e  g r o w t h  f a c t o r - 2  ( s o m a t o m e d i n  A )  
- I n s u l i n - l i k e  g r o w t h  f a c t o r - I A  
- K e r a t i n o c y t e  g r o w t h  f a c t o r  F G F - 7  
- K - f i b r o b l a s t  g r o w t h  f a c t o r  
- L e u k e m i a  i n h i b i t o r y  f a c t o r  ( L I F )  ( c h o l in e r g i c  
d i f f e r e n t i a t i o n  f a c t o r )
- M a c r o p h a g e  i n f l a m m a t o r y  p r o t e in  
- M a c r o p h a g e  in f l a m m a to r y  p r o t e in  1 b e t a  ( A c t  2 )  
- M a c r o p h a g e  in f l a m m a to r y  p r o t e i n  2  a l p h a  ( M I P  2  
a l p h a )
- M a d  r e l a t e d  p r o t e in  2  ( M A D R 2 )
- M a s t  c e l l  f a c t o r
- M o t h e r s  a g a i n s t  D P P  p r o t e i n  ( m a d  h o m o l o g  S m a d  1, 
t r a n s f o r m i n g  g r o w th  f a c t o r  b e t a  s ig n a l in g  p r o t e in )  
- N e r v e  g r o w t h  f a c t o r  a l p h a  ( a l p h a - N G F )
- N e r v e  g r o w t h  f a c t o r  b e t a  ( b e t a - N G F )
- N e u r o l e u k i n  
- O n c o s t a t i n  M
- P l a c e n t a l  r i b o n u c l e a s e  i n h i b i t o r  ( A n g io g e n i n )
- P l a t e l e t -  d e r i v e d  g r o w t h  f a c t o r  ( A  c h a in )  ( P D G F - A )
- P r e p r o - e n d o t h e l i n - 3
- T h r o m b o m o d u l i n
- T h r o m b o p o i e t i n
- T r a n s f o r m i n g  g r o w t h  f a c t o r  b e t a
- T r a n s f o r m i n g  g r o w t h  f a c t o r  b e t a  2
- T u m o r  n e c r o s i s  f a c t o r  b e t a  T N F - b e t a  ( L y m p h o to x in -
a l p h a )
- U r o m o d u l i n
- V a s c u l a r  e n d o t h e l i a l  g r o w t h  f a c t o r  ( V E G F )  
I n t e r l e u k i n s  &  I n t e r f e r o n s  
- I n t e r l e u k i n  1 b e t a  
- I n t e r l e u k i n  1 0
- I n t e r l e u k i n  11 ( a d i p o g e n e s i s  i n h i b i to r y  f a c t o r )  
- I n t e r l e u k i n  1 2  ( p 4 0 )  b e t a  c h a in  
- I n t e r l e u k i n  15 
- I n t e r l e u k i n  4
- I n t e r l e u k i n  6  ( B  c e l l  d i f f e r e n t i a t i o n  f a c t o r )
- I n t e r l e u k i n  7
C y t o s k e l e t o n  &  M o t i l i t y  P r o t e i n s
- A l p h a  c a r d i a c  m y o s in  h e a v y  c h a in
- C a m K  I I ;  C a 2 + / c a l m o d u l i n - d e p e n d e n t  p r o t e in  k in a s e  II
( b e t a  s u b u n i t )
- C D C 4 2  G T P - b i n d i n g  p r o t e in ;  G 2 5 K  
- C y t o s k e l e t a l  e p i d e r m a l  k e r a t i n  ( 1 4  h u m a n )  
- C y t o s k e l e t a l  e p i d e r m a l  k e r a t i n  ( 1 8  h u m a n )
- C y t o s k e l e t a l  e p i d e r m a l  k e r a t i n  ( 1 9  h u m a n )
- E p i d e r m a l  k e r a t i n  (1  h u m a n )
- F e t a l  m y o s in  a lk a l i  l i g h t  c h a in  
- K i n e s i n  f a m i ly  p r o t e in  K I F 1 A  
- K i n e s i n  h e a v y  c h a in  
- K i n e s i n  l i k e  p r o t e in  K I F  3 B  
- N o n - m u s c l e  m y o s in  l i g h t  c h a in  3 
- R a b - 3 b  r a s - r e l a t e d  p r o t e in  
- V i m e n t i n
- U n c o n v e n t i o n a l  m y o s in  V I  
P r o t e i n  T u r n o v e r  
P r o t e a s e s  &  I n h i b i t o r s
- A n g i o t e n s i n - c o n v e r t i n g  e n z y m e  ( A C E )  ( c l o n e  A C E .5 .)
- C a t h e p s i n  B
- C a t h e p s i n  D
- C a t h e p s i n  H
- C a t h e p s i n  L
- C o l l a g e n a s e  ty p e  IV
- C y t o t o x i c  c e l l  p r o t e a s e  2  ( B I O )
- C y t o t o x i c  T  l y m p h o c y t e - s p e c i f i c  s e r in e  p r o t e a s e  C C P  I 
g e n e  ( C T L A - 1 )
- G e l a t i n a s e  B
- I n t e r l e u k i n - c o n v e r t i n g  e n z y m e  ( I C E )
- M a s t  c e l l  p r o t e a s e  ( M M C P )  - 4  
- M e m b r a n e  t y p e  m a t r ix  m a ta l l o p r o t e i n a s e  
- P r o t e a s e  n e x i n  1 ( P N - 1 )
- T i s s u e  p l a s m i n o g e n  a c t i v a t o r  
- U r o k i n a s e  t y p e  p l a s m i n o g e n  a c t iv a t o r  
I n h i b i t o r s
- A l p h a - 1 p r o t e a s e  i n h i b i t o r  2  
- P l a s m i n o g e n  a c t i v a t o r  i n h i b i to r  
- P l a s m i n o g e n  a c t i v a t o r  in h i b i to r - 2  
- S e r in e  p r o t e a s e  i n h i b i t o r  2  ( s p i - 2 )
- S e r i n e  p r o t e a s e  i n h i b i t o r  2 .4  
- S e r i n e  p r o t e a s e  i n h i b i t o r  h o m o l o g  J 6  
- T I M P - 2  t i s s u e  i n h i b i t o r  o f  m e ta l l o p r o t e i n a s e s - 2  
- T I M P - 3  t i s s u e  i n h i b i t o r  o f  m e ta l l o p r o t e i n a s e s - 3
H o u s e k e e p i n g  G e n e s
- G l y c e r a l d e h y d e  3 - p h o s p h a te  d e h y d r o g e n a s e  ( G 3 P D H )  
- M y o s i n  1
- M u r in e  o r n i t h i n e  d e c a r b o x y l a s e  ( M O D )
- B e t a - a c t in
- C a l c i u m - b i n d i n g  p r o t e in  C a b 4 5  
- R ib o s o m a l  p r o t e i n  S 2 9  
- U b iq u i t i n  
- P h o s p h o l i p a s e  A 2
- H y p o x a n t h i n e  p h o s p h o r i b o s y l  t r a n s f e r a s e  ( H P R T )
N e g a t i v e  C o n t r o l s
- M l 3 m p l 8 ( + )  S T R A N D  D N A
- L a m b d a  D N A
- p U C 1 8
C h ap ter  5 A p p e n d ix  I
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